var title_f35_45_36560="Tuberculoid granuloma";
var content_f35_45_36560=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tuberculoid granuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 281px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tuberculoid granuloma. Epitheliod histiocytes, multinucleated giant cells, and a dense lymphocytic infiltrate are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Ma. Flordeliz Abad-Casintahan.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_45_36560=[""].join("\n");
var outline_f35_45_36560=null;
var title_f35_45_36561="Patient information: Ruptured eardrum (The Basics)";
var content_f35_45_36561=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17229\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/61/30677\">",
"         Normal ear",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?43/38/44642\">",
"         Patient information: Ear infections (otitis media) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?15/16/15619\">",
"         Patient information: Ear infections (otitis media) in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Ruptured eardrum (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/ruptured-eardrum-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H27658915\">",
"      <span class=\"h1\">",
"       What is a ruptured eardrum?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A ruptured eardrum is a hole or tear in your eardrum. The eardrum is a thin layer of tissue between the ear canal and middle ear (",
"      <a class=\"graphic graphic_figure graphicRef55121 \" href=\"mobipreview.htm?29/61/30677\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      The most common causes of a ruptured eardrum are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Ear infections &ndash; This can cause fluid to build up and press on the eardrum.",
"       </li>",
"       <li>",
"        Extreme pressure changes &ndash; This happens during scuba diving if you move up or down in the water too quickly. It is called &ldquo;barotrauma.&rdquo;",
"       </li>",
"       <li>",
"        Poking the eardrum &ndash; This happens if you poke a Q-tip, bobby pin, or other object into your ear canal.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27658930\">",
"      <span class=\"h1\">",
"       What are the symptoms of a ruptured eardrum?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people have no symptoms. But symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Very bad ear pain",
"       </li>",
"       <li>",
"        Ear pain that suddenly gets better",
"       </li>",
"       <li>",
"        Clear, pus-colored, or bloody fluid draining from the ear",
"       </li>",
"       <li>",
"        A buzzing or ringing sound in the ear",
"       </li>",
"       <li>",
"        Trouble hearing or hearing loss",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27658945\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse should be able to tell if you have a ruptured eardrum by learning about your symptoms and doing an exam. He or she will also do tests to check your hearing.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27658960\">",
"      <span class=\"h1\">",
"       How is a ruptured eardrum treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your ruptured eardrum was caused by an infection, you will need to take antibiotics. These might be given as pills or in liquid form (for children). Your doctor might also prescribe antibiotic eardrops to prevent infection of the lining of the ear.&nbsp;&nbsp;",
"     </p>",
"     <p>",
"      If your ruptured eardrum was caused an injury to the ear (for example, from a Q-tip), your doctor might prescribe only antibiotic eardrops.",
"     </p>",
"     <p>",
"      Most of the time, a ruptured eardrum heals by itself, within hours or days. You should see your doctor about 2 weeks after your first visit so he or she can check if your eardrum has healed. If it has not, you will need to see an ear, nose and throat (ENT) specialist. He or she might do surgery to put a tiny paper patch on your eardrum to help seal the hole.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27658975\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can take an over-the-counter medicine for pain, such as",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/35/20021?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (sample brand name: Tylenol&reg;) or",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (sample brand names: Advil&reg;, Motrin&reg;).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27658990\">",
"      <span class=\"h1\">",
"       Can a ruptured eardrum be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To reduce your chances of getting a ruptured eardrum, do NOT put Q-tips or other objects into your ear canal",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27659005\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/38/44642?source=see_link\">",
"       Patient information: Ear infections (otitis media) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/16/15619?source=see_link\">",
"       Patient information: Ear infections (otitis media) in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/45/36561?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17229 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.208-7855FF150B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_45_36561=[""].join("\n");
var outline_f35_45_36561=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27658915\">",
"      What is a ruptured eardrum?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27658930\">",
"      What are the symptoms of a ruptured eardrum?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27658945\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27658960\">",
"      How is a ruptured eardrum treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27658975\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27658990\">",
"      Can a ruptured eardrum be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27659005\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17229\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/61/30677\">",
"      Normal ear",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/38/44642?source=related_link\">",
"      Patient information: Ear infections (otitis media) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?15/16/15619?source=related_link\">",
"      Patient information: Ear infections (otitis media) in children (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_45_36562="Patient information: Androgen replacement in men (The Basics)";
var content_f35_45_36562=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86221\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/34/27180\">",
"         Androgen replacement medicines (testosterone)",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?30/1/30738\">",
"         Patient information: Normal sexual development (puberty) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/24/386\">",
"         Patient information: Sex problems in men (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?43/30/44513\">",
"         Patient information: When men develop breasts (gynecomastia) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/47/41713\">",
"         Patient information: Gynecomastia (breast enlargement in men) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/61/32726\">",
"         Patient information: Reducing the costs of medicines (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?28/33/29205\">",
"         Patient information: Sexual problems in men (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Androgen replacement in men (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H91530311\">",
"      <span class=\"h1\">",
"       What are androgens?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Androgens are a type of hormone the body makes naturally. Hormones are chemical messengers that turn different body processes on and off. Androgens are often called &ldquo;male hormones.&rdquo; That&rsquo;s because they are the main hormones that make men different from women.",
"     </p>",
"     <p>",
"      People often think that only men have androgens and only women have female hormones called &ldquo;estrogens.&rdquo; But the fact is, men and women both have androgens and estrogens. The difference is that men normally have much higher levels of androgen than estrogen. And women normally have much higher levels of estrogen than androgen.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H91530326\">",
"      <span class=\"h1\">",
"       Why might a man need androgen replacement?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A man might need androgen replacement if he has low levels of an androgen called &ldquo;testosterone.&rdquo; There are a few different androgens, but testosterone is the main one.",
"     </p>",
"     <p>",
"      Symptoms of low testosterone in men can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Little or no interest in sex &ndash; Doctors call this &ldquo;low libido.&rdquo;",
"       </li>",
"       <li>",
"        Feeling depressed",
"       </li>",
"       <li>",
"        Feeling tired, especially at the end of the day",
"       </li>",
"       <li>",
"        Developing breasts &ndash; Doctors call this &ldquo;gynecomastia.&rdquo;",
"       </li>",
"       <li>",
"        Being slow to go through puberty (in a boy) &ndash; Boys who are slow to go through puberty:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Do not get bigger muscles, even with lots of exercise",
"       </li>",
"       <li>",
"        Do not getting a beard, body hair, or deeper voice",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H91530343\">",
"      <span class=\"h1\">",
"       How do I know if I need androgen replacement?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have symptoms of low testosterone, the doctor or nurse will do an exam and learn about your symptoms. He or she will also order a blood test to check your testosterone level.",
"     </p>",
"     <p>",
"      Depending on your individual situation, you might also have other tests.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H91530360\">",
"      <span class=\"h1\">",
"       What are the benefits of androgen replacement in men?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The benefits include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Normal interest in sex",
"       </li>",
"       <li>",
"        Normal muscle strength",
"       </li>",
"       <li>",
"        Normal energy",
"       </li>",
"       <li>",
"        Being less depressed or irritable",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H91530377\">",
"      <span class=\"h1\">",
"       Are there side effects to androgen replacement in men?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some men who have androgen replacement with testosterone have side effects. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        High amounts of red blood cells",
"       </li>",
"       <li>",
"        Body changes that sometimes happen in the pre-teen and teen years, such as:",
"       </li>",
"       <li>",
"        Acne",
"       </li>",
"       <li>",
"        Breast enlargement",
"       </li>",
"       <li>",
"        Aggressive behavior &ndash; This is more common in boys and teens who have androgen replacement than in adult men who have the treatment.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Men who have testosterone replacement need regular exams and blood tests to check testosterone levels and look for any side effects.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H91530394\">",
"      <span class=\"h1\">",
"       How is androgen replacement given?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are several different forms. Testosterone can be given in an injection (shot), patch, gel, or tablet you put on your gums. The table lists the names of different androgen replacement medicines (",
"      <a class=\"graphic graphic_table graphicRef86166 \" href=\"mobipreview.htm?26/34/27180\">",
"       table 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Men who use testosterone replacement patches, gels, or tablets must wash their hands after putting on the medicine. That&rsquo;s because testosterone can get on other people&rsquo;s skin. It can cause harmful side effects, especially in children. Patches and gels must be put on skin that is covered by clothes. This can help keep testosterone from getting on other people.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H91530428\">",
"      <span class=\"h1\">",
"       Should men over 60 have androgen replacement?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That&rsquo;s not always clear. Testosterone levels normally decrease as men get older. That means that men who are 60 and older have less testosterone than younger men. Normal aging causes some of the same changes that happen in men with low testosterone, such as less energy or interest in sex. But taking testosterone can raise an older man&rsquo;s risk of prostate cancer. Older men already have a higher risk of prostate cancer than younger men, and doctors worry because androgen replacement with testosterone might make this risk even higher. So it is important to carefully consider the possible risks and benefits of androgen replacement.",
"     </p>",
"     <p>",
"      Men older than 60 might have androgen replacement if:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        More than 1 blood test shows very low testosterone",
"       </li>",
"       <li>",
"        They have symptoms of low testosterone",
"       </li>",
"       <li>",
"        The symptoms are not caused by another disease or condition that doctors can treat",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Older men who have androgen replacement need regular screening tests for prostate cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H91530445\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/1/30738?source=see_link\">",
"       Patient information: Normal sexual development (puberty) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/24/386?source=see_link\">",
"       Patient information: Sex problems in men (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/30/44513?source=see_link\">",
"       Patient information: When men develop breasts (gynecomastia) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/47/41713?source=see_link\">",
"       Patient information: Gynecomastia (breast enlargement in men) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=see_link\">",
"       Patient information: Reducing the costs of medicines (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/33/29205?source=see_link\">",
"       Patient information: Sexual problems in men (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?35/45/36562?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86221 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-1D88657B2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_45_36562=[""].join("\n");
var outline_f35_45_36562=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91530311\">",
"      What are androgens?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91530326\">",
"      Why might a man need androgen replacement?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91530343\">",
"      How do I know if I need androgen replacement?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91530360\">",
"      What are the benefits of androgen replacement in men?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91530377\">",
"      Are there side effects to androgen replacement in men?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91530394\">",
"      How is androgen replacement given?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91530428\">",
"      Should men over 60 have androgen replacement?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91530445\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86221\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/34/27180\">",
"      Androgen replacement medicines (testosterone)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/47/41713?source=related_link\">",
"      Patient information: Gynecomastia (breast enlargement in men) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/1/30738?source=related_link\">",
"      Patient information: Normal sexual development (puberty) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/24/386?source=related_link\">",
"      Patient information: Sex problems in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/33/29205?source=related_link\">",
"      Patient information: Sexual problems in men (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?43/30/44513?source=related_link\">",
"      Patient information: When men develop breasts (gynecomastia) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_45_36563="Benztropine: Pediatric drug information";
var content_f35_45_36563=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Benztropine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?3/55/3958?source=see_link\">",
"    see \"Benztropine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/44/39620?source=see_link\">",
"    see \"Benztropine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F140212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cogentin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F140213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Benztropine&reg;;",
"     </li>",
"     <li>",
"      Benztropine Omega;",
"     </li>",
"     <li>",
"      PMS-Benztropine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-Parkinson's Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticholinergic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Drug-induced Dystonic Reactions",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?3/55/3958?source=see_link\">",
"      see \"Benztropine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Drug-induced extrapyramidal reaction: Oral, I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;3 years: 0.02-0.05 mg/kg/dose 1-2 times/day; use in children &lt;3 years should be reserved for life-threatening emergencies",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 1-4 mg/dose 1-2 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Acute dystonia: Adults: I.M., I.V.: 1-2 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parkinsonism: Adults: Oral: 0.5-6 mg/day in 1-2 divided doses; begin with 0.5 mg/day; increase in 0.5 mg increments at 5- to 6-day intervals to achieve the desired effect",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F140194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as mesylate: 1 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cogentin&reg;: 1 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as mesylate: 0.5 mg, 1 mg, 2 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F140180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with food to decrease GI upset",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.V. route should be reserved for situations when oral or I.M. are not appropriate",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F140233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Fluconazole, tacrolimus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Chlorpromazine, fluphenazine, metoclopramide.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Haloperidol.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive treatment of parkinsonism; also used in treatment of drug-induced extrapyramidal effects (except tardive dyskinesia) and acute dystonic reactions",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F140235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Benztropine may be confused with bromocriptine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Parkinson's disease:  Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F140232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, depression, disorientation, exacerbation of preexisting psychotic symptoms, fever, listlessness, memory impairment, nervousness, toxic psychosis, visual hallucinations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Heat stroke, hyperthermia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, paralytic ileus, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention, dysuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Numbness of fingers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, mydriasis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to benztropine mesylate or any component; children &lt;3 years of age; patients with narrow-angle glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers; bladder neck obstructions; achalasia; myasthenia gravis",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1056785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in hot weather or during exercise; may cause anhydrosis and hyperthermia; increased risk of hyperthermia in alcoholics, patients with CNS disease, and with prolonged outdoor exposure",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F140223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F140189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Benztropine may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13276950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Paralytic ileus (which resolved rapidly) was reported in two newborns exposed to a combination of benztropine and chlorpromazine during the second and third trimesters and the last 6 weeks of pregnancy, respectively (Falterman, 1980).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Thought to partially block striatal cholinergic receptors to help balance cholinergic and dopaminergic activity",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1056797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Parenteral: Within 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 6-48 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1056790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/44/39620?source=see_link\">",
"      see \"Benztropine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May causes drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13024 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8E53C3882F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_45_36563=[""].join("\n");
var outline_f35_45_36563=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140212\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140213\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056791\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056786\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140194\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140180\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056795\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140233\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056794\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140235\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140232\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056798\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056785\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140223\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140189\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276950\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056784\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056797\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056790\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13024\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13024|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?3/55/3958?source=related_link\">",
"      Benztropine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?38/44/39620?source=related_link\">",
"      Benztropine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_45_36564="Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis";
var content_f35_45_36564=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Obsessive-compulsive disorder: Epidemiology, clinical manifestations, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/45/36564/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/45/36564/contributors\">",
"     Paul Ciechanowski, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/45/36564/contributors\">",
"     Wayne Katon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/45/36564/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/45/36564/contributors\">",
"     Thomas L Schwenk, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/45/36564/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/45/36564/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/45/36564/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obsessive-compulsive disorder (OCD) is one of the more disabling and potentially chronic anxiety disorders. It is characterized by anxiety-provoking intrusive thoughts and repetitive behaviors. Obsessions may consist of aggressive thoughts and impulses, fears of contamination by germs or dirt, or fears of harm befalling someone. Compulsions such as washing, checking, or counting are rituals whose purpose is to neutralize or reverse the fears. Related disorders include trichotillomania (hair-pulling) and Tourette syndrome.",
"   </p>",
"   <p>",
"    The epidemiology, pathophysiology, clinical manifestations, and diagnosis of OCD are reviewed here. Psychotherapy and psychopharmacology for OCD are reviewed separately. OCD in pregnant and postpartum women is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/0/23561?source=see_link\">",
"     \"Pharmacotherapy for obsessive-compulsive disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34391?source=see_link\">",
"     \"Psychotherapy for obsessive-compulsive disorder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42582?source=see_link\">",
"     \"Obsessive-compulsive disorder in pregnant and postpartum women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND SPECTRUM OF DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;OCD occurs in 2 to 3 percent of the United States population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36564/abstract/1\">",
"     1",
"    </a>",
"    ]. There is probably a bimodal distribution of the age of onset, with studies of juvenile OCD finding a mean age at onset of around 10 years, and adult OCD studies finding a mean age at onset of 21 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36564/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Early onset OCD has been associated with a higher frequency of tic-like compulsions and comorbid tic disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36564/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22664?source=see_link\">",
"     \"Tourette syndrome\"",
"    </a>",
"    .) In general, the modal age of onset is younger for males than for females [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36564/abstract/7\">",
"     7",
"    </a>",
"    ]. There has traditionally been a significant delay between symptom onset and treatment seeking because of patient embarrassment and the long held perception (by both the patient and the medical community) that little can be done about the symptoms of OCD. OCD may occur at a higher during pregnancy and postpartum.",
"   </p>",
"   <p>",
"    OCD shares many features with somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and neurologic disorders (",
"    <a class=\"graphic graphic_figure graphicRef55509 \" href=\"mobipreview.htm?12/50/13102\">",
"     figure 1",
"    </a>",
"    ). These diseases have been classified under the rubric \"obsessive-compulsive spectrum disorders\" and are thought to approach a prevalence rate in the primary care setting of 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36564/abstract/8\">",
"     8",
"    </a>",
"    ]. An expert consensus guideline has determined that bulimia and body dysmorphic syndrome also are conditions in this spectrum that can be treated with similar pharmacologic agents as in OCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36564/abstract/9\">",
"     9",
"    </a>",
"    ]. Hypochondriasis, trichotillomania, nail-biting, and skin-picking are conditions commonly seen in the medical setting that also are possibly responsive to OCD treatment.",
"   </p>",
"   <p>",
"    In addition to significant disability and burden to patients and their families, total costs of OCD were estimated at $8 billion in 1990 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36564/abstract/10\">",
"     10",
"    </a>",
"    ]. More recent analyses estimate lifetime indirect costs due to lost wages at $40 billion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36564/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a higher incidence of OCD among first degree relatives of patients with OCD than in the general population. Orbitofrontal dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36564/abstract/12\">",
"     12",
"    </a>",
"    ] and",
"    <span class=\"nowrap\">",
"     frontal/parietal",
"    </span>",
"    white matter changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36564/abstract/13\">",
"     13",
"    </a>",
"    ] have been identified in patients with OCD, as well as their unaffected first degree relatives, suggesting a possible endophenotype for this disorder.",
"   </p>",
"   <p>",
"    Functional imaging studies over the past several years have implicated prefrontal cortex, cingulate gyrus, and basal ganglia (especially caudate nucleus) dysfunction in the pathogenesis of this disorder. As an example, treatment studies using PET scans have shown that patients with OCD who improved during pharmacological or cognitive-behavioral treatment had reductions in cerebral metabolism or blood flow in specific regions of the brain, including the right caudate nucleus; the degree of reduction correlated with the degree of response to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36564/abstract/14\">",
"     14",
"    </a>",
"    ]. Serotonin is also believed to play a primary role in OCD.",
"   </p>",
"   <p>",
"    A pediatric subgroup of patients has been identified that developed OCD characterized by prepubertal acute onset after group A beta-hemolytic streptococcal pharyngitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36564/abstract/15\">",
"     15",
"    </a>",
"    ]. It has been postulated that the basal ganglia is involved in this process, a hypothesis that is supported by neuropsychological and neuroimaging evidence of basal ganglia dysfunction in both OCD and Sydenham's chorea, and by demonstrations of similar antineuronal antibodies in both disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with OCD present with persistent thoughts, ideas, and images that intrude into conscious awareness, are recognized as a product of one's mind, and are perceived as senseless and intrusive. Commonly these obsessions have a theme that a small oversight will result in inconceivable catastrophe. Other common themes are contamination, a need for ordering things, aggressive impulses, and sexual imagery.",
"   </p>",
"   <p>",
"    Compulsions are urges or impulses for repetitive intentional behavior performed in a stereotyped manner (eg, touching, counting, arranging) in an attempt to alleviate the anxiety which most frequently results from the obsessions. Often these behaviors are believed to help defend the patient and others from potential harm. Such behaviors may cause minor physical signs that can be recognized by the physician. As examples, the compulsive hand washer may present with a serious dermatitis, the skin-picker may develop dermatologic lesions, or the patient with trichotillomania will have alopecia. Other behaviors can be disabling by virtue of the time required to perform them. As with many anxiety disorders, symptoms worsen at times of stress.",
"   </p>",
"   <p>",
"    Quality of life is considerably decreased in patients with OCD due to the shame, distress, and time consumed in carrying out compulsive behaviors. Interpersonal relationships suffer, with resulting interference in family relationships, friendships, and academic and work achievement. The potentially devastating consequences of OCD were illustrated in a study which found that 13 percent of patients had attempted suicide secondary to OCD symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36564/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic criteria for OCD suggest that the obsessions and compulsions are time consuming, cause significant distress, or interfere with daily routine, social, or occupational functioning (",
"    <a class=\"graphic graphic_table graphicRef78513 \" href=\"mobipreview.htm?15/1/15387\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36564/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a correct diagnosis is often difficult to make because many of the symptoms of OCD overlap with generalized anxiety disorder and major depression, or OCD may coexist with these disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36564/abstract/17\">",
"     17",
"    </a>",
"    ]. One study reported a 17-year gap on average between the onset of symptoms and appropriate treatment for OCD, due in part to the difficulty in establishing the diagnosis and to the reluctance of these patients to seek help [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36564/abstract/11\">",
"     11",
"    </a>",
"    ]. This gap is expected to decrease with increasing media attention and increased diagnostic sophistication among the medical and psychiatric community.",
"   </p>",
"   <p>",
"    Patients seldom present complaining of intrusive obsessive thoughts because of the inherent shame that accompanies these symptoms. Thus, physicians must actively screen for OCD, particularly when presenting symptomatology suggests the diagnosis. Examples of useful questions include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Are there certain thoughts that go through your mind over and over that you cannot get rid of?",
"     </li>",
"     <li>",
"      Are there behaviors or habits that you feel compelled to repeat?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, a short version of the Yale-Brown Obsessive Compulsive Screen can be a useful adjunct to the interview in diagnosing OCD (",
"    <a class=\"graphic graphic_figure graphicRef80107 \" href=\"mobipreview.htm?11/7/11378\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36564/abstract/18\">",
"     18",
"    </a>",
"    ]. It can also be used to assess the severity of OCD and to monitor treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of OCD was described in a long-term follow-up study of 144 patients with the disorder followed for 40 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36564/abstract/19\">",
"     19",
"    </a>",
"    ]. Although two-thirds of patients had some degree of improvement within one decade of the onset of their illness, only one-fifth of the cohort achieved full remission, with two-thirds continuing to experience clinical or subclinical symptoms. One-fifth of patients who recovered early had a late relapse after being symptom free for more than 20 years. The authors point out that during the most of the study period, there were no effective and lasting therapies for OCD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obsessive-compulsive disorder (OCD) is characterized by anxiety-provoking intrusive thoughts",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      repetitive behaviors. Obsessions most commonly relate to concerns regarding catastrophic events, contamination, need for ordering things, aggressive impulses and sexual imagery. Compulsions are urges for stereotyped repetitive behaviors to alleviate anxiety. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      OCD occurs in 2 to 3 percent of the United States population. There is probably a bimodal distribution of the age of onset, with studies of juvenile OCD finding a mean age at onset of around 10 years, and adult OCD studies finding a mean age at onset of 21 years. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and spectrum of disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Natural history over a decade, in the absence of treatment, is improvement in two-thirds of patients, but full remission in only 20 percent. Suicide attempts have been reported in over 10 percent of patients. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36564/abstract/1\">",
"      Karno M, Golding JM, Sorenson SB, Burnam MA. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 1988; 45:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36564/abstract/2\">",
"      Geller D, Biederman J, Jones J, et al. Is juvenile obsessive-compulsive disorder a developmental subtype of the disorder? A review of the pediatric literature. J Am Acad Child Adolesc Psychiatry 1998; 37:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36564/abstract/3\">",
"      Geller DA, Biederman J, Griffin S, et al. Comorbidity of juvenile obsessive-compulsive disorder with disruptive behavior disorders. J Am Acad Child Adolesc Psychiatry 1996; 35:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36564/abstract/4\">",
"      Rasmussen SA, Eisen JL. The epidemiology and differential diagnosis of obsessive compulsive disorder. J Clin Psychiatry 1992; 53 Suppl:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36564/abstract/5\">",
"      Rosario-Campos MC, Leckman JF, Mercadante MT, et al. Adults with early-onset obsessive-compulsive disorder. Am J Psychiatry 2001; 158:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36564/abstract/6\">",
"      Diniz JB, Rosario-Campos MC, Shavitt RG, et al. Impact of age at onset and duration of illness on the expression of comorbidities in obsessive-compulsive disorder. J Clin Psychiatry 2004; 65:22.",
"     </a>",
"    </li>",
"    <li>",
"     Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Primary Care Version (DSM-IV-PC), American Psychiatric Association, Washington, DC 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36564/abstract/8\">",
"      Higgins ES. Obsessive-compulsive spectrum disorders in primary care: the possibilities and the pitfalls. J Clin Psychiatry 1996; 57 Suppl 8:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36564/abstract/9\">",
"      March, JS, Frances, A, Carpenter, D, (Eds). Treatment of Obsessive-Compulsive Disorder: The Expert Consensus Guideline Series. J Clin Psychiatry 1997; 58(Suppl 4):26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36564/abstract/10\">",
"      Dupont, R, Rice, D, Shiraki, S, et al. Economic costs of obsessive-compulsive disorder. Pharmacoeconomics 1995; April:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36564/abstract/11\">",
"      Hollander E, Kwon JH, Stein DJ, et al. Obsessive-compulsive and spectrum disorders: overview and quality of life issues. J Clin Psychiatry 1996; 57 Suppl 8:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36564/abstract/12\">",
"      Chamberlain SR, Menzies L, Hampshire A, et al. Orbitofrontal dysfunction in patients with obsessive-compulsive disorder and their unaffected relatives. Science 2008; 321:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36564/abstract/13\">",
"      Menzies L, Williams GB, Chamberlain SR, et al. White matter abnormalities in patients with obsessive-compulsive disorder and their first-degree relatives. Am J Psychiatry 2008; 165:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36564/abstract/14\">",
"      Baxter LR Jr, Schwartz JM, Bergman KS, et al. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry 1992; 49:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36564/abstract/15\">",
"      Swedo SE, Leonard HL, Garvey M, et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 1998; 155:264.",
"     </a>",
"    </li>",
"    <li>",
"     Hollander, E, Stein, D, Broatch, J, et al. A pharmaco-economic and quality of life study of OCD. In: Scientific Abstracts of the 34th Annual Meeting of the American College of Neuropsychopharmacology; December 11-15, 1995; San Juan, Puerto Rico. p.155.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36564/abstract/17\">",
"      Eisen JL, Goodman WK, Keller MB, et al. Patterns of remission and relapse in obsessive-compulsive disorder: a 2-year prospective study. J Clin Psychiatry 1999; 60:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36564/abstract/18\">",
"      Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 1989; 46:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36564/abstract/19\">",
"      Skoog G, Skoog I. A 40-year follow-up of patients with obsessive-compulsive disorder [see commetns]. Arch Gen Psychiatry 1999; 56:121.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 498 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-FA3CAE7412-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_45_36564=[""].join("\n");
var outline_f35_45_36564=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND SPECTRUM OF DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/498\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/498|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/50/13102\" title=\"figure 1\">",
"      OCD related diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/7/11378\" title=\"figure 2\">",
"      Yale Brown OCD rating scale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/498|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/1/15387\" title=\"table 1\">",
"      Diagnostic criteria for obsessive-compulsive disorder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42582?source=related_link\">",
"      Obsessive-compulsive disorder in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/0/23561?source=related_link\">",
"      Pharmacotherapy for obsessive-compulsive disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/37/34391?source=related_link\">",
"      Psychotherapy for obsessive-compulsive disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/8/22664?source=related_link\">",
"      Tourette syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_45_36565="Iopamidol: Drug information";
var content_f35_45_36565=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Iopamidol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/33/2580?source=see_link\">",
"    see \"Iopamidol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F183910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Isovue Multipack&reg;;",
"     </li>",
"     <li>",
"      Isovue-M&reg;;",
"     </li>",
"     <li>",
"      Isovue&reg; 200;",
"     </li>",
"     <li>",
"      Isovue&reg; 250;",
"     </li>",
"     <li>",
"      Isovue&reg; 300;",
"     </li>",
"     <li>",
"      Isovue&reg; 370",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F183913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Iodinated Contrast Media;",
"     </li>",
"     <li>",
"      Radiological/Contrast Media (Nonionic, Low Osmolality)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7914544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosing is based numerous variables including: type of examination, route of administration, patient age/weight ,and product. Consult specific product information for detailed dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F7976883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosing is based numerous variables including: type of examination, route of administration, patient age/weight ,and product. Consult specific product information for detailed dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7914545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15962264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. Use caution in severe impairment and in setting of combined renal and hepatic disease.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15962265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. Use caution in patients with combined hepatic and renal disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F183902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isovue Multipack&reg;: 51% (200 mL) [contains edetate calcium disodium, sodium ~0.036 mg (0.002 mEq)/mL; provides organically-bound iodine 250 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isovue Multipack&reg;: 61% (200 mL, 500 mL) [contains edetate calcium disodium, sodium ~0.043 mg (0.002 mEq)/mL; provides organically-bound iodine 300 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isovue Multipack&reg;: 76% (200 mL, 500 mL) [contains edetate calcium disodium, sodium ~0.053 mg (0.002 mEq)/mL; provides organically-bound iodine 370 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isovue&reg; 200: 41% (50 mL, 200 mL) [contains edetate calcium disodium, sodium ~0.029 mg (0.001 mEq)/mL; provides organically-bound iodine 200 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isovue&reg; 250: 51% (50 mL, 100 mL, 150 mL) [contains edetate calcium disodium, sodium ~0.036 mg (0.002 mEq)/mL; provides organically-bound iodine 250 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isovue&reg; 300: 61% (30 mL, 50 mL, 75 mL, 100 mL, 125 mL [DSC], 150 mL) [contains edetate calcium disodium, sodium ~0.043 mg (0.002 mEq)/mL; provides organically-bound iodine 300 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isovue&reg; 370: 76% (50 mL, 75 mL, 100 mL, 125 mL, 150 mL) [contains edetate calcium disodium, sodium ~0.053 mg (0.002 mEq)/mL; provides organically-bound iodine 370 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, intrathecal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isovue-M&reg;: 41% (10 mL, 20 mL) [contains edetate calcium disodium, sodium ~0.029 mg (0.001 mEq)/mL; provides organically-bound iodine 200 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isovue-M&reg;: 61% (15 mL) [contains edetate calcium disodium, sodium ~0.043 mg (0.002 mEq)/mL; provides organically-bound iodine 300 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F183898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7914546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Withdrawal of contrast agents from container should be completed with aseptic technique. Intrathecal doses should be administered slowly over 1-2 minutes to avoid excessive mixing with CSF through a lumbar needle under fluoroscopic control. Intravenous doses should be at body temperature prior to administration. In angiography, use meticulous intravascular administration technique to minimize thrombotic events including use of plastic syringes, frequent catheter flushing, and close attention to catheter and guidewire manipulation.",
"     <b>",
"      Note:",
"     </b>",
"     Isovue&reg; and Isovue Multipack&reg; are",
"     <b>",
"      not",
"     </b>",
"     for intrathecal use; caution should be used during product selection.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F13791579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Fenoldopam.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Ampicillin, chloramphenicol, cimetidine, diphenhydramine, epinephrine, gentamicin, heparin, hydrocortisone sodium succinate, methylprednisolone sodium succinate, papaverine, protamine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F183903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intrathecal (Isovue-M&reg;): Myelography contrast enhancement of computed tomographic cisternography and ventriculography; thoracolumbar myelography",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intravascular (Isovue&reg;, Isovue Multipack&reg;): Angiography (eg, coronary, cerebral, peripheral arteriogram), pediatric angiocardiography, excretory urography; contrast enhancement of computed tomographic imaging (in adults and children); evaluation of certain malignancies; image enhancement of non-neoplastic lesions",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7914491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Central nervous system: Headache (1% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &ge;1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Angina pectoris (3%), flushing (2%), bradycardia (1%), hypertension (1%), hypotension (1%), arrhythmias, circulatory collapse, MI, tachycardia, ventricular fibrillation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Hot flashes (3%), pain (3%), chills, faintness, fever, vasovagal reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Hives (1%), pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (1% to 7%), vomiting (1% to 4%), anorexia, taste alterations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Burning sensation (1%), thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal:  Muscle pain (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea, nasal congestion, pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Amnesia, anaphylactoid reaction, apnea, arterial spasms, asthma, ataxia, cardiopulmonary arrest, chest pain, cortical blindness, coma, confusion, dizziness, edema, hallucinations, hypersensitivity reactions, involuntary muscle movements, laryngeal edema, nephropathy (contrast-associated), neuralgia, paralysis, seizure, sciatica, syncope",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F183905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to iopamidol or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intrathecal iopamidol: Use is contraindicated with concurrent intrathecal corticosteroid administration; significant bacterial infection",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7914489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Allergic reactions: Use extreme caution with history of previous reaction to contrast dye, iodine-based contrast media, or patients with a known clinical hypersensitivity (eg, bronchial asthma, hay fever, or food allergies). Premedication with antihistamines or corticosteroids can be considered to reduce incidence and severity of reaction. Severe, potentially life-threatening reactions and delayed reactions may occur.  Monitor closely after injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Contrast-associated nephropathy:  Patients should be well hydrated before and after examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Seizures: Caution in patients with history of epilepsy; focal and generalized motor seizures have been reported when higher than recommended doses used; antiepileptic therapy should be continued. Prophylactic anticonvulsant therapy should be considered in patients requiring a concentrated solution or large bolus of contrast media. CNS-acting agents, primarily those which lower seizure threshold (eg, phenothiazines, MAO inhibitors, tricyclic antidepressants, CNS stimulants), should be discontinued 24-72 hours prior to intrathecal use and not resumed for 24 hours postprocedure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thromboembolism: Serious, rarely fatal, thromboembolic events causing myocardial infarction (MI) and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Ionic iodinated contrast media may inhibit blood coagulation. Use meticulous intravascular administration techniques during angiographic procedures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular disease: Use caution in severe cardiovascular disease and heart failure; transitory increase in circulatory osmotic load could occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Chronic alcoholism: Use caution in patients with alcoholism taking metformin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatorenal insufficiency: Use caution in hepatorenal insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperthyroidism: Reports of thyroid storm following administration of iodinated contrast media have been reported in patients with hyperthyroidism or with an autonomously functioning thyroid nodule.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Multiple myeloma: Use with caution in multiple myeloma; use of intravascular contrast agents may lead to renal dysfunction, especially with concurrent dehydration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pheochromocytoma: Use extreme caution in patients with pheochromocytoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal disease: Use caution in renal disease. May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in diabetics, elderly, advanced vascular disease, and those who are dehydrated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sickle cell disease: Use caution in homozygous sickle cell patients; administration of contrast media may result in disease exacerbation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Intrathecal administration: Inadvertent administration of iodinated contrast media that is not indicated for intrathecal use has resulted in serious adverse events. Precautions should be taken to ensure Isovue&reg; and Isovue Multipack&reg; are",
"     <b>",
"      not",
"     </b>",
"     administered intrathecally.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Contrast Media (Non-ionic) may enhance the potential for allergic or hypersensitivity reactions to Aldesleukin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Iodinated Contrast Agents may enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis.  Management: Withhold metformin from all patients receiving intravascular iodinated contrast agents prior to or at the time of the procedure and for at least 48 hrs thereafter.  Document adequate renal function before restarting metformin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F183900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F183907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fetal harm was not observed in animal studies. Diagnostic iodinated contrast agents have been shown to cross the placenta. There are no adequate or well-controlled studies in pregnant women. In general, iodinated contrast media agents are avoided during pregnancy unless essential for diagnosis.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F183911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7914488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A very small percentage of iodinated contrast medium is excreted into breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9836149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Isovue-200 Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     41% (50 mL): $50.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Isovue-250 Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     51% (100 mL): $92.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Isovue-300 Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     61% (100 mL): $105.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Isovue-370 Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     76% (100 mL): $117.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Isovue-M 200 Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     41% (10 mL): $73.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Isovue-M 300 Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     61% (15 mL): $98.14",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F183908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Iopamed (PE);",
"     </li>",
"     <li>",
"      Iopamiro (BG, CH, CL, EE, GR, HK, HN, IL, IT, NL, PL, PT, SE, SG, TR, TW);",
"     </li>",
"     <li>",
"      Iopamiron (AR, BR, CO, EC, FR, PY, UY, VE);",
"     </li>",
"     <li>",
"      Isovue (AU, NZ);",
"     </li>",
"     <li>",
"      Jopamiro (AT);",
"     </li>",
"     <li>",
"      Pamiray (DO, KP);",
"     </li>",
"     <li>",
"      Pamitra (PE);",
"     </li>",
"     <li>",
"      Radiomiron (CN);",
"     </li>",
"     <li>",
"      Radisense (PK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7914497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Opacification of vessels and anatomical structures in the path of flow of the contrast media which allows for radiographic visualization",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7914499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, elimination: 2 hours; prolonged in renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (80% to 90% unchanged)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee on Obstetric Practice, &ldquo;ACOG Committee Opinion. Guidelines for Diagnostic Imaging During Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2004, 104(3):647-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/45/36565/abstract-text/15339791/pubmed\" id=\"15339791\" target=\"_blank\">",
"        15339791",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Radiology, &ldquo;Manual on Contrast Media, Version 7.0&rdquo;, 2010. Available at file://gm.acr.org/SecondaryMainMenuCategories/quality_safety/contrast_manual.aspx",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Radiology, &ldquo;Practice Guideline for the Performance of Myelography and Cisternography,&rdquo; Available at  file://www.acr.org/SecondaryMainMenuCategories/quality_safety/guidelines/dx/head-neck/myelography.aspx",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jneid H, Anderson JL, Wright RS, et al, &ldquo;2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(7):875-910.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/45/36565/abstract-text/22800849/pubmed\" id=\"22800849\" target=\"_blank\">",
"        22800849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klein LW, Sheldon MW, Brinker J, et al, &ldquo;The Use of Radiographic Contrast Media During PCI: A Focused Review: A Position Statement of the Society of Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Catheter Cardiovasc Interv",
"      </i>",
"      , 2009, 74(4):728-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/45/36565/abstract-text/19830793/pubmed\" id=\"19830793\" target=\"_blank\">",
"        19830793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Laskey WK, Jenkins C, Selzer F, et al, &ldquo;Volume-to-Creatinine Clearance Ratio: A Pharmacokinetically Based Risk Factor for Prediction of Early Creatinine Increase After Percutaneous Coronary Intervention,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):584-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/45/36565/abstract-text/17692741/pubmed\" id=\"17692741\" target=\"_blank\">",
"        17692741",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/45/36565/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8932 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-85.214.214.87-D5DBC4741A-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_45_36565=[""].join("\n");
var outline_f35_45_36565=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183910\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183913\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914544\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7976883\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914545\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962264\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962265\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183902\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183898\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914546\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13791579\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183903\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174549\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914491\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183905\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914489\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299531\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221095\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183900\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183907\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183911\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914488\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9836149\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323205\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183908\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914497\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914499\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8932\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8932|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?2/33/2580?source=related_link\">",
"      Iopamidol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_45_36566="Apical 4 chamber echo endocarditis tricuspid valve";
var content_f35_45_36566=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Apical 4 chamber echocardiogram showing tricuspid valve infective endocarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 276px; height: 509px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The apical four chamber view (panel A) shows irregular masses, which are bulky vegetations (veg) due to endocarditis, attached to the tricuspid leaflets and prolapsing into an enlarged right atrium (RA) which bulges (via the interatrial septum, arrow) into the left atrium (LA). The enlarged right sided chambers makes the presence of severe tricuspid insufficiency highly likely. The M-mode of a vegetation of the septal leaflet of the tricuspid valve is seen in panel B; the mass has a large excursion because it is highly mobile, large, and prolapses into the right atrium. The phonocardiogram (PCG) shows a diastolic (DM) and systolic murmur (SM) which are variable due to the mobility of the vegetations.",
"    <div class=\"footnotes\">",
"     RV: right ventricle; LV: left ventricle; MV: mitral valve.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_45_36566=[""].join("\n");
var outline_f35_45_36566=null;
var title_f35_45_36567="Management of myasthenia gravis in pregnancy";
var content_f35_45_36567=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of myasthenia gravis in pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/45/36567/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/45/36567/contributors\">",
"     Shawn J Bird, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/45/36567/contributors\">",
"     Irene P Stafford, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/45/36567/contributors\">",
"     Gary A Dildy, III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/45/36567/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/45/36567/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/45/36567/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/45/36567/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/45/36567/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/45/36567/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/45/36567/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myasthenia gravis (MG) is an autoimmune disorder characterized by a fluctuating degree and variable combination of weakness in ocular, bulbar, limb, and respiratory muscles. It results from abnormal T cell regulation and the production of autoantibodies directed against nicotinic acetylcholine receptors on the neuromuscular end plate of skeletal muscle. Affected patients (most often young women and older men) usually present with fatigable weakness after repetitive muscle use.",
"   </p>",
"   <p>",
"    This topic will discuss the effect of pregnancy on MG and management of MG in pregnancy. It will also briefly review clinical and treatment issues related to MG that are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17206?source=see_link\">",
"     \"Clinical manifestations of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32968?source=see_link\">",
"     \"Diagnosis of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7066?source=see_link\">",
"     \"Treatment of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL ASPECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two clinical forms of myasthenia: ocular and generalized. In ocular myasthenia gravis (OMG), the weakness is limited to the eyelids and extraocular muscles. In generalized disease, the weakness may also commonly affect ocular muscles, but it also involves a variable combination of bulbar, limb, and respiratory muscles.",
"   </p>",
"   <p>",
"    Patients who have detectable antibodies to the acetylcholine receptor (AChR) are called seropositive (SPMG) and those without are called seronegative (SNMG). About half of patients with purely OMG are seropositive, compared with nearly four-fifths of those with generalized disease. An important consideration is that about 10 to 15 percent of those with MG have an underlying thymoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;MG is a relatively uncommon disorder. It occurs at any age, but there tends to be a bimodal distribution to the age of onset with an early peak in the second and third decades (female predominance) and a late peak in the sixth to eighth decade (male predominance). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17206?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations of myasthenia gravis\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardinal feature of MG is fluctuating skeletal muscle weakness, often with true muscle fatigue. The fatigue is manifest by worsening contractile force of the muscle, not a sensation of tiredness. The weakness may fluctuate throughout the day, but it is most commonly worse later in the day or evening, or after exercise.",
"   </p>",
"   <p>",
"    More than 50 percent of patients present with ocular symptoms of ptosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diplopia. Muscles of jaw closure are often involved and produce weakness with prolonged chewing. Oropharyngeal muscle weakness produces dysarthria and dysphagia. Facial muscle weakness may make the patient appear expressionless. With neck muscle weakness, the weight of the head may overcome the extensors, producing a \"dropped head syndrome.\" Involvement of the limbs produces predominantly proximal weakness similar to other muscle diseases. Predominantly distal presentations of otherwise typical myasthenia can occur. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17206?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations of myasthenia gravis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Involvement of the muscles of respiration produces the most serious symptoms in MG, such as respiratory insufficiency and pending respiratory failure, termed myasthenic crisis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/10/6311?source=see_link\">",
"     \"Myasthenic crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic approach to myasthenia is focused on confirming the clinical diagnosis established by the history and typical examination findings. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17206?source=see_link\">",
"     \"Clinical manifestations of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32968?source=see_link\">",
"     \"Diagnosis of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bedside tests (the Tensilon test and the ice pack test) are sensitive and easy to perform, but have major limitations due to concerns about excess false-positive results. Confirmation of the diagnosis by these tests alone is unwise. More reliable laboratory methods that aid in the confirmation are serologic tests for autoantibodies and electrophysiologic studies (repetitive nerve stimulation studies and single-fiber EMG). The diagnostic sensitivity of these studies also varies considerably depending on whether the patient has ocular or generalized disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32968?source=see_link\">",
"     \"Diagnosis of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EFFECT OF PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy has a variable effect on the course of myasthenia gravis (MG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In one review of 322 pregnancies in 225 myasthenic patients, exacerbation, remission, and no change in disease occurred in 41, 29, and 30 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/1\">",
"     1",
"    </a>",
"    ]. Additionally, postpartum exacerbations were noted in 30 percent of all patients. These findings have been confirmed by other, smaller studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/3-7\">",
"     3-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first trimester and the acute postpartum period are times of highest risk for exacerbation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/8\">",
"     8",
"    </a>",
"    ]. Mortality risk is inversely proportionate to the duration of disease, with the highest risk being within the first year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/4\">",
"     4",
"    </a>",
"    ]. Myasthenic flare may occur after therapeutic abortion secondary to the stress of surgery, but it usually remits following spontaneous abortion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MANAGEMENT DURING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following general principles apply to the management of women with myasthenia gravis (MG) during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the normal physiologic changes associated with pregnancy may affect the course of MG, the treatment of MG in pregnancy is similar to that in patients who are not pregnant. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7066?source=see_link\">",
"       \"Treatment of myasthenia gravis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Initial evaluation of the pregnant patient with MG includes assessment of baseline motor strength, respiratory status, and pulmonary function tests. Cardiac status should be followed with ECGs, since rare occurrences of focal myocardial necrosis have been recorded in patients with MG [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. Thyroid function tests should be performed, since there is an association between MG and other autoimmune diseases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      All infections should be treated promptly. In one study of 65 pregnant women with MG, four women who had underlying infection (pyelonephritis, endometritis, or mastitis) all developed MG exacerbations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Complaints of dyspnea or cough call for prompt evaluation of possible myasthenic flare with diaphragm and respiratory muscle weakness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Physical and emotional stress can exacerbate MG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acetylcholinesterase inhibitors such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    are the standard first-line treatment for MG. Dose adjustment may be required in pregnancy as a result of increased renal clearance, expanded maternal blood volume, delayed gastric emptying, and frequent emesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/12\">",
"     12",
"    </a>",
"    ]. Increasing the dose of pyridostigmine should first be accomplished by decreasing the interval of administration, followed by increasing the dose if symptoms persist. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7066?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of myasthenia gravis\", section on 'Symptomatic treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    may be used if anticholinesterases fail to control MG exacerbations. These medications have been well studied in pregnancy, mainly in transplant recipients and patients with autoimmune diseases other than MG, and have been found to be relatively safe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. However, high doses of cyclosporine and azathioprine have been linked to spontaneous abortion, preterm labor, low birth weight, chromosomal damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/2,13,14\">",
"     2,13,14",
"    </a>",
"    ], and hematologic suppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/2,13-15\">",
"     2,13-15",
"    </a>",
"    ]. The risk of continuing these medications in high doses should be weighed against the benefit of controlling myasthenic symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/17/11546?source=see_link\">",
"     \"Chronic immunomodulating therapies for myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of glucocorticoids to treat MG, including dosing and tapering schedules, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/17/11546?source=see_link&amp;anchor=H3#H3\">",
"     \"Chronic immunomodulating therapies for myasthenia gravis\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Caution should be exercised when initiating therapy with glucocorticoids, since a transient worsening of MG may occur. Glucocorticoids may also produce carbohydrate intolerance, especially during pregnancy. Even though there are no teratogenic effects from glucocorticoids, pregnant patients with MG who rely on these medications should be maintained on the lowest possible dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/2,9\">",
"     2,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plasmapheresis and high-dose intravenous immune globulin have been used for myasthenic crisis with variable results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/2,4,8,9,16\">",
"     2,4,8,9,16",
"    </a>",
"    ]. These interventions should be reserved for cases where conventional therapy has failed and developing respiratory failure or profound dysphagia and weakness threatens the mother and fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/5,17\">",
"     5,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/10/6311?source=see_link&amp;anchor=H7#H7\">",
"     \"Myasthenic crisis\", section on 'Rapid therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     Magnesium sulfate",
"    </a>",
"    is commonly administered in contemporary obstetrics for management of",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia",
"    </span>",
"    and preterm labor but is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in patients who have MG since it can precipitate a severe myasthenic crisis (",
"    <a class=\"graphic graphic_table graphicRef62302 \" href=\"mobipreview.htm?11/61/12254\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Severe hypertension can be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    , while beta blockers and calcium channel blockers should be avoided if possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/52/43847?source=see_link\">",
"     Levetiracetam",
"    </a>",
"    or valproic acid can be used for seizure prophylaxis, whereas",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    can potentially exacerbate weakness and is therefore reserved for refractory seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/10,12\">",
"     10,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A list of medications that may exacerbate weakness in the myasthenic patient are found in the table (",
"    <a class=\"graphic graphic_table graphicRef62302 \" href=\"mobipreview.htm?11/61/12254\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The patient with preeclampsia and myasthenia on high-dose glucocorticoids is at high risk for pulmonary edema and should be monitored closely. In addition, decreased urine output is often found in patients with preeclampsia and may require dosage modifications in order to avoid toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Fetal assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of fetal abnormalities related to transplacental passage of IgG anti-acetylcholine receptor (AChR) antibodies is a major concern during pregnancy in mothers with MG. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/10/166?source=see_link&amp;anchor=H2#H2\">",
"     \"Neuromuscular junction disorders in newborns and infants\", section on 'Neonatal myasthenia gravis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Assessment of fetal well being may include the oxytocin challenge test, since a nonstress test is often inconclusive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/10\">",
"     10",
"    </a>",
"    ]. The perception of fetal movement may be altered in patients with MG. Continuous fetal monitoring is indicated during a myasthenic crisis if the fetus is at a viable gestational age (eg, at least 24 menstrual weeks of gestation) given the high risk of maternal and fetal hypoxia.",
"   </p>",
"   <p>",
"    Abnormal sonographic findings in affected pregnancies may include polyhydramnios due to impaired fetal swallowing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Decreased fetal movement and breathing have also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fetal arthrogryposis multiplex congenita is the most severe finding in the fetus with neonatal MG; lack of generalized fetal movement and diaphragmatic excursion may rarely produce joint contractures and pulmonary hypoplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/20,22\">",
"     20,22",
"    </a>",
"    ]. Several studies describe a direct relationship between high maternal titers of AChR antibodies and fetal arthrogryposis multiplex congenital [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/20,22\">",
"     20,22",
"    </a>",
"    ]. Whereas ultrasound may be able to detect these abnormalities during the antepartum period, efficacy on clinical outcome is not well defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LABOR AND DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first stage of labor is not affected by MG because the uterus is composed of smooth muscle and lacks the post-synaptic acetylcholine receptor. In contrast, the second stage of labor may be affected because the voluntary striated muscles used during expulsive efforts may easily weaken. Excessive maternal fatigue may result. Appropriate steps should be taken to circumvent the effects of maternal fatigue on delivery, since stress and exertion can precipitate a myasthenic crisis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/11\">",
"     11",
"    </a>",
"    ]. Operative vaginal delivery may reduce maternal fatigue and weakness.",
"   </p>",
"   <p>",
"    Consultation with an anesthesiologist before labor is recommended, since patients with myasthenia who undergo general anesthesia may be at increased risk for requiring mechanical ventilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Selection of anesthetic technique is dependent on several factors. Regional anesthesia is recommended for mild to moderate disease when vaginal delivery is anticipated, allowing for adequate anesthesia if vacuum or forceps are needed. General endotracheal anesthesia is recommended for the patient with severe disease and compromised respiratory or bulbar status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Non-depolarizing muscle relaxants should be avoided (",
"    <a class=\"graphic graphic_table graphicRef62302 \" href=\"mobipreview.htm?11/61/12254\">",
"     table 1",
"    </a>",
"    ), since patients with MG have altered acetylcholinesterase activity. Due to the relative resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    , larger doses are often required leading to a prolonged block [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients with MG are more sensitive to inhaled anesthetics including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/47/34548?source=see_link\">",
"     enflurane",
"    </a>",
"    , halothane, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/63/17397?source=see_link\">",
"     isoflurane",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sedatives, opioids, and tranquilizers can potentiate respiratory depression in this population and should be administered judiciously. When using opioids or other sedatives for pain control, pulse oximetry and frequent assessment of respiratory rate is recommended. Nonsteroidal anti-inflammatory medications such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    &nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/29/43475?source=see_link\">",
"     tromethamine",
"    </a>",
"    may also be used for postpartum or postoperative pain.",
"   </p>",
"   <p>",
"    During labor, anticholinesterase medications should be administered parenterally to avoid erratic gastrointestinal absorption. The parenteral dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    is equivalent to one-thirtieth of the patient's oral dose.",
"   </p>",
"   <p>",
"    The maternal respiratory status (respiratory rate, pulse oximetry) should be monitored carefully because stress and fatigue associated with labor and delivery may precipitate worsening of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women with MG have an increased incidence of preterm labor and delivery in some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/25,26\">",
"     25,26",
"    </a>",
"    ], although this is not confirmed by other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estimates of perinatal mortality rates for infants born of women with MG vary widely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/1,25\">",
"     1,25",
"    </a>",
"    ]. In a retrospective population study, perinatal mortality was not significantly higher among 127 births by Norwegian women with MG compared with those of a reference group without MG (2.4 versus 1.4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/25\">",
"     25",
"    </a>",
"    ]. However, mothers with MG had a significantly higher risk of delivery complications than the reference group (41 versus 33 percent); the most common complication was premature rupture of membranes. Cesarean deliveries were also performed more frequently in mothers with MG (17 versus 9 percent of deliveries); half were elective. In contrast, a population based study from Taiwan found no significant differences between pregnant women with MG and controls for the risk of delivery complicated by low birth weight, small for gestational age, or cesarean delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An earlier study found that the death rate due to fetal anomalies was higher in the myasthenic population compared with the normal population (18 versus 2.2 per 1000 live births) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids can be used safely in lactation, but breastfeeding is not recommended for patients with myasthenia taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . Small doses of these medications and their metabolites have been isolated from the breast milk of patients taking these agents. Further studies examining the effects of these medications on the newborn are needed before further recommendations can be made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/28\">",
"     28",
"    </a>",
"    ]. Anticholinesterase drugs are found in breast milk in low levels and are therefore considered safe in lactation unless high dosages are required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     EFFECT ON THE FETUS AND NEONATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient neonatal MG develops in 10 to 20 percent of infants born to myasthenic mothers due to transplacental passage of IgG anti-acetylcholine receptor antibodies. Though definitive data are lacking, a small retrospective study found no correlation between neonatal MG and the maternal IgG anti-acetylcholine receptor titer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, a small prospective study found that the duration of maternal disease and medication usage for MG were not associated with the occurrence of neonatal MG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms of respiratory distress, poor feeding, and flaccid tone usually appear within 48 hours of birth and may persist for up to three months. Thus, all infants of myasthenic mothers should be observed in a special care nursery for the first 48 to 72 hours of life.",
"   </p>",
"   <p>",
"    Among mothers with a child affected by transient neonatal MG, the risk of recurrence with subsequent pregnancies is approximately 75 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/10/166?source=see_link&amp;anchor=H2#H2\">",
"     \"Neuromuscular junction disorders in newborns and infants\", section on 'Neonatal myasthenia gravis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retrospective analysis of data from the Medical Birth Registry of Norway found that neonates of mothers with MG who had undergone thymectomy were less likely to develop neonatal MG than those born to mothers without thymectomy",
"    <span class=\"nowrap\">",
"     (9/72",
"    </span>",
"    [13 percent] versus",
"    <span class=\"nowrap\">",
"     17/63",
"    </span>",
"    [27 percent], relative risk 0.4, 95% CI 0.16-0.94) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/31\">",
"     31",
"    </a>",
"    ]. These results suggest that thymectomy has a protective effect against neonatal MG. However, the strength of this study is limited by the retrospective design, lack of randomization and blinding, and wide confidence intervals.",
"   </p>",
"   <p>",
"    It is important to note that the beneficial effects thymectomy are delayed for all patients and may take years to accrue. The one-year remission rate of myasthenia after thymectomy is &lt;20 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/59/41910?source=see_link&amp;anchor=H3#H3\">",
"     \"Thymectomy for myasthenia gravis\", section on 'Efficacy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, thymectomy in the year prior to conception is unlikely to result in clinical remission of myasthenia in the mother before pregnancy, and its impact on the risk of neonatal MG is undetermined. In the study discussed above, 25 of the 41 thymectomized mothers had undergone thymectomy an average of five years before the first birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36567/abstract/31\">",
"     31",
"    </a>",
"    ], allowing more time for the benefit of thymectomy to accumulate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/14/14562?source=see_link\">",
"       \"Patient information: Myasthenia gravis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cardinal feature of myasthenia gravis (MG) is fluctuating skeletal muscle weakness, often with true muscle fatigue. The diagnostic approach to myasthenia is focused on confirming the clinical diagnosis established by the history and typical examination findings. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17206?source=see_link\">",
"       \"Clinical manifestations of myasthenia gravis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32968?source=see_link\">",
"       \"Diagnosis of myasthenia gravis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pregnancy has a variable effect on the course of MG. The first trimester and the acute postpartum period are times of highest risk for exacerbation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Effect of pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anticholinesterase agents such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/55/27509?source=see_link\">",
"       pyridostigmine",
"      </a>",
"      are the standard first-line treatment for MG. Dose adjustment may be required in pregnancy. Glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      may be used if anticholinesterases fail to control MG exacerbations. These medications are relatively safe in pregnancy, but high doses of cyclosporine and azathioprine have been linked to serious adverse events. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment issues'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7066?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of myasthenia gravis\", section on 'Symptomatic treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link\">",
"       \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Plasmapheresis and high-dose intravenous immune globulin are reserved for cases where conventional therapy of MG has failed and developing respiratory failure or profound dysphagia and weakness threatens the mother and fetus. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment issues'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/10/6311?source=see_link\">",
"       \"Myasthenic crisis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"       Magnesium sulfate",
"      </a>",
"      is contraindicated in patients who have MG, since it can precipitate a severe myasthenic crisis (",
"      <a class=\"graphic graphic_table graphicRef62302 \" href=\"mobipreview.htm?11/61/12254\">",
"       table 1",
"      </a>",
"      ). Severe hypertension can be treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/15/28918?source=see_link\">",
"       methyldopa",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      , while beta blockers and calcium channel blockers should be avoided if possible.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/52/43847?source=see_link\">",
"       Levetiracetam",
"      </a>",
"      or valproic acid can be used for seizure prophylaxis, whereas",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      can potentially exacerbate weakness and is therefore reserved for refractory seizures. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment issues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The second stage of labor may be affected in patients with MG because the voluntary striated muscles used during expulsive efforts may easily weaken. Appropriate steps should be taken to circumvent the effects of maternal fatigue on delivery since stress and exertion can precipitate a myasthenic crisis. Non-depolarizing muscle relaxants should be avoided. During labor, anticholinesterase medications should be administered parenterally to avoid erratic gastrointestinal absorption. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Labor and delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , and other immunosuppressive agents can cause immunosuppression in the infant and are therefore contraindicated in breastfeeding mothers. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Breastfeeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All infants of myasthenic mothers should be observed in a special care nursery for the first 48 to 72 hours of life, as transient neonatal MG develops in 10 to 20 percent of infants born to myasthenic mothers. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Effect on the fetus and neonate'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/10/166?source=see_link&amp;anchor=H2#H2\">",
"       \"Neuromuscular junction disorders in newborns and infants\", section on 'Neonatal myasthenia gravis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/1\">",
"      Plauch&eacute; WC. Myasthenia gravis in mothers and their newborns. Clin Obstet Gynecol 1991; 34:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/2\">",
"      Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/3\">",
"      Batocchi AP, Majolini L, Evoli A, et al. Course and treatment of myasthenia gravis during pregnancy. Neurology 1999; 52:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/4\">",
"      Djelmis J, Sostarko M, Mayer D, Ivanisevic M. Myasthenia gravis in pregnancy: report on 69 cases. Eur J Obstet Gynecol Reprod Biol 2002; 104:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/5\">",
"      Mitchell PJ, Bebbington M. Myasthenia gravis in pregnancy. Obstet Gynecol 1992; 80:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/6\">",
"      Floyd RC, Roberts WE. Autoimmune diseases in pregnancy. Obstet Gynecol Clin North Am 1992; 19:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/7\">",
"      T&eacute;llez-Zenteno JF, Hern&aacute;ndez-Ronquillo L, Salinas V, et al. Myasthenia gravis and pregnancy: clinical implications and neonatal outcome. BMC Musculoskelet Disord 2004; 5:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/8\">",
"      Ciafaloni E, Massey JM. The management of myasthenia gravis in pregnancy. Semin Neurol 2004; 24:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/9\">",
"      Lu CH, Liou CM, Chen YS, et al. Anesthetic management in myasthenic parturient. Ma Zui Xue Za Zhi 1992; 30:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/10\">",
"      Burke ME. Myasthenia gravis and pregnancy. J Perinat Neonatal Nurs 1993; 7:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/11\">",
"      Uncu G, K&uuml;&ccedil;&uuml;kerdogan I, Ozan H, Cengiz C. Pregnancy and myasthenia gravis. A case report. Clin Exp Obstet Gynecol 1995; 22:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/12\">",
"      Stafford IP, Dildy GA. Myasthenia gravis and pregnancy. Clin Obstet Gynecol 2005; 48:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/13\">",
"      Ramsey-Goldman R, Schilling E. Immunosuppressive drug use during pregnancy. Rheum Dis Clin North Am 1997; 23:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/14\">",
"      Haugen G, Fauchald P, S&oslash;dal G, et al. Pregnancy outcome in renal allograft recipients in Norway. The importance of immunosuppressive drug regimen and health status before pregnancy. Acta Obstet Gynecol Scand 1994; 73:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/15\">",
"      Alstead EM, Ritchie JK, Lennard-Jones JE, et al. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology 1990; 99:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/16\">",
"      Watson WJ, Katz VL, Bowes WA Jr. Plasmapheresis during pregnancy. Obstet Gynecol 1990; 76:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/17\">",
"      Gracey DR, Howard FM Jr, Divertie MB. Plasmapheresis in the treatment of ventilator-dependent myasthenia gravis patients. Report of four cases. Chest 1984; 85:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/18\">",
"      Benshushan A, Rojansky N, Weinstein D. Myasthenia gravis and preeclampsia. Isr J Med Sci 1994; 30:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/19\">",
"      Piura B. The association of preeclampsia and myasthenia gravis: double trouble. Isr J Med Sci 1994; 30:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/20\">",
"      Verspyck E, Mandelbrot L, Dommergues M, et al. Myasthenia gravis with polyhydramnios in the fetus of an asymptomatic mother. Prenat Diagn 1993; 13:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/21\">",
"      Morel E, Bach JF, Briard ML, Aubry JP. Neonatal myasthenia gravis. Anti-acetylcholine receptor antibodies in the amniotic fluid. J Neuroimmunol 1984; 6:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/22\">",
"      Carr SR, Gilchrist JM, Abuelo DN, Clark D. Treatment of antenatal myasthenia gravis. Obstet Gynecol 1991; 78:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/23\">",
"      Leventhal SR, Orkin FK, Hirsh RA. Prediction of the need for postoperative mechanical ventilation in myasthenia gravis. Anesthesiology 1980; 53:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/24\">",
"      Naguib M, el Dawlatly AA, Ashour M, Bamgboye EA. Multivariate determinants of the need for postoperative ventilation in myasthenia gravis. Can J Anaesth 1996; 43:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/25\">",
"      Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis: consequences for pregnancy, delivery, and the newborn. Neurology 2003; 61:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/26\">",
"      Giwa-Osagie OF, Newton JR, Larcher V. Obstetric performance of patients with my asthenia gravis. Int J Gynaecol Obstet 1981; 19:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/27\">",
"      Wen JC, Liu TC, Chen YH, et al. No increased risk of adverse pregnancy outcomes for women with myasthenia gravis: a nationwide population-based study. Eur J Neurol 2009; 16:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/28\">",
"      Ciafaloni E, Massey JM. Myasthenia gravis and pregnancy. Neurol Clin 2004; 22:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/29\">",
"      Cheng I, Lin CH, Lin MI, et al. Outcome of myasthenia gravis mothers and their infants. Acta Paediatr Taiwan 2007; 48:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/30\">",
"      Gveric-Ahmetasevic S, Coli A, Elvedji-Gasparovi V, et al. Can neonatal myasthenia gravis be predicted? J Perinat Med 2008; 36:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36567/abstract/31\">",
"      Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care. Eur J Neurol 2007; 14:38.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5132 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-84581B2B62-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_45_36567=[""].join("\n");
var outline_f35_45_36567=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL ASPECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EFFECT OF PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MANAGEMENT DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Fetal assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LABOR AND DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      EFFECT ON THE FETUS AND NEONATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5132\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5132|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/61/12254\" title=\"table 1\">",
"      Drugs that may worsen MG",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/17/11546?source=related_link\">",
"      Chronic immunomodulating therapies for myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17206?source=related_link\">",
"      Clinical manifestations of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32968?source=related_link\">",
"      Diagnosis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/10/6311?source=related_link\">",
"      Myasthenic crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/10/166?source=related_link\">",
"      Neuromuscular junction disorders in newborns and infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/14/14562?source=related_link\">",
"      Patient information: Myasthenia gravis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/59/41910?source=related_link\">",
"      Thymectomy for myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7066?source=related_link\">",
"      Treatment of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_45_36568="Superficial basal cell carcinoma";
var content_f35_45_36568=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57990%7EDERM%2F65704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57990%7EDERM%2F65704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superficial basal cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This erythematous, slightly scaly patch is representative of a superficial basal cell carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular basal cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This pearly papule with telangiectasias is representative of a nodular basal cell carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_45_36568=[""].join("\n");
var outline_f35_45_36568=null;
var title_f35_45_36569="Deep neck space infections";
var content_f35_45_36569=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Deep neck space infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/45/36569/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/45/36569/contributors\">",
"     Anthony W Chow, MD, FRCPC, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/45/36569/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/45/36569/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/45/36569/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/45/36569/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/45/36569/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep neck space infections most commonly arise from a septic focus of the mandibular teeth, tonsils, parotid gland, deep cervical lymph nodes, middle ear, or sinuses. These deep cervical space infections have become relatively uncommon in the postantibiotic era. Consequently, many clinicians are unfamiliar with these conditions. In addition, with widespread use of antibiotics",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    profound immunosuppression, the classic manifestations of these infections, such as high fever, systemic toxicity, and local signs of erythema, edema, and fluctuance, may be absent.",
"   </p>",
"   <p>",
"    Deep neck space infections often have a rapid onset and can progress to life-threatening complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, clinicians must be aware of such infections and should not underestimate their potential extent or severity.",
"   </p>",
"   <p>",
"    The relevant anatomy, microbial etiology, clinical manifestations, diagnosis, and treatment of deep neck space infections will be reviewed here. Peritonsillar abscesses and submandibular space infections (Ludwig's angina), suppurative parotitis, and odontogenic, middle ear, and sinus infections are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/61/31705?source=see_link\">",
"     \"Peritonsillar cellulitis and abscess\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35622?source=see_link\">",
"     \"Submandibular space infections (Ludwig's angina)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22758?source=see_link\">",
"     \"Suppurative parotitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16873?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29642?source=see_link\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/62/39913?source=see_link\">",
"     \"Acute otitis media in adults (suppurative and serous)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/48/39688?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/15/2297?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge of the cervical compartments and interfascial spaces is essential for understanding the pathogenesis, clinical manifestations, and potential routes of spread of infections involving these spaces.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cervical fascia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscles, vessels, and visceral structures of the neck are enveloped by the cervical fascia, which has a superficial and deep component (",
"    <a class=\"graphic graphic_figure graphicRef61704 \" href=\"mobipreview.htm?31/24/32137\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef74998 \" href=\"mobipreview.htm?11/33/11797\">",
"     figure 2",
"    </a>",
"    ). The superficial cervical fascia consists of the subcutaneous tissues of the neck, which completely enclose the head and neck and is continuous with the platysma anteriorly.",
"   </p>",
"   <p>",
"    The deep cervical fascia has three layers: superficial, middle, and deep, which can be thought of as defining a series of cylindrical compartments that extend longitudinally from the base of the skull to the mediastinum (",
"    <a class=\"graphic graphic_figure graphicRef61704 \" href=\"mobipreview.htm?31/24/32137\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The superficial or investing layer of the deep cervical fascia encloses all of the deeper parts of the neck, beginning at the nuchal line and extending anteriorly, dividing to enclose the trapezius, sternocleidomastoid, and strap muscles as well as the submaxillary and parotid glands.",
"     </li>",
"     <li>",
"      The middle or pretracheal fascia encloses the cervical viscera including the pharynx, esophagus, larynx, trachea, thyroid, and parathyroid glands.",
"     </li>",
"     <li>",
"      The deep or prevertebral fascia arises from the nuchal ligament and encloses the vertebral column and muscles of the spine. The prevertebral fascia originates posteriorly on the spinous processes and encircles the splenius, erector spinae, and semispinalis muscles (",
"      <a class=\"graphic graphic_figure graphicRef61704 \" href=\"mobipreview.htm?31/24/32137\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef74998 \" href=\"mobipreview.htm?11/33/11797\">",
"       figure 2",
"      </a>",
"      ). Prior to completing its circle anterior to the vertebral bodies, it fuses to the transverse processes. At this point, it is split into two layers: the alar fascia anteriorly and the prevertebral fascia posteriorly. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All three layers of the deep cervical fascia contribute to the carotid sheath, which forms a neurovascular compartment that encloses the carotid artery, the internal jugular vein, and the vagus nerve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fascial spaces",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three spaces between the planes of the deep cervical fascia that are of major clinical importance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The submandibular space",
"     </li>",
"     <li>",
"      The parapharyngeal space",
"     </li>",
"     <li>",
"      The retropharyngeal space",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other spaces arising from the cervical fascia with potential for deep neck infections include: the &ldquo;danger&rdquo; space, the prevertebral space, the peritonsillar space, and the parotid space. The masticator space, which lies lateral and anterior to the parapharyngeal space and consists of the masseteric, pterygoid, and temporal spaces, is described in detail elsewhere; infection of the masticator space arises most frequently from molar teeth, particularly the third molars (wisdom teeth). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/53/20313?source=see_link\">",
"     \"Complications, diagnosis, and treatment of odontogenic infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Submandibular space",
"    </span>",
"    &nbsp;&mdash;&nbsp;The submandibular space lies within the submental and submandibular triangles between the mucosa of the floor of the mouth and the superficial layer of the deep cervical fascia. It is subdivided by the mylohyoid muscle into the sublingual space (which contains the sublingual gland, hypoglossal nerve, part of the submandibular gland, and loose connective tissue), and the submylohyoid space (also known as the submaxillary space, which contains the submandibular salivary gland and lymph nodes) (",
"    <a class=\"graphic graphic_figure graphicRef81946 \" href=\"mobipreview.htm?4/57/5012\">",
"     figure 3",
"    </a>",
"    ). The two divisions communicate posteriorly around the mylohyoid muscle. It is this space that is primarily involved in Ludwig&rsquo;s angina. Infection within the sublingual space results in gross swelling of the tongue that can result in acute airway obstruction. Infection of the submylohyoid space may spread posteriorly along the styloglossus muscle into the parapharyngeal space and continue to spread into the loose areolar tissue of the retropharyngeal space, and then further inferiorly into the superior mediastinum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Parapharyngeal space",
"    </span>",
"    &nbsp;&mdash;&nbsp;Also known as the lateral",
"    <strong>",
"    </strong>",
"    pharyngeal or pharyngomaxillary space, the parapharyngeal space is located in the lateral aspect of the neck and is shaped like an inverted cone, with its base at the skull and its apex at the hyoid bone (",
"    <a class=\"graphic graphic_figure graphicRef79036 \" href=\"mobipreview.htm?0/49/792\">",
"     figure 4",
"    </a>",
"    ). It lies deep to the pharyngeal constrictor muscle, and is contiguous medially with the pretracheal fascia of the visceral compartment, and laterally with the superficial fascia (which invests the parotid gland), the internal pterygoid muscle, and the mandible.",
"   </p>",
"   <p>",
"    The parapharyngeal space is divided into an anterior (prestyloid or muscular) compartment and a posterior (retrostyloid or neurovascular) compartment by the styloid process and its attached muscles, the stylomandibular ligament, and the insertion of these structures into the hyoid bone (",
"    <a class=\"graphic graphic_figure graphicRef79036 \" href=\"mobipreview.htm?0/49/792\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The anterior compartment contains no vital structures but rather only fat, lymph nodes, connective tissue, and muscle. It is the compartment most closely related to the tonsillar fossa and the internal pterygoid muscle. The posterior compartment contains the ninth to twelfth cranial nerves superiorly and the tenth cranial nerve more inferiorly, the carotid sheath and its contents, and the cervical sympathetic trunk. The carotid sheath, which runs in the posterior aspect of the parapharyngeal space, pierces the cone at its apex to enter the mediastinum (",
"    <a class=\"graphic graphic_figure graphicRef79036 \" href=\"mobipreview.htm?0/49/792\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Infection of the lateral pharyngeal space may result from pharyngitis, tonsillitis, parotitis, otitis, or mastoiditis, as well as odontogenic infections, especially if the masticator space is involved. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/53/20313?source=see_link\">",
"     \"Complications, diagnosis, and treatment of odontogenic infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Retropharyngeal space",
"    </span>",
"    &nbsp;&mdash;&nbsp;The retropharyngeal space is bound anteriorly by the constrictor muscles of the neck and posteriorly by the alar layer of the deep cervical fascia. It is situated behind the hypopharynx and the esophagus, and lies between the alar fascia posteriorly and the posterior aspect of the pretracheal fascia anteriorly (",
"    <a class=\"graphic graphic_figure graphicRef61704 \" href=\"mobipreview.htm?31/24/32137\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef74998 \" href=\"mobipreview.htm?11/33/11797\">",
"     figure 2",
"    </a>",
"    ). It communicates with the parapharyngeal space laterally where the carotid sheaths reside.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H988692066\">",
"    <span class=\"h3\">",
"     Danger space",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posterior to the retropharyngeal space is the danger space, which is bound by the alar fascia anteriorly and the prevertebral fascia posteriorly (",
"    <a class=\"graphic graphic_figure graphicRef61704 \" href=\"mobipreview.htm?31/24/32137\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef74998 \" href=\"mobipreview.htm?11/33/11797\">",
"     figure 2",
"    </a>",
"    ). It extends from the base of the skull and descends freely through the entire posterior mediastinum to the level of the diaphragm (T1 to T2) where the two fascial layers fuse. Thus, the danger space provides the most important anatomic route for contiguous spread between the neck and the chest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H988692074\">",
"    <span class=\"h3\">",
"     Prevertebral space",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevertebral space is bound by the prevertebral fascia, which originates posteriorly on the spinous processes and encircles the splenius, erector spinae, and semispinalis muscles (",
"    <a class=\"graphic graphic_figure graphicRef61704 \" href=\"mobipreview.htm?31/24/32137\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef74998 \" href=\"mobipreview.htm?11/33/11797\">",
"     figure 2",
"    </a>",
"    ). Prior to completing its circle anterior to the vertebral bodies, it fuses to the transverse processes. At this point, it is split into two layers: the alar fascia anteriorly and the prevertebral fascia posteriorly. The prevertebral space extends from the base of the skull to the coccyx, thus allowing organisms to spread as far down as the psoas muscle sheath.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H988692083\">",
"    <span class=\"h3\">",
"     Peritonsillar space",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peritonsillar space lies between the capsule of the palatine (faucial) tonsil medially, the superior constrictor muscle laterally, and the tonsillar pillars anteriorly and posteriorly (",
"    <a class=\"graphic graphic_figure graphicRef53388 \" href=\"mobipreview.htm?6/6/6244\">",
"     figure 5",
"    </a>",
"    ). A dreaded complication of a peritonsillar abscess (Quinsy) is to rupture through the superior constrictor muscle and extend directly into the parapharyngeal space, which lies posterior to the tonsillar bed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H988692090\">",
"    <span class=\"h3\">",
"     Parotid space",
"    </span>",
"    &nbsp;&mdash;&nbsp;The parotid space is formed by the splitting of the investing fascia at the level of the stylomandibular ligament to enclose the parotid gland within a superficial capsule and a deep capsule (",
"    <a class=\"graphic graphic_figure graphicRef65210 \" href=\"mobipreview.htm?12/14/12516\">",
"     figure 6",
"    </a>",
"    ). The superficial capsule is thick and strong, tightly adherent to the superficial pole of the parotid gland. The deep capsule adjacent to the dorsal lobe of the parotid gland, however, is thin and infection in the gland can easily penetrate through this capsule and extend through the stylomandibular tunnel into the parapharyngeal space. The stylomandibular ligament effectively separates the parotid space from the submylohyoid space.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lymph nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lymph nodes of the head and neck can be divided into 10 principal groups (",
"    <a class=\"graphic graphic_figure graphicRef69528 \" href=\"mobipreview.htm?18/53/19285\">",
"     figure 7",
"    </a>",
"    ). Six of these (occipital, mastoid, parotid, facial, submandibular, and submental nodes) form a collar at the junction of the head and neck. Within this collar, the sublingual and retropharyngeal nodes lie near the base of the tongue. The anterior and lateral cervical nodes form a chain along the front and side of the neck, respectively. The lateral cervical chain serves as a common root for drainage. The final conduit from all lymphatics in the head and neck is the large deep chain situated along the carotid sheath. When inflamed, these nodes become adherent to the fascial sheath of the vessels; thus, a suppurative infection of the cervical lymph nodes may frequently invade the bloodstream.",
"   </p>",
"   <p>",
"    In addition to the regional lymph nodes of the head and neck, both the nasopharynx and the oropharynx are richly endowed with mucosa-associated lymphoid tissues similar to the bronchus-associated lymphoid tissues and the gut-associated lymphoid tissues. In particular, the aggregation of lymphoid tissues surrounding the nasopharynx is known as Waldeyer's ring and comprises the palatine, lingual, adenoidal, and tonsillar lymphoid tissues. Acute inflammation involving these tissues, such as during acute tonsillopharyngitis, croup, otitis media, retropharyngeal abscess or Epstein-Barr virus (EBV) mononucleosis, may result in acute airway compromise and constitutes a medical emergency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Potential routes of spread",
"    </span>",
"    &nbsp;&mdash;&nbsp;The deep cervical fascial spaces are normally bound together by loose connective tissue and intercommunicate to varied degrees. The potential pathways of extension from one space to another are illustrated in the accompanying figure (",
"    <a class=\"graphic graphic_figure graphicRef64597 \" href=\"mobipreview.htm?10/0/10254\">",
"     figure 8",
"    </a>",
"    ). A thorough understanding of the potential anatomic routes of infection not only provides valuable information on the nature and extent of infection but also suggests the optimal surgical approach for effective drainage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep neck space infections are typically polymicrobial and represent the normal resident flora of the contiguous mucosal surfaces from which the infection originated. Due to the close anatomic relationships, the resident flora of the oral cavity, upper respiratory tract, and certain parts of the ears and eyes share many common organisms (",
"    <a class=\"graphic graphic_figure graphicRef56883 \" href=\"mobipreview.htm?10/33/10771\">",
"     figure 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/5\">",
"     5",
"    </a>",
"    ]. Although as many as 50 to 100 bacterial species may be present on the oral or nasopharyngeal mucosal surface, the typical deep neck space infection includes, on average, five or six bacterial types [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Anaerobes generally outnumber aerobes on all mucosal surfaces",
"    <strong>",
"    </strong>",
"    of the oral cavity",
"    <strong>",
"    </strong>",
"    by a factor of 10:1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common organism isolated from deep neck space infections is Streptococcus viridans, reflecting its abundance in the mouth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Most abscesses originating from the teeth also harbor oral anaerobes, including Peptostreptococcus species, Fusobacterium nucleatum, pigmented Prevotella species such as Prevotella melaninogenica (formerly Bacteroides melaninogenicus), and Actinomyces species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional organisms, such as Staphylococcus aureus and facultative gram-negative rods, including Pseudomonas aeruginosa and extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, may be present, particularly in patients with risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/13\">",
"     13",
"    </a>",
"    ]. Immunocompromised hosts (eg, patients with chemotherapy-induced neutropenia) are particularly likely to harbor such pathogens, but those with diabetes mellitus, postoperative infection, or trauma are also at increased risk.",
"   </p>",
"   <p>",
"    Klebsiella pneumoniae has been frequently isolated from deep neck space infections in Taiwan, particularly from diabetic patients. This species is a more common pathogen in various infections in Southeast Asia than in most other regions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/10,14,15\">",
"     10,14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38426?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infections arising from the pharynx frequently contain oral anaerobes and facultative streptococci, particularly Streptococcus pyogenes. In a study of 847 patients with peritonsillar abscess, Fusobacterium necrophorum was the most commonly detected species (23 percent), followed by S. pyogenes (17 percent), and group C or G streptococci (5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/30/27110?source=see_link\">",
"     \"Complications of streptococcal tonsillopharyngitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infections of the prevertebral space usually originate from contiguous spread of a cervical spine infection (such as discitis or vertebral osteomyelitis), by local instrumentation of the trachea or esophagus, or by hematogenous seeding. There is a predominance of gram-positive organisms, the most common being Staphylococcus aureus. Less common organisms include various facultative gram-negative bacilli, mycobacteria, and fungi. Intravenous drug use, immunosuppression, alcoholism, and diabetes mellitus are known risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Thus, the microbiology of prevertebral space infections is quite different from that of retropharyngeal or odontogenic deep neck infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     GENERAL CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deep neck space infections share some typical clinical features. It is important to consider the primary source of infection (ie, odontogenic versus non-odontogenic, oropharyngeal, otogenic, or rhinogenic) and special host factors (such as comorbid disease, hospitalization, antecedent surgery or trauma, or immunocompromised state). In patients who have undergone radical neck surgery or radiation to the neck for cancer, diffuse cellulitis and lymphedema may be a prominent clinical feature. Similarly, in patients who have undergone tracheostomy and prolonged ventilation, a tracheo-esophageal fistula may develop with spread of infection into the mediastinum. Patients in the intensive care unit with prolonged internal jugular central venous catheters may develop suppurative thrombophlebitis of the internal jugular vein (variant of Lemierre&rsquo;s syndrome).",
"   </p>",
"   <p>",
"    Each of the major deep neck space infections are discussed in greater detail below or in separate topic reviews. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Specific deep neck space infections'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because of the dense superficial layer of the deep cervical fascia and its musculofascial planes, a fluctuant mass is not readily appreciated in deep neck space infections. Palpation of the oral cavity, when possible, may help in identifying such a mass or focal tenderness. The characteristic signs of deep pus are pitting or a doughy feeling on firm deep palpation.",
"   </p>",
"   <p>",
"    Specific sites of infection are often associated with characteristic clinical manifestations and physical findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peritonsillar, parotid, parapharyngeal, and submandibular abscesses are generally associated with sore throat and trismus (the inability to open the jaw). Trismus indicates pressure or infection of the muscles of mastication (the masseter and the pterygoids) or involvement of the motor branch of the trigeminal nerve. Findings on physical examination include swelling of the face and neck, erythema, and purulent oral discharge. There may be pooling of saliva in the mouth and asymmetry of the oropharynx. Lymphadenopathy is usually present.",
"     </li>",
"     <li>",
"      Dysphagia and odynophagia are secondary to inflammation of the cricoarytenoid joints.",
"     </li>",
"     <li>",
"      Dysphonia and hoarseness are late findings in neck infections and may indicate involvement of the tenth cranial nerve",
"     </li>",
"     <li>",
"      Unilateral tongue paresis indicates involvement of the twelfth cranial nerve.",
"     </li>",
"     <li>",
"      Stridor and dyspnea signify airway obstruction and may be manifestations of local pressure or spread of infection to the mediastinum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H988692187\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) is the imaging modality of choice for the diagnosis of deep neck space infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/19\">",
"     19",
"    </a>",
"    ]. CT allows the critical evaluation of soft tissues and especially bone from a single exposure (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51505 \" href=\"mobipreview.htm?11/46/12015\">",
"     image 1",
"    </a>",
"    ). In addition, the axial imaging format of CT is particularly well suited to the head and neck. Because CT can localize a process and define its extent, particularly extension into the mediastinum or the cranial vault, it is also an invaluable tool for planning and guiding aspiration for culture or open drainage.",
"   </p>",
"   <p>",
"    Magnetic resonance imaging (MRI) is useful for assessing the extent of soft tissue involvement and for delineating vascular complications. However, MRI takes significantly longer than CT to obtain good quality images, which may cause discomfort or claustrophobia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, individuals with certain implanted devices cannot undergo MRI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/35/5689?source=see_link\">",
"     \"Principles of magnetic resonance imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Plain radiography is of limited utility for the evaluation of deep neck space infections; it is sometimes helpful for detecting retropharyngeal swelling or epiglottitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H990948194\">",
"     'Clinical features and diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SPECIFIC DEEP NECK SPACE INFECTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H990950053\">",
"    <span class=\"h2\">",
"     Peritonsillar abscess (quinsy)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritonsillar abscess, also known as quinsy, is a suppurative complication of acute tonsillitis with extension into the peritonsillar space. The latter consists of loose areolar tissue overlying the tonsil and is surrounded by the superior pharyngeal constrictor muscle and the anterior and posterior tonsillar pillars. Peritonsillar abscesses may affect patients of all ages but are most common among young adults between the ages of 15 and 30 years. The infection begins as a cellulitis and progresses to abscess formation, most commonly near the superior pole of the tonsil. Patients complain of high fever, odynophagia, unilateral sore throat, and otalgia. Classic signs include a muffled voice, trismus, unilateral deviation of the uvula towards the unaffected side, and soft palate fullness or edema. The oral airway may be compromised and drooling may occur. Peritonsillar abscesses are often polymicrobial. The predominant bacterial species are Streptococcus pyogenes (group A streptococcus) and oral anaerobes. Peritonsillar abscess is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/61/31705?source=see_link\">",
"     \"Peritonsillar cellulitis and abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H990950079\">",
"    <span class=\"h2\">",
"     Parotid space infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute suppurative parotitis is characterized by the sudden onset of unilateral induration and erythema that extends from the cheek to the angle of the jaw. The parotid gland becomes swollen and extremely tender. Purulent discharge may be expressed from the orifice of the parotid duct with gentle pressure. Although a stone obstructing the salivary duct may predispose to bacterial infection, inspissated secretions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stasis are more common predisposing features. Three factors that predispose to suppurative parotitis are: acutely diminished salivary flow, poor oral hygiene, and increased susceptibility to infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/20\">",
"     20",
"    </a>",
"    ]. Thus, acute suppurative parotitis is typically seen in elderly, debilitated,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dehydrated patients who may be diabetic or taking anticholinergic medications that decrease salivary flow.",
"   </p>",
"   <p>",
"    The microbiology of acute suppurative parotitis is quite variable and is often polymicrobial. Staphylococcus aureus is by far the most frequently isolated pathogen, but anaerobes are also common. Acute suppurative parotitis is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22758?source=see_link\">",
"     \"Suppurative parotitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H990947603\">",
"    <span class=\"h2\">",
"     Submandibular space infections (Ludwig's angina)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ludwig's angina is a bilateral infection of the submandibular space (which includes the submylohyoid and sublingual spaces) that begins in the floor of the mouth, most commonly related to the second or third mandibular molar teeth.",
"    <strong>",
"    </strong>",
"    It is typically a polymicrobial infection involving the flora of the oral cavity (",
"    <a class=\"graphic graphic_table graphicRef81076 \" href=\"mobipreview.htm?26/38/27244\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/21\">",
"     21",
"    </a>",
"    ]. It is an aggressive, rapidly spreading \"woody\" or brawny cellulitis without lymphadenopathy. Airway compromise is a potential complication, and requires careful monitoring and rapid intervention to prevent asphyxia and aspiration pneumonia. Ludwig's angina is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35622?source=see_link\">",
"     \"Submandibular space infections (Ludwig's angina)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H990950098\">",
"    <span class=\"h2\">",
"     Prevertebral space infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections of the prevertebral space usually originate from contiguous spread of a cervical spine infection (such as discitis or vertebral osteomyelitis), by local instrumentation of the trachea or esophagus, or by hematogenous seeding. There is a predominance of gram-positive organisms, the most common being Staphylococcus aureus. Less common organisms include various facultative gram-negative bacilli, mycobacteria, and fungi. Intravenous drug use, immunosuppression, alcoholism, and diabetes mellitus are known risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Thus, the microbiology of prevertebral space infections is quite different from that of retropharyngeal or odontogenic deep neck infections.",
"   </p>",
"   <p>",
"    The diagnosis of a prevertebral space infection may be difficult to make clinically because only 75 percent of patients complain of back or neck pain, 50 percent present with fever, and one-third have neurologic deficits ranging from nerve root pain to paralysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/18\">",
"     18",
"    </a>",
"    ]. Computed tomography or magnetic resonance imaging is immensely helpful for differentiating a prevertebral space infection from a retropharyngeal abscess. Complications of prevertebral space infections arise from spinal epidural collections that cause cord compression. Irreversible paralysis occurs in 4 to 22 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/18\">",
"     18",
"    </a>",
"    ]. Spread of infection to or from the disc or vertebrae may cause local destruction with mechanical instability of the spine. Since the prevertebral space extends from the base of the skull down to the coccyx and is contiguous with the psoas muscle sheath, seemingly distant abscesses can form within the psoas muscle in a patient who has a prevertebral space infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H990947868\">",
"    <span class=\"h2\">",
"     Parapharyngeal space infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parapharyngeal space infections are potentially life-threatening because of the possibility of involving the carotid sheath and its vital contents (eg, common carotid artery, internal jugular vein, vagus nerve), propensity for airway impingement, and bacteremic dissemination. Since the clinical presentation may be dominated by the symptoms and signs of the primary source of infection, the diagnosis of parapharyngeal space involvement is often delayed.",
"   </p>",
"   <p>",
"    Infection of the parapharyngeal space may arise from different sources throughout the neck. Dental infections are the most common underlying cause, followed by peritonsillar abscess, and rarely parotitis, otitis, or mastoiditis (Bezold's abscess). Infection of the anterior compartment of the parapharyngeal space",
"    <strong>",
"    </strong>",
"    is more common than the posterior compartment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16873?source=see_link\">",
"     \"Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/53/20313?source=see_link\">",
"     \"Complications, diagnosis, and treatment of odontogenic infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22758?source=see_link\">",
"     \"Suppurative parotitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H990947875\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardinal clinical features of parapharyngeal space infections are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Trismus",
"     </li>",
"     <li>",
"      Induration and swelling below the angle of the mandible",
"     </li>",
"     <li>",
"      Medial bulging of the pharyngeal wall",
"     </li>",
"     <li>",
"      Systemic toxicity with fever and rigors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dyspnea may be prominent as edema and swelling involve the epiglottis and larynx. Swelling of the pharyngeal wall, if present, will be behind the palatopharyngeal arch and is easily missed. Suppuration may advance quickly to other spaces, particularly to the retropharyngeal and \"danger\" spaces, possibly reaching the mediastinum inferiorly or the base of the skull superiorly.",
"   </p>",
"   <p>",
"    An abscess localized to the posterior neurovascular compartment of the parapharyngeal space may result in septicemia and neurologic signs indicating cranial nerve involvement (eg, Horner syndrome, hoarseness, unilateral tongue paresis) but with minimal trismus. The posterior tonsillar pillar is displaced.",
"   </p>",
"   <p>",
"    Swelling and displacement of the parotid gland usually occur with infection in either the anterior or posterior compartment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H990947882\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The source and extent of infection is best evaluated by computed tomography (CT) or magnetic resonance imaging (MRI). (See",
"    <a class=\"local\" href=\"#H988692187\">",
"     'Imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H990947896\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Carotid sheath involvement &mdash;",
"      </strong>",
"      Involvement of the carotid sheath is a dreaded complication of parapharyngeal space infections because of the potential for carotid artery erosion and suppurative jugular thrombophlebitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/23\">",
"       23",
"      </a>",
"      ]. The carotid sheath abuts all three layers of the deep cervical fascia. Thus, infection may arise by spread from the parapharyngeal space, submandibular space (Ludwig's angina), or suppuration of the deep cervical lymph nodes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35622?source=see_link\">",
"       \"Submandibular space infections (Ludwig's angina)\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      There are no characteristic symptoms or signs of a carotid sheath infection. A history of sore throat is usually but not always present, and may be mild or unilateral; there may be a latent period of up to three weeks before obvious manifestations of a deep neck space infection develop. The patient presents either in a toxic condition or insidiously with a fever of undetermined origin. Trismus is absent, and signs of local suppuration may be subtle initially because of the tight connective tissue around and within the carotid sheath. In some patients, there is diffuse swelling along the sternocleidomastoid muscle with marked tenderness and torticollis to the opposite side.",
"      <br/>",
"      <br/>",
"      Carotid artery mycotic aneurysms have a mortality rate of approximately 20 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/25\">",
"       25",
"      </a>",
"      ].",
"      <strong>",
"      </strong>",
"      Erosion of the carotid artery is a potentially devastating complication. This complication arises from an arteritis due to contiguous inflammation, resulting eventually in the formation of a false aneurysm, which may rupture. Erosion and rupture of the carotid artery may be heralded by recurrent small hemorrhages from the nose, mouth, or ear (\"herald bleeds\"). This is followed by hematoma formation in the surrounding tissues, a protracted clinical course, and eventually the onset of shock due to exsanguination. Ligation of the carotid artery may be necessary in cases of major hemorrhage, but the mortality rate remains high, and the risk of stroke is significant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Suppurative jugular thrombophlebitis &mdash;",
"      </strong>",
"      Suppurative jugular thrombophlebitis (also known as Lemierre's syndrome or postanginal sepsis) should be suspected in patients with antecedent pharyngitis, septic pulmonary emboli, and persistent fever despite antimicrobial therapy. It is caused most commonly by Fusobacterium necrophorum, which is often present in the bloodstream. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/0/2055?source=see_link\">",
"       \"Suppurative (septic) thrombophlebitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H990948187\">",
"    <span class=\"h2\">",
"     Retropharyngeal and danger space infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retropharyngeal abscesses are among the most serious of deep space infections, since infection can extend directly into the anterior or posterior regions of the superior mediastinum, or into the entire length of the posterior mediastinum via the danger space (",
"    <a class=\"graphic graphic_figure graphicRef61704 \" href=\"mobipreview.htm?31/24/32137\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef74998 \" href=\"mobipreview.htm?11/33/11797\">",
"     figure 2",
"    </a>",
"    ). Retropharyngeal infections can occur in both children and adults. Retropharyngeal infections in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43992?source=see_link\">",
"     \"Retropharyngeal infections in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H990948194\">",
"    <span class=\"h3\">",
"     Clinical features and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection may reach the retropharyngeal space from either local or distant sites. Penetrating trauma (eg, from chicken bones or following instrumentation) is the usual source of local spread; in such cases, a sore throat or difficulty in swallowing or breathing may be the first indication of infection. More distant sources of infection include odontogenic sepsis and peritonsillar abscess (now a rare cause). Infection from these sources may often obscure the diagnosis of a retropharyngeal abscess because of associated trismus, which makes direct examination of the posterior pharyngeal wall difficult.",
"   </p>",
"   <p>",
"    The differential diagnosis includes cervical osteomyelitis, Pott's disease, meningitis, and calcific tendonitis of the long muscle of the neck [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/26\">",
"     26",
"    </a>",
"    ]. In this setting, CT scans",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    x-rays of the lateral neck are especially helpful and may demonstrate cervical lordosis with swelling and gas collections in the retropharyngeal space, causing anterior displacement of the larynx and trachea (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65501 \" href=\"mobipreview.htm?35/28/36288\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51505 \" href=\"mobipreview.htm?11/46/12015\">",
"     image 1",
"    </a>",
"    ). The radiograph should be evaluated for increased thickness of the prevertebral soft tissues, air or air-fluid levels, and the presence of foreign bodies. The soft tissues of the posterior wall of the hypopharynx are normally about 5 mm deep, less than one third the diameter of the fourth cervical vertebra (C4). In the presence of a retropharyngeal space infection, the pharynx or upper airway is displaced anteriorly by more than one half the width of the C4 vertebral body. Radiographs may also help to differentiate retropharyngeal from prevertebral space infection arising from cervical vertebral osteomyelitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H988692187\">",
"     'Imaging'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H990948208\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute necrotizing mediastinitis is the most feared complication of a retropharyngeal space infection. An infection in the \"danger\" space between the alar and prevertebral fasciae may drain by gravity into the posterior mediastinum, resulting in mediastinitis and empyema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/29\">",
"     29",
"    </a>",
"    ]. In the past, 70 percent of cases of mediastinitis were the result of infection spread in this manner. However, with the introduction of antibiotics, mediastinal extension has become uncommon, and most cases of acute mediastinitis result from esophageal perforation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinically, the onset of acute necrotizing mediastinitis is rapid and is characterized by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Widespread necrotizing process extending the length of the posterior mediastinum, occasionally into the retroperitoneal space",
"     </li>",
"     <li>",
"      Rupture of mediastinal abscess into the pleural cavity with empyema or development of loculations",
"     </li>",
"     <li>",
"      Pleural or pericardial effusions, frequently with tamponade",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mortality of acute necrotizing mediastinitis in adults is high (25 percent), even when appropriate antibiotics are administered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=see_link\">",
"     \"Aspiration pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aspiration pneumonia is another potential complication of retropharyngeal space infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36569/abstract/31\">",
"     31",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Pneumonia may result from impairment of swallowing or spontaneous rupture of the abscess into the airway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate antibiotics in conjunction with surgical drainage of loculated infection are essential for a successful outcome of deep neck space infections (",
"    <a class=\"graphic graphic_table graphicRef77338 \" href=\"mobipreview.htm?42/20/43342\">",
"     table 2",
"    </a>",
"    ). It should be noted that the primary pathologic finding in deep neck space infections is cellulitis that involves the connective tissues, fasciae, and muscles, and frequently undergoes necrosis. This necrotizing cellulitis results in a serosanguinous, putrid infiltration of the cervical tissues, usually with little or no frank pus present. During this stage of infection, treatment is primarily medical, directed at eradicating the causative microorganisms and preventing local or systemic spread of infection. Maximum doses of systemic antimicrobials should be administered in order to optimize tissue penetration. Surgical drainage should be implemented only if the cellulitic process has localized into a discrete abscess. Premature incision into an area of cellulitis area may actually worsen the situation by breaking down the natural defenses and hastening the spread of infection. The choice of antimicrobial regimens for the treatment of deep neck space infections has not been evaluated in clinical trials. Empiric regimens are based upon the expected microbiology and immune status of the host, and coverage should be narrowed if microbiologic data become available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H393046\">",
"    <span class=\"h2\">",
"     Peritonsillar abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of peritonsillar abscesses is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/61/31705?source=see_link\">",
"     \"Peritonsillar cellulitis and abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H990950263\">",
"    <span class=\"h2\">",
"     Suppurative parotitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of suppurative parotitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22758?source=see_link\">",
"     \"Suppurative parotitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H990948343\">",
"    <span class=\"h2\">",
"     Submandibular space infections (Ludwig's angina)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of Ludwig's angina is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35622?source=see_link\">",
"     \"Submandibular space infections (Ludwig's angina)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H990950301\">",
"    <span class=\"h2\">",
"     Prevertebral space infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of prevertebral space infections consists of expeditious drainage of the abscess and broad-spectrum antibiotics with coverage of Staphylococcus aureus and gram-negative bacilli. Some examples of appropriate regimens follow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H393014\">",
"    <span class=\"h3\">",
"     Immunocompetent host",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest one of the following regimens in the",
"    <strong>",
"     immunocompetent host",
"    </strong>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/36/1608?source=see_link\">",
"       Nafcillin",
"      </a>",
"      (1.5 g IV every 4 hours)",
"      <strong>",
"       or",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours),",
"      <strong>",
"       plus",
"      </strong>",
"      either:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       Gentamicin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"       tobramycin",
"      </a>",
"      (1.7",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 8 hours or 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 24 hours),",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      (400 mg IV q12h),",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/45/42710?source=see_link\">",
"       Ticarcillin-clavulanate",
"      </a>",
"      (3.1 g IV every 4 hours)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with risk factors for MRSA infection should be treated empirically with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    (600 mg orally or IV every 12 hours). Risk factors for MRSA include a history of intravenous drug use, comorbid disease (eg, diabetes mellitus), and residing in a community or hospital where there is a substantial incidence of MRSA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H393007\">",
"    <span class=\"h3\">",
"     Immunocompromised host",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest one of the following regimens in the",
"    <strong>",
"     immunocompromised",
"    </strong>",
"    <strong>",
"     host",
"    </strong>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       Vancomycin",
"      </a>",
"      (15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      (600 mg orally or IV every 12 hours)",
"      <strong>",
"       plus",
"      </strong>",
"      either:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"       Cefepime",
"      </a>",
"      (2 g IV every 12 hours)",
"      <strong>",
"       plus",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (500 mg IV every six to eight hours)",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      Imipenem (500 mg IV every six hours)",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       Meropenem",
"      </a>",
"      (1 g IV every eight hours)",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"       Piperacillin-tazobactam",
"      </a>",
"      (4.5 g IV every six hours)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H393000\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;For uncomplicated prevertebral space infections without evidence of discitis or osteomyelitis, two to three weeks of therapy is adequate. We favor intravenous antibiotics for the entire duration of treatment. When adjacent osteomyelitis is present, at least six to eight weeks of intravenous antibiotics is necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H990948371\">",
"    <span class=\"h2\">",
"     Parapharyngeal or retropharyngeal space infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of parapharyngeal or retropharyngeal space infections initially depends upon whether local suppuration has developed or whether the initial phase of diffuse cellulitis persists. This differentiation is important because surgical drainage should be delayed in the cellulitis stage, whereas loculated abscesses should be drained. Unfortunately, this is often difficult to determine clinically. Imaging studies such as computed tomography or magnetic resonance imaging should be performed and image-guided needle aspiration may be required. Endoscopic drainage is contraindicated owing to the proximity of the great vessels. In retropharyngeal space infection complicated by acute necrotizing mediastinitis, surgical drainage of the mediastinum is required and may be performed by either the cervico-mediastinal or the transthoracic approach. Although the cervical approach may be effective in early mediastinitis, thoracotomy is generally indicated once the necrotizing process has entered the \"danger\" space. &nbsp;",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    In patients who are recovering, it is important to restrict all oral intake until the swallowing impairment, which may have a prolonged course, has resolved completely.",
"   </p>",
"   <p>",
"    Antimicrobial treatment of parapharyngeal or retropharyngeal space infections is based upon the probable site of origin in the immunocompetent host (odontogenic, from the teeth; rhinogenic, from the nose; or otogenic, from the ear). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Microbiology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/62/39913?source=see_link\">",
"     \"Acute otitis media in adults (suppurative and serous)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29642?source=see_link&amp;anchor=H27#H27\">",
"     \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Complications and sequelae'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/15/2297?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7812107\">",
"    <span class=\"h3\">",
"     Oral or odontogenic source",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest one of the following regimens in the",
"    <strong>",
"     immunocompetent host",
"    </strong>",
"    with an oral or odontogenic source:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"       Ampicillin-sulbactam",
"      </a>",
"      (3 g IV every six hours)",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/42/22183?source=see_link\">",
"       Penicillin G",
"      </a>",
"      (2 to 4 MU IV every four to six hours)",
"      <strong>",
"       plus",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (500 mg IV every six to eight hours)",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      (600 mg IV every six to eight hours)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, patients with risk factors for MRSA infection should be treated empirically with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    (600 mg orally or IV every 12 hours). Risk factors for MRSA include a history of intravenous drug use, comorbid disease (eg, diabetes mellitus), and residing in a community or hospital where there is a substantial incidence of MRSA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7812116\">",
"    <span class=\"h3\">",
"     Rhinogenic or otogenic source",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest one of the following regimens in the",
"    <strong>",
"     immunocompetent host",
"    </strong>",
"    with a rhinogenic or otogenic source:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"       Ampicillin-sulbactam",
"      </a>",
"      (3 g IV every six hours)",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      1 g IV every 24 hours",
"      <strong>",
"       plus",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      500 mg IV every six to eight hours",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      (400 mg IV every 12 hours)",
"      <strong>",
"       plus",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (600 mg IV every six to eight hours)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, patients with risk factors for MRSA infection should be treated empirically with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    (600 mg orally or IV every 12 hours). Risk factors for MRSA include a history of intravenous drug use, comorbid disease (eg, diabetes mellitus), and residing in a community or hospital where there is a substantial incidence of MRSA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7812123\">",
"    <span class=\"h3\">",
"     Immunocompromised host",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest one of the following regimens for parapharyngeal or retropharyngeal space infections in the",
"    <strong>",
"     immunocompromised host",
"    </strong>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"       Cefepime",
"      </a>",
"      (2 g IV every 12 hours)",
"      <strong>",
"       plus",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (500 mg IV every six to eight hours)",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      Imipenem (500 mg IV every six hours)",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/38/32359?source=see_link\">",
"       Meropenem",
"      </a>",
"      (1 g IV every eight hours)",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24216?source=see_link\">",
"       Piperacillin-tazobactam",
"      </a>",
"      (4.5 g every six hours)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, patients with risk factors for MRSA infection should be treated empirically with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    (600 mg orally or IV every 12 hours). Risk factors for MRSA include a history of intravenous drug use, comorbid disease (eg, diabetes mellitus), and residing in a community or hospital where there is a substantial incidence of MRSA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3227148\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy should generally be continued for two to three weeks for parapharyngeal or retropharyngeal space infections until fever and leukocytosis have resolved and local tenderness and swelling have subsided. Longer courses are required when complications are present. We favor intravenous antibiotics for the entire duration of treatment.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H990948952\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deep neck space infections most commonly arise from a septic focus of the mandibular teeth, tonsils, parotid gland, deep cervical lymph nodes, middle ear, or sinuses. Since these infections often have a rapid onset and may progress to life-threatening complications, clinicians must be aware of such infections and should not underestimate their potential extent or severity. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Knowledge of the cervical compartments and interfascial spaces is essential for understanding the pathogenesis, clinical manifestations, and potential routes of spread of infections involving these spaces. The deep cervical fascia has three layers: superficial, middle, and deep, which can be thought of as defining a series of cylindrical compartments that extend longitudinally from the base of the skull to the mediastinum (",
"      <a class=\"graphic graphic_figure graphicRef61704 \" href=\"mobipreview.htm?31/24/32137\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomic considerations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Potential routes of spread'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Deep neck space infections are typically polymicrobial and represent the normal resident flora of the contiguous mucosal surfaces from which the infection originated. Due to the close anatomic relationships, the resident flora of the oral cavity, upper respiratory tract, and certain parts of the ears and eyes share many common organisms (",
"      <a class=\"graphic graphic_figure graphicRef56883 \" href=\"mobipreview.htm?10/33/10771\">",
"       figure 9",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common organism isolated from deep neck space infections is Streptococcus viridans, reflecting its abundance in the mouth. Most abscesses originating from the teeth also harbor oral anaerobes, including Peptostreptococcus species, Fusobacterium nucleatum, pigmented Prevotella species such as Prevotella melaninogenica (formerly Bacteroides melaninogenicus), and Actinomyces species. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Computed tomography is the imaging modality of choice for the diagnosis of deep neck space infections. Magnetic resonance imaging is useful for assessing the extent of soft tissue involvement and for delineating vascular complications. (See",
"      <a class=\"local\" href=\"#H988692187\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For deep neck space infections that involve a drainable collection, aspiration or surgical drainage should be performed. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Appropriate antibiotics based upon the likely microbiology of the infection are essential for a successful outcome of deep neck space infections. Empiric regimens for each type of deep neck space infection are discussed above (",
"      <a class=\"graphic graphic_table graphicRef77338 \" href=\"mobipreview.htm?42/20/43342\">",
"       table 2",
"      </a>",
"      ). The final selection of antimicrobial therapy should be guided by culture results and susceptibility data, whenever possible. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For both",
"      <strong>",
"      </strong>",
"      immunocompetent and immunocompromised patients who are at risk for methicillin-resistant Staphylococcus aureus (MRSA) carriage or infection, such as those with a history of intravenous drug use or comorbid disease (eg, diabetes mellitus), or those in communities or hospitals where there is a substantial incidence of MRSA, we suggest that MRSA coverage be included in the treatment regimen (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For parapharyngeal, retropharyngeal, or prevertebral space infections, therapy should generally be continued for two to three weeks. Longer courses are required when complications are present. (See",
"      <a class=\"local\" href=\"#H990947868\">",
"       'Parapharyngeal space infections'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H990948187\">",
"       'Retropharyngeal and danger space infections'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H990950301\">",
"       'Prevertebral space infections'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Chow AW. Life-threatening infections of the head, neck, and upper respiratory tract. In: Principles of Critical Care, Hall JB, Schmidt GA, Wood LD (Eds), McGraw-Hill, New York 1998. p.887.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/2\">",
"      Grodinsky, M. Ludwig's angina, retropharyngeal abscess, and other deep abscesses of the head and neck. JAMA 1940; 114:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/3\">",
"      Timon CI, Cafferkey M, Walsh M. Infection of Waldeyer's ring: value of pernasal retropharyngeal swabs. J Otolaryngol 1991; 20:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/4\">",
"      Bernstein JM. Waldeyer's ring and otitis media: the nasopharyngeal tonsil and otitis media. Int J Pediatr Otorhinolaryngol 1999; 49 Suppl 1:S127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/5\">",
"      Todd JK. Bacteriology and clinical relevance of nasopharyngeal and oropharyngeal cultures. Pediatr Infect Dis 1984; 3:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/6\">",
"      Tanner A, Stillman N. Oral and dental infections with anaerobic bacteria: clinical features, predominant pathogens, and treatment. Clin Infect Dis 1993; 16 Suppl 4:S304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/7\">",
"      Chow AW, Roser SM, Brady FA. Orofacial odontogenic infections. Ann Intern Med 1978; 88:392.",
"     </a>",
"    </li>",
"    <li>",
"     Roscoe, DL, Chow, AW. Normal flora and mucosal immunity of the head and neck. Infect Dis Clin North Am 1988; 2:1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/9\">",
"      Rega AJ, Aziz SR, Ziccardi VB. Microbiology and antibiotic sensitivities of head and neck space infections of odontogenic origin. J Oral Maxillofac Surg 2006; 64:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/10\">",
"      Huang TT, Tseng FY, Yeh TH, et al. Factors affecting the bacteriology of deep neck infection: a retrospective study of 128 patients. Acta Otolaryngol 2006; 126:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/11\">",
"      Parhiscar A, Har-El G. Deep neck abscess: a retrospective review of 210 cases. Ann Otol Rhinol Laryngol 2001; 110:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/12\">",
"      Brook I. Anaerobic bacteria in upper respiratory tract and other head and neck infections. Ann Otol Rhinol Laryngol 2002; 111:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/13\">",
"      Hull MW, Chow AW. An Approach to Oral Infections and Their Management. Curr Infect Dis Rep 2005; 7:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/14\">",
"      Huang TT, Liu TC, Chen PR, et al. Deep neck infection: analysis of 185 cases. Head Neck 2004; 26:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/15\">",
"      Lin HT, Tsai CS, Chen YL, Liang JG. Influence of diabetes mellitus on deep neck infection. J Laryngol Otol 2006; 120:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/16\">",
"      Ehlers Klug T, Rusan M, Fuursted K, Ovesen T. Fusobacterium necrophorum: most prevalent pathogen in peritonsillar abscess in Denmark. Clin Infect Dis 2009; 49:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/17\">",
"      Gordon RJ, Lowy FD. Bacterial infections in drug users. N Engl J Med 2005; 353:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/18\">",
"      Reynolds SC, Chow AW. Severe soft tissue infections of the head and neck: a primer for critical care physicians. Lung 2009; 187:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/19\">",
"      Hurley MC, Heran MK. Imaging studies for head and neck infections. Infect Dis Clin North Am 2007; 21:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/20\">",
"      Cohen MA, Docktor JW. Acute suppurative parotitis with spread to the deep neck spaces. Am J Emerg Med 1999; 17:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/21\">",
"      Brook I. Microbiology and principles of antimicrobial therapy for head and neck infections. Infect Dis Clin North Am 2007; 21:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/22\">",
"      M&uuml;ckley T, Sch&uuml;tz T, Kirschner M, et al. Psoas abscess: the spine as a primary source of infection. Spine (Phila Pa 1976) 2003; 28:E106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/23\">",
"      Laupland KB. Vascular and parameningeal infections of the head and neck. Infect Dis Clin North Am 2007; 21:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/24\">",
"      Alexander DW, Leonard JR, Trail ML. Vascular complications of deep neck abscesses. A report of four cases. Laryngoscope 1968; 78:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/25\">",
"      Knouse MC, Madeira RG, Celani VJ. Pseudomonas aeruginosa causing a right carotid artery mycotic aneurysm after a dental extraction procedure. Mayo Clin Proc 2002; 77:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/26\">",
"      Haug RH, Picard U, Indresano AT. Diagnosis and treatment of the retropharyngeal abscess in adults. Br J Oral Maxillofac Surg 1990; 28:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/27\">",
"      Jang YJ, Rhee CK. Retropharyngeal abscess associated with vertebral osteomyelitis and spinal epidural abscess. Otolaryngol Head Neck Surg 1998; 119:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/28\">",
"      Faidas A, Ferguson JV Jr, Nelson JE, Baddour LM. Cervical vertebral osteomyelitis presenting as a retropharyngeal abscess. Clin Infect Dis 1994; 18:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/29\">",
"      Chen KC, Chen JS, Kuo SW, et al. Descending necrotizing mediastinitis: a 10-year surgical experience in a single institution. J Thorac Cardiovasc Surg 2008; 136:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/30\">",
"      Brook I, Frazier EH. Microbiology of mediastinitis. Arch Intern Med 1996; 156:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36569/abstract/31\">",
"      Daya H, Lo S, Papsin BC, et al. Retropharyngeal and parapharyngeal infections in children: the Toronto experience. Int J Pediatr Otorhinolaryngol 2005; 69:81.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3415 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-D5AC4AD6BF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_45_36569=[""].join("\n");
var outline_f35_45_36569=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H990948952\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cervical fascia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fascial spaces",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Submandibular space",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Parapharyngeal space",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Retropharyngeal space",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H988692066\">",
"      - Danger space",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H988692074\">",
"      - Prevertebral space",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H988692083\">",
"      - Peritonsillar space",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H988692090\">",
"      - Parotid space",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Potential routes of spread",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      GENERAL CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H988692187\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SPECIFIC DEEP NECK SPACE INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H990950053\">",
"      Peritonsillar abscess (quinsy)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H990950079\">",
"      Parotid space infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H990947603\">",
"      Submandibular space infections (Ludwig's angina)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H990950098\">",
"      Prevertebral space infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H990947868\">",
"      Parapharyngeal space infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H990947875\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H990947882\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H990947896\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H990948187\">",
"      Retropharyngeal and danger space infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H990948194\">",
"      - Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H990948208\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H393046\">",
"      Peritonsillar abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H990950263\">",
"      Suppurative parotitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H990948343\">",
"      Submandibular space infections (Ludwig's angina)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H990950301\">",
"      Prevertebral space infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H393014\">",
"      - Immunocompetent host",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H393007\">",
"      - Immunocompromised host",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H393000\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H990948371\">",
"      Parapharyngeal or retropharyngeal space infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7812107\">",
"      - Oral or odontogenic source",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7812116\">",
"      - Rhinogenic or otogenic source",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7812123\">",
"      - Immunocompromised host",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3227148\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H990948952\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3415\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3415|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?11/46/12015\" title=\"diagnostic image 1\">",
"      Retropharyngeal abscess CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?35/28/36288\" title=\"diagnostic image 2\">",
"      Retropharyngeal abscess xray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3415|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/24/32137\" title=\"figure 1\">",
"      Cervical fascial spaces anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/33/11797\" title=\"figure 2\">",
"      Deep neck space anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/57/5012\" title=\"figure 3\">",
"      Submandibular space anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/49/792\" title=\"figure 4\">",
"      Parapharyngeal space anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/6/6244\" title=\"figure 5\">",
"      Peritonsillar space",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/14/12516\" title=\"figure 6\">",
"      Parotid space anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/53/19285\" title=\"figure 7\">",
"      Lymph nodes head and neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/0/10254\" title=\"figure 8\">",
"      Deep cervical infx extension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/33/10771\" title=\"figure 9\">",
"      Colonizing flora head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3415|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/38/27244\" title=\"table 1\">",
"      Cultivable flora oral cavity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/20/43342\" title=\"table 2\">",
"      Treatment of deep neck space infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/62/39913?source=related_link\">",
"      Acute otitis media in adults (suppurative and serous)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/48/39688?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/15/2297?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38426?source=related_link\">",
"      Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/30/27110?source=related_link\">",
"      Complications of streptococcal tonsillopharyngitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/53/20313?source=related_link\">",
"      Complications, diagnosis, and treatment of odontogenic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16873?source=related_link\">",
"      Epidemiology, pathogenesis, and clinical manifestations of odontogenic infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/61/31705?source=related_link\">",
"      Peritonsillar cellulitis and abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/35/5689?source=related_link\">",
"      Principles of magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43992?source=related_link\">",
"      Retropharyngeal infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35622?source=related_link\">",
"      Submandibular space infections (Ludwig's angina)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/0/2055?source=related_link\">",
"      Suppurative (septic) thrombophlebitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22758?source=related_link\">",
"      Suppurative parotitis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_45_36570="Assessment of kidney function";
var content_f35_45_36570=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Assessment of kidney function",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/45/36570/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/45/36570/contributors\">",
"     Lesley A Inker, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/45/36570/contributors\">",
"     Ronald D Perrone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/45/36570/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/45/36570/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/45/36570/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/45/36570/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/45/36570/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with kidney disease may have a variety of different clinical presentations. Some have symptoms that are directly referable to the kidney (gross hematuria, flank pain) or to extrarenal symptoms (edema, hypertension, signs of uremia). Many patients, however, are asymptomatic and are noted on routine examination to have an elevated serum creatinine concentration or an abnormal urinalysis.",
"   </p>",
"   <p>",
"    Once kidney disease is discovered, the presence or degree of kidney dysfunction and rapidity of progression are assessed, and the underlying disorder is diagnosed. Although the history and physical examination can be helpful, the most useful information is initially obtained from estimation of the glomerular filtration rate (GFR) and examination of the urinary sediment.",
"   </p>",
"   <p>",
"    Estimation of the GFR is used clinically to assess the degree of kidney impairment and to follow the course of the disease. However, the GFR provides no information on the cause of the kidney disease. This is achieved by the urinalysis, measurement of urinary protein excretion, and, if necessary, radiologic studies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    kidney biopsy.",
"   </p>",
"   <p>",
"    This topic will provide an overview of the issues concerning assessment of the GFR in the patient with chronic kidney disease. The utility of the urinalysis, radiologic studies, and kidney biopsy are discussed separately, as is the general approach to the patient with kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/34/22058?source=see_link\">",
"     \"Urinalysis in the diagnosis of kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39509?source=see_link\">",
"     \"Radiologic assessment of renal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21690?source=see_link\">",
"     \"Indications for and complications of renal biopsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35785?source=see_link\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF KIDNEY FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to discussing the evaluation of kidney function, it is helpful to first briefly review normal kidney physiology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38198?source=see_link\">",
"     \"Chapter 1A: Introduction to renal function\"",
"    </a>",
"    .) The kidney performs a number of essential processes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It participates in the maintenance of the constant extracellular environment that is required for adequate functioning of the cells. This is achieved by excretion of some of the waste products of metabolism (such as urea, creatinine, and uric acid) and by specifically adjusting the urinary excretion of water and electrolytes to match net intake and endogenous production. The kidney is able to regulate individually the excretion of water and solutes such as sodium, potassium, and hydrogen, largely by changes in tubular reabsorption or secretion.",
"     </li>",
"     <li>",
"      It secretes hormones that participate in the regulation of systemic and renal hemodynamics (renin, prostaglandins, and bradykinin), red blood cell production (erythropoietin), and calcium, phosphorus, and bone metabolism (1,25-dihydroxyvitamin D3 or calcitriol).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the patient with kidney disease, some or all of these functions may be diminished or entirely absent. As an example, patients with nephrogenic diabetes insipidus have a decreased urinary concentrating ability, but other functions are entirely normal. By comparison, all kidney functions may be significantly impaired in the patient with end-stage renal disease, thereby resulting in the retention of uremic toxins, marked abnormalities in fluid and electrolyte balance, and anemia and bone disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GLOMERULAR FILTRATION RATE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Normal GFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The glomerular filtration rate (GFR) is equal to the sum of the filtration rates in all of the functioning nephrons; thus, the GFR gives a rough measure of the number of functioning nephrons. The filtering units of the kidney, the glomeruli, filter approximately 180 liters per day (125",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    of plasma. The normal value for GFR depends on age, sex, and body size, and is approximately 130 and 120",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    for men and women, respectively, with considerable variation even among normal individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20658511\">",
"    <span class=\"h3\">",
"     Change in GFR with aging",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between age and decreasing GFR has been suggested by several studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Baltimore Longitudinal study, 254 normal individuals (without renal disease or hypertension and not taking diuretics) were followed between the years 1958 and 1981 with serial creatinine clearances as a means to estimate GFR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/4\">",
"       4",
"      </a>",
"      ]. The mean rate of decline in creatinine clearance was found to be 0.75",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per year, and was greater in patients with hypertension. A fall in GFR was not observed in approximately one-third of individuals. (See",
"      <a class=\"local\" href=\"#H20663240\">",
"       'Creatinine clearance'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Using GFR estimated by the modified Modification of Diet in Renal Disease (MDRD) Study equation among participants in the NHANES III study, 38 percent of individuals age 70 or older without hypertension or diabetes had estimated GFRs of less than 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/2\">",
"       2",
"      </a>",
"      ]. By comparison, such low values were seen in only 0.7 percent of such participants between the ages of 20 to 39 years. (See",
"      <a class=\"local\" href=\"#H20659783\">",
"       'MDRD study equations'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      One study from Japan calculated the creatinine clearance using the Cockcroft-Gault method among nearly 100,000 subjects older than 20 years of age who participated in a mass screening [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/5\">",
"       5",
"      </a>",
"      ]. Over 80 percent of those older than 70 years of age had a calculated clearance of less than 60",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"      However, this remarkably high prevalence in the very old may be an artifact of how strongly age influences the Cockcroft-Gault equation. (See",
"      <a class=\"local\" href=\"#H20659776\">",
"       'Cockcroft-Gault equation'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20658680\">",
"    <span class=\"h2\">",
"     Significance of a declining GFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with kidney disease, a reduction in GFR implies either progression of the underlying disease or the development of a superimposed and often reversible problem, such as decreased renal perfusion due to volume depletion. In addition, the level of GFR has prognostic implications in patients with chronic kidney disease, and such patients are staged, in part, according to GFR. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35785?source=see_link\">",
"     \"Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/29/5594?source=see_link\">",
"     \"Definition and staging of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there is",
"    <strong>",
"     not",
"    </strong>",
"    an exact correlation between the loss of kidney mass (ie, nephron loss) and the loss of GFR. The kidney adapts to the loss of some nephrons by compensatory hyperfiltration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increasing solute and water reabsorption in the remaining, normal nephrons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Thus, an individual who has lost one-half of total kidney mass will not necessarily have one-half the normal amount of GFR. (See",
"    <a class=\"local\" href=\"#H20664189\">",
"     'Using creatinine to estimate GFR'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These concepts have important consequences:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A stable GFR does not necessarily imply stable disease. Signs of disease progression other than a change in GFR must be investigated, including increased activity of the urine sediment, a rise in protein excretion, or an elevation in blood pressure.",
"     </li>",
"     <li>",
"      Similarly, an increase in GFR may indicate improvement in the kidney disease or may imply a counterproductive increase in filtration (hyperfiltration) due to hemodynamic factors. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=see_link\">",
"       \"Secondary factors and progression of chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some patients who have true underlying renal disease may go unrecognized because they have a normal GFR. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20658806\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF GFR",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20658260\">",
"    <span class=\"h2\">",
"     How to evaluate GFR: Measurement versus estimation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of glomerular filtration rate (GFR) is complex, time consuming, and cumbersome to do in clinical practice. In addition, exact knowledge of the GFR is not required for most clinical settings. As such, GFR is usually estimated from serum markers. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Estimation of GFR'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As an example, knowing that the GFR is 40",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    rather than 30 or 50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    usually provides little useful information. What is important to know is whether the GFR (and therefore disease severity) is changing or is stable. This can usually be determined by monitoring the change in serum creatinine or estimated GFR in most patients with a relatively constant body mass and diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, it is occasionally important to have more precise knowledge of the GFR. Clinical situations in which this is the case include: dose adjustment of medications, especially toxic medications with narrow therapeutic indices, such as chemotherapy; prior to kidney donation; and prior to determining the need for preemptive transplant. In such circumstances, it would be reasonable to consider measuring GFR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Measurement of GFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although GFR cannot be measured directly, the best method for determining GFR is measurement of the urinary clearance of an ideal filtration marker. Using a filtration marker (x), the equation to calculate the clearance of x (Cx) is:",
"   </p>",
"   <p>",
"    Equation 1: &nbsp; &nbsp; &nbsp;Cx = (Ux &nbsp;x &nbsp;",
"    <span class=\"nowrap\">",
"     V)/Px",
"    </span>",
"   </p>",
"   <p>",
"    where Px is the serum concentration of the marker, Ux is the urinary concentration of x, and V is the urine flow rate.",
"   </p>",
"   <p>",
"    An ideal filtration marker is defined as a solute that is freely filtered at the glomerulus, nontoxic, neither secreted nor reabsorbed by the kidney tubules, and not changed during its excretion by the kidney. If these criteria are met, the filtered load is equal to the rate of urinary excretion:",
"   </p>",
"   <p>",
"    Equation 2: &nbsp; &nbsp; &nbsp;GFR x &nbsp;Px = (Ux &nbsp;x &nbsp;V)",
"   </p>",
"   <p>",
"    Where GFR X Px is the filtered load, and Ux X V is the urinary excretion rate. By substitution into Equation 1:",
"   </p>",
"   <p>",
"    Equation 3: &nbsp; &nbsp; &nbsp;GFR = Cx",
"   </p>",
"   <p>",
"    The gold standard of exogenous filtration markers is inulin. Inulin is a physiologically inert substance that is freely filtered at the glomerulus, and is neither secreted, reabsorbed, synthesized, nor metabolized by the kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, the amount of inulin filtered at the glomerulus is equal to the amount excreted in the urine, which can be measured. Inulin, however, is in short supply, expensive, and difficult to assay. Furthermore, the classic protocol for measuring inulin clearance requires a continuous intravenous infusion, multiple blood samples, and bladder catheterization.",
"   </p>",
"   <p>",
"    Various less cumbersome methods for measuring clearance are available: using alternative filtration markers (such as radioactive or nonradioactive iothalamate,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30949?source=see_link\">",
"     iohexol",
"    </a>",
"    , DTPA, or EDTA), bolus administration of the marker (subcutaneous or intravenous), spontaneous bladder emptying, and plasma clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. While these methods are simpler, all have disadvantages that limit their application in clinical practice and affect the interpretation of research studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Estimation of GFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, the most common methods utilized to estimate the GFR are: measurement of the creatinine clearance; and estimation equations based upon serum creatinine such as the Cockcroft-Gault equation, the Modification of Diet in Renal Disease (MDRD) Study equations, and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. The abbreviated MDRD study and CKD-EPI equations are being increasingly utilized. (See",
"    <a class=\"local\" href=\"#H20663240\">",
"     'Creatinine clearance'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20659769\">",
"     'Estimation equations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Both measurement of the creatinine clearance and estimation equations rely upon creatinine as a marker of kidney function. Issues related to the use of creatinine to estimate GFR are presented below. (See",
"    <a class=\"local\" href=\"#H20664189\">",
"     'Using creatinine to estimate GFR'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other markers of kidney function include the blood urea nitrogen, which is less useful than the serum creatinine, and serum cystatin C, which has been measured principally in research studies. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'BUN and GFR'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H23\">",
"     'Serum cystatin C'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The reciprocal of the serum creatinine concentration to assess changes in GFR over time is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/0/41988?source=see_link\">",
"     \"Reciprocal serum creatinine concentration and chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20664189\">",
"    <span class=\"h3\">",
"     Using creatinine to estimate GFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Creatinine is derived from the metabolism of creatine in skeletal muscle and from dietary meat intake. It is released into the circulation at a relatively constant rate. Creatinine is freely filtered across the glomerulus and is neither reabsorbed nor metabolized by the kidney. However, approximately 10 to 40 percent of urinary creatinine is derived from tubular secretion by the organic cation secretory pathways in the proximal tubule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/15\">",
"     15",
"    </a>",
"    ]. Thus, if GFR, creatinine secretion by the renal tubules, creatine intake (ie, diet), and the creatinine pool size (ie, muscle mass) all remain constant, then the plasma creatinine concentration should remain constant.",
"   </p>",
"   <p>",
"    Creatinine excretion (GFR &nbsp;x &nbsp;SCr), where SCr is serum creatinine, equals creatinine production in the steady state and creatinine production is relatively constant on a stable diet and with stable muscle mass. As a result:",
"   </p>",
"   <p>",
"    &nbsp;GFR &nbsp;x &nbsp;SCr &nbsp; = &nbsp; constant",
"   </p>",
"   <p>",
"    Thus, the serum creatinine concentration varies inversely with the GFR. If, for example, the GFR falls by 50 percent, creatinine excretion will initially be reduced. Assuming that tubular creatinine secretion, diet, and muscle mass do not change, this reduction in GFR will lead to creatinine retention and a rise in the serum creatinine until it has doubled (",
"    <a class=\"graphic graphic_figure graphicRef59518 \" href=\"mobipreview.htm?0/1/19\">",
"     figure 1",
"    </a>",
"    ); at this point, the filtered load will again be equal to excretion:",
"   </p>",
"   <p>",
"    &nbsp;",
"    <span class=\"nowrap\">",
"     GFR/2",
"    </span>",
"    &nbsp;x &nbsp;2SCr &nbsp; &nbsp;= &nbsp; &nbsp;GFR &nbsp;x &nbsp;SCr &nbsp; &nbsp;= &nbsp; &nbsp;constant",
"   </p>",
"   <p>",
"    The shape of the curve relating the GFR to serum creatinine has an important clinical implication (",
"    <a class=\"graphic graphic_figure graphicRef59518 \" href=\"mobipreview.htm?0/1/19\">",
"     figure 1",
"    </a>",
"    ): in patients with mild kidney disease, a small rise in serum creatinine usually reflects a marked fall in GFR, whereas a marked rise in serum creatinine in patients with advanced disease reflects a small absolute reduction in GFR.",
"   </p>",
"   <p>",
"    However, this curve depicts a hypothetical relationship between GFR and serum creatinine (",
"    <a class=\"graphic graphic_figure graphicRef59518 \" href=\"mobipreview.htm?0/1/19\">",
"     figure 1",
"    </a>",
"    ). In reality, a reduction in GFR results in increased tubular creatinine secretion that blunts the rise in serum creatinine. Thus, a 50 percent reduction in GFR does not produce a doubling of serum creatinine, but rather a smaller rise than would have occurred if the decrease in GFR had occurred without an increase in secretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1505493\">",
"    <span class=\"h4\">",
"     Normal values",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Third National Health and Nutrition Examination Survey in the United States, the mean serum creatinine values for men and women were 1.13 and 0.93",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (100 and 82",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    respectively (",
"    <a class=\"graphic graphic_figure graphicRef76830 \" href=\"mobipreview.htm?8/15/8446\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/16\">",
"     16",
"    </a>",
"    ]. The mean values also varied by race. For non-Hispanic blacks, the mean serum creatinine was 1.25",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in men and 1.01",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in women. The values were lower in non-Hispanic whites (1.16",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in men and 0.97",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in women) and in Mexican-Americans (1.07",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in men and 0.86",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in women) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/16\">",
"     16",
"    </a>",
"    ]. The mean values will all be lower with the adoption of newer creatinine assays traceable to reference materials.",
"   </p>",
"   <p>",
"    Serum creatinine values are lower in women because they have less muscle mass, and therefore a lower rate of creatinine production. It is presumed that the higher values for blacks and lower values for Hispanics similarly reflect greater and lesser, respectively, muscle mass and creatinine production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1505542\">",
"    <span class=\"h4\">",
"     Requirement for stable kidney function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum creatinine can only be used to estimate GFR in individuals with stable kidney function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/17\">",
"     17",
"    </a>",
"    ]. Early in the course of acute kidney injury, for example, the GFR is markedly reduced but there has not yet been time for creatinine to accumulate and, therefore, for the serum creatinine to reflect the degree of renal dysfunction.",
"   </p>",
"   <p>",
"    With stable kidney function, as seen in patients with normal kidney function or chronic kidney disease, a rise in serum creatinine almost always represents a reduction in GFR. However, certain drugs can interfere with either creatinine secretion or the assay used to measure the serum creatinine, and dietary changes or dietary supplements can alter creatinine production. In these settings, there will be no change in GFR and no concurrent elevation in the BUN. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41875?source=see_link\">",
"     \"Drugs that elevate the serum creatinine concentration\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H20665137\">",
"     'Limitations of using creatinine'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20665137\">",
"    <span class=\"h4\">",
"     Limitations of using creatinine",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several key limitations of using creatinine to estimate GFR. These include variations in creatinine production, variations in creatinine secretion, extrarenal creatinine excretion, and issues associated with creatinine measurement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1505177\">",
"    <span class=\"h5\">",
"     Variation in creatinine production",
"    </span>",
"    &nbsp;&mdash;&nbsp;The production of creatinine differs among and within people over time. As examples, individuals with significant variations in dietary intake (vegetarian diet, creatine supplements) or reduction in muscle mass (amputation, malnutrition, muscle wasting) produce different amounts of creatinine than the general population. The accuracy of estimation equations is affected to a greater extent among lower extremity amputees, given the much greater reduction in muscle mass, compared with upper extremity amputations.",
"    <br/>",
"    <br/>",
"    There are certain settings in which there may be an acute increase in creatinine load. One example is a recent meat meal. In addition, it has been suggested that the serum creatinine rises more rapidly with rhabdomyolysis (up to 2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 220",
"    <span class=\"nowrap\">",
"     micromol/L",
"    </span>",
"    per day) than with other causes of acute kidney injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/18\">",
"     18",
"    </a>",
"    ]. Release of preformed creatinine from injured muscle",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    release of creatine phosphate that is then converted into creatinine in the extracellular fluid have been proposed as explanations for this finding. However, neither of these mechanisms appears to account for most of the increase in the serum creatinine concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/19\">",
"     19",
"    </a>",
"    ]. An alternative explanation is that rhabdomyolysis often affects otherwise healthy men with a high muscle mass and a higher rate of creatinine production while other forms of acute kidney injury frequently affect patients who are chronically ill [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1505184\">",
"    <span class=\"h5\">",
"     Variations in creatinine secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accuracy of GFR estimation with both the creatinine clearance and creatinine-based estimation equations is limited by the fact that as the GFR falls, the rise in the serum creatinine is partially opposed by enhanced proximal tubular creatinine secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/6,7,12,20,21\">",
"     6,7,12,20,21",
"    </a>",
"    ]. In early renal disease when the GFR is still near normal, an initial decline in GFR may lead to only a slight increase (0.1 to 0.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [9 to 18",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    in the serum creatinine. The net effect is that patients with a true GFR as low as 60 to 80",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    (as measured by the clearance of a true filtration marker such as inulin or radioisotopic iothalamate or DTPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/12,22,23\">",
"     12,22,23",
"    </a>",
"    ]) may still have a serum creatinine that is &le;1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (88",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/15\">",
"     15",
"    </a>",
"    ]. Thus, a relatively stable serum creatinine in the normal or near-normal range does",
"    <strong>",
"     not",
"    </strong>",
"    necessarily imply that the disease is stable.",
"   </p>",
"   <p>",
"    However, once the serum creatinine exceeds 1.5 to 2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (132 to 176",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    the secretory process is effectively saturated. After this, a stable value usually represents a stable GFR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following clinical examples are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A man with unrecognized renal disease and an initial serum creatinine of 0.9",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (79.6",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      has a decline in his true GFR from 120 to 70",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      (loss of 50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      , or approximately 40 percent of his GFR). Using the hypothetical relationship between GFR and creatinine (which ignores creatinine secretion), the serum creatinine multiplied by GFR is a constant, and the serum creatinine would be expected to rise to approximately 1.7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (150.3",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      (",
"      <a class=\"graphic graphic_figure graphicRef59518 \" href=\"mobipreview.htm?0/1/19\">",
"       figure 1",
"      </a>",
"      ). However, his actual rise in serum creatinine is much smaller, to 1.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (106.1",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      because of increased creatinine secretion. Although a serum creatinine of 1.2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      is in the normal range, this should",
"      <strong>",
"       not",
"      </strong>",
"      be mistakenly assumed to be normal or indicative of only mild disease. The severity of the GFR decline was not apparent due to an increase in creatinine secretion. Early detection of progressive kidney disease is particularly important because of the availability of therapies, particularly blood pressure lowering with angiotensin converting enzyme inhibitors, which can slow the rate of progression in many patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"       \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In another patient with more advanced disease, the serum creatinine is 4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (354",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      and the GFR 15",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"      Because creatinine secretion is saturated, a rise in serum creatinine (SCr) to 6",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (530",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      reflects a GFR of 10",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      or a loss of only 5",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"      Assuming that generation and extrarenal elimination of creatinine in this patient are constant, then GFR &nbsp;x &nbsp;SCr is constant, so: GFR &nbsp;x &nbsp;SCr &nbsp;= &nbsp;15 &nbsp;x &nbsp;4 &nbsp;= &nbsp;10 &nbsp;x &nbsp;6 &nbsp;= &nbsp;60.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, creatinine secretion may be enhanced or inhibited in certain clinical situations. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tubular creatinine secretion is significantly increased in patients with the nephrotic syndrome. In one study, in which GFR was determined by inulin clearance, decreased serum albumin levels were associated with a marked increase in tubular creatinine secretion (36",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      for nephrotic patients with serum albumin levels less than 2.6",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      versus 11",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      for normal controls) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/24\">",
"       24",
"      </a>",
"      ]. Patients with sickle cell disease may also have an increase in creatinine secretion. Thus, patients with nephrotic syndrome and sickle cell disease may have a GFR that is substantially lower than what can be estimated from the serum creatinine.",
"     </li>",
"     <li>",
"      The degree of creatinine secretion may vary with time, affecting the serum creatinine independent of the GFR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/12,25\">",
"       12,25",
"      </a>",
"      ]. In effectively treated lupus nephritis, for example, a rise in the GFR may not be accompanied by the expected reduction in the serum creatinine due to a fall (via an uncertain mechanism) in creatinine secretion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/25\">",
"       25",
"      </a>",
"      ]. In this setting, decreased activity of the urine sediment, diminished protein excretion, and lack of further elevation in the serum creatinine all point toward possible improvement.",
"     </li>",
"     <li>",
"      The presence of certain drugs may increase the level of the serum creatinine by decreasing creatinine secretion. These drugs include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      (which is most often given in combination with sulfamethoxazole) and the H2-blocker",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/54/2921?source=see_link\">",
"       cimetidine",
"      </a>",
"      , which result in a self-limited and reversible rise in the serum creatinine of as much as 0.4 to 0.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (35 to 44",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41875?source=see_link\">",
"       \"Drugs that elevate the serum creatinine concentration\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1505415\">",
"    <span class=\"h5\">",
"     Extrarenal creatinine excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extrarenal creatinine elimination is increased in advanced kidney failure (eg, estimated GFR &lt;15",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ). In this setting, there is intestinal bacterial overgrowth and increased bacterial creatininase activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/26\">",
"     26",
"    </a>",
"    ]. As a result, the serum creatinine concentration is lower than would be expected from the GFR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1505422\">",
"    <span class=\"h5\">",
"     Measurement issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum creatinine is most often measured by the alkaline picrate method. Certain substances may interfere with the assay, thereby artifactually increasing the serum creatinine concentration. This colorimetric assay can recognize other compounds as creatinine chromogens, particularly acetoacetate in diabetic ketoacidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. In this setting, the serum creatinine can rise by 0.5 to &gt;2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (44 to 176",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    a change that is rapidly reversed with insulin therapy.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"     Cefoxitin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    are drugs that can produce a similar effect. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41875?source=see_link\">",
"     \"Drugs that elevate the serum creatinine concentration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Differences in method and equipment can lead to variation in reported serum creatinine values (random measurement error) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/30\">",
"     30",
"    </a>",
"    ]. In a study evaluating over 5000 laboratories using 20 different instruments to measure serum creatinine by up to three different methods (alkaline picrate and enzymatic), the mean serum creatinine concentration on a standardized sample ranged from 0.84 to 1.21",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (74.3 to 107",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/28\">",
"     28",
"    </a>",
"    ]. Bias related to instrument manufacturer was greater than that due to method. This variation has been substantially reduced by the national program established by the National Kidney Disease Education Program (NKDEP) to standardize creatinine assays so that they are all traceable to reference materials. Most manufacturers now use such calibrators and therefore most clinical laboratories in the United States have assays traceable to these reference materials.",
"   </p>",
"   <p>",
"    The variation in serum creatinine measurement methods leads to variation in creatinine based GFR estimation. This was shown in a study that examined frozen samples from 212 and 342 MDRD and NHANES III participants, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/30\">",
"     30",
"    </a>",
"    ]. Creatinine was measured in MDRD and NHANES III with different assays. When creatinine was measured on the same blood samples using both assays, the serum creatinine was on average 0.23",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (20.3",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    higher with the NHANES III assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/30\">",
"     30",
"    </a>",
"    ]. This difference can result in substantial variations in GFR estimation when the serum creatinine concentration is relatively normal. These data also suggest that changes in serum creatinine of &plusmn;0.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (26",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    measured in different laboratories may represent variations in the assay rather than variations in GFR; the variation is much smaller in repeated measurements in the same laboratory. The recognition that variations in serum creatinine measurements can have a substantial impact on the assessment of kidney function has led to ongoing efforts to standardize creatinine measurements across laboratories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20663240\">",
"    <span class=\"h3\">",
"     Creatinine clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Creatinine is freely filtered across the glomerulus and is neither reabsorbed nor metabolized by the kidney. However, approximately 10 to 40 percent of urinary creatinine is derived from tubular secretion by the organic cation secretory pathways in the proximal tubule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the effect of secretion is ignored, then all of the filtered creatinine (equal to the product of the GFR and the serum creatinine concentration [SCr]) will be excreted (equal to product of the urine creatinine concentration [UCr] and the urine flow rate). Thus:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp;GFR x SCr &nbsp;= &nbsp;UCr x V",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp;GFR = &nbsp;[UCr x",
"    <span class=\"nowrap\">",
"     V]/SCr",
"    </span>",
"   </p>",
"   <p>",
"    This formula is called the creatinine clearance and tends to exceed the true GFR by approximately 10 to 20 percent or more, since this is the fraction of urinary creatinine that is derived from tubular secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/20\">",
"     20",
"    </a>",
"    ]. However, historically, this error has been balanced by an opposing error of almost equal magnitude in the measurement of the serum creatinine using the Jaffe (alkaline picrate) method [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35190?source=see_link\">",
"     \"Calculation of the creatinine clearance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    National standardization of serum creatinine assays to creatinine reference materials should abolish this measurement error in serum creatinine. If so, creatinine clearance measurements utilizing urine collection will be consistently 10 to 20 percent higher than GFR, reflecting the impact of creatinine secretion. However, this effect is variable across laboratories due to the methods used to assay urine versus serum creatinine.",
"   </p>",
"   <p>",
"    The creatinine clearance (CrCl) is usually determined from a 24-hour urine collection, since shorter collections tend to give less accurate results. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/41/21151?source=see_link\">",
"     \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Suppose that the following results are obtained in a 60 kg woman:",
"   </p>",
"   <p>",
"    &nbsp;SCr &nbsp; &nbsp;= &nbsp; &nbsp;1.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    &nbsp;(106",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;UCr &nbsp; &nbsp;= &nbsp; &nbsp;100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    &nbsp;(8800",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"   </p>",
"   <p>",
"    V &nbsp; &nbsp; &nbsp; = &nbsp; &nbsp;1.2",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"   </p>",
"   <p>",
"    Thus:",
"   </p>",
"   <p>",
"    &nbsp;CrCl &nbsp; &nbsp;= &nbsp; &nbsp;[100 &nbsp;x &nbsp;",
"    <span class=\"nowrap\">",
"     1.2]/1.2",
"    </span>",
"    &nbsp; &nbsp;= &nbsp; &nbsp;100",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"   </p>",
"   <p>",
"    This value has to be multiplied by 1000 to convert into mL and then divided by 1440 (the number of minutes in a day) to convert into units of",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;CrCl &nbsp; &nbsp;= &nbsp; &nbsp;[100 &nbsp;x &nbsp;",
"    <span class=\"nowrap\">",
"     1000]/1440",
"    </span>",
"    &nbsp; &nbsp;= &nbsp; &nbsp;70",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"   </p>",
"   <p>",
"    This unadjusted creatinine clearance value should be used for determination of drug dosages (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?16/8/16513?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). However, a patient's creatinine clearance should be adjusted to body surface area (BSA) when comparing it with normal values to determine the presence and severity of kidney disease (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?4/27/4529?source=see_link\">",
"     calculator 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As an example, a creatinine clearance of 70",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    in a small 50 year-old woman with a weight and height of 50 kg and 160 cm, who has a BSA of 1.5, is corrected to a body surface area of 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    as follows:",
"   </p>",
"   <p>",
"    CrCl x",
"    <span class=\"nowrap\">",
"     1.73/BSA",
"    </span>",
"    = [70",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    x 1.73]",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    1.5 = 80",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"   </p>",
"   <p>",
"    In turn, for a large person with a body surface area of 1.9, the adjusted CrCl would be 64",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20663247\">",
"    <span class=\"h4\">",
"     Limitations of using creatinine clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major errors that can limit the accuracy of the creatinine clearance: an inaccurate urine collection, and increasing creatinine secretion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35190?source=see_link\">",
"     \"Calculation of the creatinine clearance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An incomplete urine collection &ndash; The completeness of the collection can be estimated from knowledge of the normal rate of creatinine excretion (which is equal to creatinine production in the steady state). As a general rule in adults under the age of 50, daily creatinine excretion should be 20 to 25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (177 to 221",
"      <span class=\"nowrap\">",
"       micromol/kg)",
"      </span>",
"      of lean body weight in men and 15 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (133 to 177",
"      <span class=\"nowrap\">",
"       micromol/kg)",
"      </span>",
"      of lean body weight in women. From the ages of 50 to 90, there is a progressive 50 percent decline in creatinine excretion (to about 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in men), due primarily to a fall in muscle mass. Formulas that incorporate race and weight with or without serum phosphorous in addition to age and sex may improve the estimation of creatinine excretion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]:",
"      <br/>",
"      <br/>",
"      Estimated creatinine excretion",
"      <span class=\"nowrap\">",
"       (mg/day)",
"      </span>",
"      = 1115.89 + (11.97 x weight in kg) &ndash; (5.83 x age) + (52.82 if black) &ndash; (368.75 if female)",
"      <br/>",
"      <br/>",
"      As an example, suppose a 50 year-old white woman weighing 50 kg excreted 1200 mg (10,600 micromol) of creatinine in 24 hours (24",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      [177",
"      <span class=\"nowrap\">",
"       micromol/kg]).",
"      </span>",
"      According to the simple rule based upon age and sex alone, this patient provided an accurate collection. However, according to the formula above, the expected excretion for someone of her age, race, and weight would have been 844",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/32\">",
"       32",
"      </a>",
"      ], suggesting this may be an over collection. The clinical context, such as the muscle mass and diet of the patient compared with the average person, should be considered when determining the adequacy of collection. In addition, repeating the creatinine clearance and averaging the two would minimize the effect of any error.",
"      <br/>",
"      <br/>",
"      However, variability in urine collections can lead to the following frequent misinterpretation. The 24-hour creatinine clearance is measured on two separate occasions in a patient with known kidney disease and a stable weight and diet. The serum creatinine is unchanged but the creatinine clearance has declined by 20",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"      The latter finding suggests that kidney function has deteriorated. However, if the serum creatinine concentration is stable, then from the formula for creatinine clearance ([UCr &nbsp;x &nbsp;",
"      <span class=\"nowrap\">",
"       V]/SCr),",
"      </span>",
"      the only way for the measured creatinine clearance to fall is if creatinine excretion (UCr &nbsp;x &nbsp;V) has fallen. Assuming constant muscle mass and diet, the most likely explanation for reduced creatinine excretion is an incomplete urine collection. It is therefore likely that the stable serum creatinine in this patient represents a stable creatinine clearance (which, as described below, may or may not represent a constant GFR because of changes in creatinine secretion). Similar considerations apply to a rise in creatinine clearance without change in the serum creatinine. In this setting, an over collection increasing apparent daily creatinine excretion is most probable.",
"     </li>",
"     <li>",
"      Increasing creatinine secretion &ndash; The increase in creatinine secretion as GFR falls can limit the interpretation of the creatinine clearance. (See",
"      <a class=\"local\" href=\"#H1505184\">",
"       'Variations in creatinine secretion'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      As an example, if the true GFR falls to a range of 40 to 80",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      (as measured by an exogenous filtration marker), and the absolute amount of creatinine secreted rises by more than 50 percent, creatinine secretion would now account for as much as 35 percent of urinary creatinine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/20\">",
"       20",
"      </a>",
"      ]. Thus, in some patients with CKD, creatinine excretion may be much greater than the filtered load, resulting in a potentially large overestimation of the GFR when creatinine clearance is used to assess the level of GFR. The net effect is that the creatinine clearance may be normal (&gt;90",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      in about one-half of patients with a true GFR of 61 to 70",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      and one-quarter of those with a true GFR of 51 to 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/21\">",
"       21",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Some patients with advanced disease have a creatinine clearance that exceeds the GFR by more than twofold [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/33\">",
"       33",
"      </a>",
"      ]. This was best shown in a systematic review and meta-analysis of seven studies of 193 patients with liver cirrhosis in which the measured creatinine clearance was compared with true GFR (assessed by inulin clearance) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/33\">",
"       33",
"      </a>",
"      ]. Overall, the measured creatinine clearance overestimated inulin clearance by a mean of 13",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      , with the overestimation being highest in those with the lowest true GFRs. Among those with inulin clearance of less than 30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      (true stage 4 to 5 CKD), the measured creatinine clearance correctly classified 64 percent of patients, incorrectly classified 23 percent of patients as having GFRs between 30 to 59",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      , and incorrectly classified 14 percent as having GFRs &ge;60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      . Another method to help estimate the GFR in these patients is to average both the creatinine and urea clearances",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    From the above considerations, all that can be concluded is that the creatinine clearance represents an upper limit of what the true GFR may be. An alternative, although not widely used clinically, is to competitively inhibit creatinine secretion by the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    , which is secreted by the same pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/6\">",
"     6",
"    </a>",
"    ]. However, there is inter- and intra-patient variability in the effect of cimetidine blockade, which can make the results difficult to interpret. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35190?source=see_link&amp;anchor=H5#H5\">",
"     \"Calculation of the creatinine clearance\", section on 'Use of cimetidine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues concerning the use of the creatinine clearance in patients with liver disease and decreased GFR, a setting in which increased tubular secretion of creatinine is also observed, are discussed below. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'BUN and GFR'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20659769\">",
"    <span class=\"h3\">",
"     Estimation equations",
"    </span>",
"    &nbsp;&mdash;&nbsp;GFR estimating equations improve upon the serum creatinine by incorporating known demographic and clinical variables as observed surrogates for the unmeasured physiological factors other than GFR that affect the serum creatinine concentration, such as generation and tubular secretion. Estimation equations also appear to be reasonably accurate for following changes in GFR over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/34\">",
"     34",
"    </a>",
"    ]. Similar to the serum creatinine, these equations do",
"    <strong>",
"     not",
"    </strong>",
"    provide accurate estimates of GFR in settings where the GFR is changing rapidly (eg, acute kidney injury).",
"   </p>",
"   <p>",
"    The most common equations used in the United States are the Cockcroft-Gault and the MDRD study equations. The Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation is more accurate than the MDRD study equation. The MDRD and CKD-EPI equations are normalized to body surface area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20659776\">",
"    <span class=\"h4\">",
"     Cockcroft-Gault equation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Cockcroft-Gault equation allows the creatinine clearance to be estimated from the serum creatinine in a patient with a stable serum creatinine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;(140 - age) &nbsp;x &nbsp;lean body weight [kg]",
"    <br/>",
"    CCr",
"    <span class=\"nowrap\">",
"     (mL/min)",
"    </span>",
"    &nbsp;= &nbsp;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Cr",
"    <span class=\"nowrap\">",
"     [mg/dL]",
"    </span>",
"    &nbsp;x &nbsp;72",
"   </p>",
"   <p>",
"    This formula takes into account assumptions that creatinine production decreases with advancing age, and is greater in individuals with greater weight. However, this equation was developed at a point in history when obesity was far less common. In the current era, higher weight may mean greater fat mass, and not greater muscle mass. For women, the formula requires multiplication by 0.85 to account for smaller muscle mass compared with men (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?29/57/30609?source=see_link\">",
"     calculator 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The equation is not adjusted for body surface area. Therefore, to compare with normal values, the result should be adjusted for body surface area. Normalization for body surface increases the accuracy of this equation, particularly among those with decreased renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20663240\">",
"     'Creatinine clearance'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The Cockcroft-Gault equation was developed prior to the use of standardized creatinine assays, and has",
"    <strong>",
"     not",
"    </strong>",
"    been revised for use with creatinine values traceable to standardized reference materials. Thus, using the Cockcroft-Gault equation with creatinine values measured by most laboratories in the United States today will result in a 10 to 40 percent",
"    <strong>",
"     overestimate",
"    </strong>",
"    of creatinine clearance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20659783\">",
"    <span class=\"h4\">",
"     MDRD study equations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several equations were derived from data on adult patients enrolled in the MDRD study who had GFR measured at baseline using urinary clearance of iothalamate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/37\">",
"     37",
"    </a>",
"    ]. The six-variable equation was described in the original publication:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;GFR, in",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    &nbsp;= &nbsp;170 x",
"    <span class=\"nowrap\">",
"     (SCr[mg/dL])exp[-0.999]",
"    </span>",
"    &nbsp;x",
"    <br/>",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;(Age)exp[-0.176] &nbsp;x &nbsp;(BUN",
"    <span class=\"nowrap\">",
"     [mg/dL])exp[-0.170]",
"    </span>",
"    &nbsp;x",
"    <br/>",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;(Alb",
"    <span class=\"nowrap\">",
"     [g/dL])exp[+0.318]",
"    </span>",
"    &nbsp;x &nbsp;(0.762 if female) &nbsp;x &nbsp;(1.18 if black)",
"   </p>",
"   <p>",
"    where SCr is serum creatinine concentration, BUN is the blood urea nitrogen concentration, and exp is the exponential.",
"   </p>",
"   <p>",
"    To facilitate the calculation of the GFR using a simpler formula, the following abbreviated MDRD equation was also developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;GFR, in",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    &nbsp;= &nbsp;186.3 &nbsp;x &nbsp;SCr (exp[-1.154]) &nbsp;x",
"    <br/>",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;Age (exp[-0.203]) &nbsp;x &nbsp;(0.742 if female) &nbsp;x &nbsp;(1.21 if black)",
"   </p>",
"   <p>",
"    where exp is the exponential (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/61/10194?source=see_link\">",
"     calculator 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The MDRD study equation has been re-expressed for use with creatinine values that are standardized to creatinine reference materials measured using gold standard techniques (",
"    <a class=\"external\" href=\"file://www.cap.org/apps/cap.portal?_nfpb=true&amp;cntvwrptlt_actionoverride=/portlets/contentviewer/show&amp;_windowlabel=cntvwrptlt&amp;cntvwrptlt{actionform.contentreference}=committees/chemistry/chemistry_resources.html&amp;_state=maximized&amp;_pagelabel=cntvwr\">",
"     www.cap.org/apps",
"    </a>",
"    ). Standardized creatinine assays are used by most clinical laboratories in the United States.",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;GFR, in",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    = 175 &nbsp;x &nbsp;SCr (exp[-1.154]) &nbsp;x",
"    <br/>",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;Age (exp[-0.203]) &nbsp;x &nbsp;(0.742 if female) &nbsp;x &nbsp;(1.21 if black)",
"   </p>",
"   <p>",
"    Websites are also available to aid in the calculation of the GFR through these formulas. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.kidney.org/professionals/KLS/gfr_calculator.cfm\">",
"       www.kidney.org/professionals/KLS/gfr_calculator.cfm",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://nephron.com/mdrd/default.html\">",
"       nephron.com/mdrd/default.html",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20659790\">",
"    <span class=\"h4\">",
"     Evaluation of the MDRD and Cockcroft-Gault equations in specific populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The MDRD study equation was derived from primarily white subjects (mean age of 51 years",
"    <span class=\"nowrap\">",
"     plus/minus",
"    </span>",
"    12.7 years) who had nondiabetic kidney disease, with mean GFR of 40",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    . Subsequently, there has been extensive evaluation of the performance of the equation in other populations including African Americans, Europeans, and Asians with non-diabetic kidney disease, diabetic patients with and without kidney disease, patients with liver disease, kidney transplant recipients, and potential kidney donors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/23,39-60\">",
"     23,39-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following illustrate some of these important observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The MDRD study equation is reasonably accurate in non-hospitalized patients known to have CKD, regardless of diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/39-41,43\">",
"       39-41,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The MDRD study equation and Cockcroft-Gault equation appear to be somewhat less accurate in obese individuals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/43,56,61\">",
"       43,56,61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The MDRD study and the Cockcroft-Gault equations are less accurate in populations with normal or near normal GFR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/39,41-43,45,51,59\">",
"       39,41-43,45,51,59",
"      </a>",
"      ]. As an example, in a retrospective study of healthy potential kidney donors, the MDRD study equation underestimated the measured GFR (iothalamate clearance) by 9 to 29 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/39\">",
"       39",
"      </a>",
"      ]. In addition, a meta-analysis that included 5504 patients demonstrated that, for those with an initial estimated GFR of 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      or greater, the median difference between measured and estimated GFR was 8.3",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      (95% CI of 7.4-9.2), which was an underestimation of GFR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among recipients of renal allografts, there have been variable results related to the accuracy of the MDRD study and other estimation equations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/47,53,58,63-67\">",
"       47,53,58,63-67",
"      </a>",
"      ]. This was illustrated in a prospective study of 95 consecutive kidney transplant recipients with stable function, the GFR as measured by (99m)Tc-DTPA clearance was compared with the Cockcroft-Gault and several MDRD study equations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/53\">",
"       53",
"      </a>",
"      ]. Accuracy within 50 percent of measured GFR was 91, 83, and 56 percent for the six variable MDRD study and Cockcroft and Gault equations, respectively. Although the MDRD study equation has limitations in transplant recipients, most experts use the abbreviated formula in this setting.",
"     </li>",
"     <li>",
"      Estimation equations may also be less accurate in populations of different ethnicities and from outside of the United States [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/46,68-73\">",
"       46,68-73",
"      </a>",
"      ]. Available data suggest that these equations overestimate GFR in Japan and some other Asian populations, possibly related to differences in body mass and diet [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/60,68-71,74-76\">",
"       60,68-71,74-76",
"      </a>",
"      ], although a study in China showed that the MDRD study equation underestimated GFR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/73\">",
"       73",
"      </a>",
"      ]. Furthermore, the definition of what constitutes normal GFR is not well defined in some of these populations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These examples illustrate the performance of estimating equations in specific populations. In addition, the performance of the MDRD study equation and Cockcroft-Gault equation may not be similarly accurate in different age groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/2,43,56,61,77\">",
"     2,43,56,61,77",
"    </a>",
"    ]. In the Third National Health and Nutrition Examination Survey (NHANES III), for example, the abbreviated MDRD study equations and the Cockcroft-Gault equations provide similar values within a wide-range of patient ages, which were consistent with age-specific historic inulin clearance values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/2\">",
"     2",
"    </a>",
"    ]. However, the Cockcroft-Gault equation provided higher estimates at younger ages, and lower estimates at older ages (eg, greater than 70 years of age) than that obtained with the simplified MDRD study equation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20659797\">",
"    <span class=\"h4\">",
"     CKD-EPI equation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the MDRD study and the Cockcroft-Gault equations are less accurate in populations with normal or near normal GFR. (See",
"    <a class=\"local\" href=\"#H20659790\">",
"     'Evaluation of the MDRD and Cockcroft-Gault equations in specific populations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20659804\">",
"    <span class=\"h5\">",
"     CKD-EPI is superior when GFR is normal or mildly reduced",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CKD-EPI equation was developed to provide a more accurate estimate of GFR among individuals with normal or only mildly reduced GFR (ie, above 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/78\">",
"     78",
"    </a>",
"    ]. This equation was developed using data pooled from 10 studies and validated against data derived from 16 additional studies, in which the gold standard was direct measurement of GFR using external filtration markers (eg, iothalamate). The study population included people with and without kidney disease who had a wide range of GFRs. A calculator for the estimation of GFR using the CKD-EPI equation may be obtained at the following website:",
"    <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/gfr_calculator.cfm\">",
"     www.kidney.org/professionals/kdoqi/gfr_calculator.cfm",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In the validation dataset, the CKD-EPI equation was as accurate as the MDRD study equation among individuals with estimated GFR less than 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    and somewhat more accurate in those with higher GFRs (",
"    <a class=\"graphic graphic_figure graphicRef78254 \" href=\"mobipreview.htm?41/13/42199\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Although the CKD-EPI equation was more accurate and less biased than the MDRD equation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/78\">",
"     78",
"    </a>",
"    ], precision was not substantially improved. Half of the study population had an estimated GFR that differed from the measured GFR by at least 16",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    using the CKD-EPI equation, and by 18",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    or more using the MDRD study equation (",
"    <a class=\"graphic graphic_figure graphicRef78254 \" href=\"mobipreview.htm?41/13/42199\">",
"     figure 3",
"    </a>",
"    ). Similarly, the percentage of patients whose estimated GFR differed by more than 30 percent of the measured GFR was similar with the two equations (12 versus 15 percent).",
"   </p>",
"   <p>",
"    The accuracy and bias of the CKD-EPI equation as compared with the MDRD study equation may differ according to the GFR and to various patient characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/79-81\">",
"     79-81",
"    </a>",
"    ]. The CKD-EPI equation, for example, performs better at higher levels of GFR and in subgroups defined by sex, race, diabetes and transplant status, in the elderly, and at higher levels of BMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. In contrast, the MDRD study equation performs better at lower levels of GFR and, at lower levels of BMI (&lt;20",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    there was a larger overestimate of measured GFR with the CKD-EPI equation compared with the MDRD study equation; however, the sample size of this subgroup was small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20659811\">",
"    <span class=\"h5\">",
"     CKD-EPI results in lower prevalence of CKD and better risk prediction",
"    </span>",
"    &nbsp;&mdash;&nbsp;When both equations were used to estimate GFR in over 16,000 NHANES participants, GFR estimates by CKD-EPI were higher than estimates obtained using the MDRD study equation among individuals with a measured GFR greater than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    . As a result, the overall prevalence of CKD was lower when the CKD-EPI equation was used to define the CKD population (13 versus 11.5 percent).",
"   </p>",
"   <p>",
"    The finding of a lower overall prevalence of CKD in the general population with the CKD-EPI equation was confirmed in additional studies. These studies also demonstrated a lower risk of adverse outcomes in people who were reclassified to a lower CKD Stage using the CKD-EPI equation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/82-88\">",
"     82-88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most comprehensive data comparing the CKD-EPI and MDRD equations with respect to CKD stage and risk prediction come from a meta-analysis that included 1.1 million adults from 25 general population cohorts, 7 vascular disease high-risk cohorts, and 13 CKD cohorts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/82\">",
"     82",
"    </a>",
"    ]. Individuals in this meta-analysis had GFR estimated by both the CKD-EPI and MDRD equations, and were followed for a median of 7.4 years (interquartile range, 4.2-10.5 years) for all-cause mortality, cardiovascular mortality, and end-stage renal disease (ESRD). The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with the MDRD study equation, 24.4 and 0.6 percent of participants from general population cohorts were reclassified to a higher and lower estimated GFR category, respectively, by the CKD-EPI equation; the prevalence of CKD stages 3 to 5 (estimated GFR &lt;60",
"      <span class=\"nowrap\">",
"       mL/min/1.73",
"      </span>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"      ) in these general population cohorts was reduced from 8.7 to 6.3 percent when the CKD-EPI equation was used.",
"     </li>",
"     <li>",
"      Of those whose estimated GFR was 45 to 59",
"      <span class=\"nowrap\">",
"       mL/min/1.73",
"      </span>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"      according to the MDRD study equation, 35 percent of were reclassified to an estimated GFR of 60 to 89",
"      <span class=\"nowrap\">",
"       mL/min/1.73",
"      </span>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"      by the CKD-EPI equation. These individuals who were reclassified had a significantly lower risk for all cause mortality (9.9 versus 34.5 events per 1000 patient years), cardiovascular mortality (2.7 versus 13 events per 1000 patient years), and ESRD (0.5 versus 0.8 per 1000 patient years) compared with those whose estimated GFR was 45 to 59",
"      <span class=\"nowrap\">",
"       mL/min/1.73",
"      </span>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"      with both equations",
"     </li>",
"     <li>",
"      The findings were similar in the high-risk and CKD cohorts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data show that, across multiple populations, the use of the CKD-EPI equation results in a lower prevalence estimate of CKD and more accurate risk prediction for adverse outcomes compared with the MDRD study equation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20659818\">",
"    <span class=\"h4\">",
"     Choice of equation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the data on the improved performance, especially at higher levels of GFR, we suggest using the CKD-EPI equation for the general population. This includes people with a GFR near or above 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    , as specific values in that range can be used with somewhat more confidence. The CKD-EPI equation has a similar performance to the MDRD study equation for people with lower levels of GFR, and therefore can be used for people with lower levels of GFR as well. A calculator for the estimation of GFR using the CKD-EPI equation may be obtained at the following website:",
"    <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/gfr_calculator.cfm\">",
"     file://www.kidney.org/professionals/kdoqi/gfr_calculator.cfm",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20659825\">",
"    <span class=\"h4\">",
"     Limitations of estimation equations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three estimation equations described above are limited by their use of the serum creatinine. (See",
"    <a class=\"local\" href=\"#H20665137\">",
"     'Limitations of using creatinine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For estimation equations, this is particularly true when there are variations in creatinine production. In these situations, collection of a 24-hour urine sample for measurement of creatinine clearance, or measurement of clearance of an exogenous filtration marker, provide better estimates of GFR than prediction equations. (See",
"    <a class=\"local\" href=\"#H1505177\">",
"     'Variation in creatinine production'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition to the problems associated with reliance upon serum creatinine, the commonly utilized estimation equations are less accurate in certain populations. These include individuals with normal GFR, children, elderly patients, specific ethnic groups (eg, Asians in the United States), pregnant women, and those with unusual muscle mass, body habitus, and weight (eg, morbid obesity, amputees). In these settings, some recommend measuring GFR using exogenous markers, or measuring creatinine clearance to estimate the GFR in patients with stable renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20659832\">",
"    <span class=\"h4\">",
"     Drug dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug dosing guidelines have historically been developed using the Cockcroft-Gault equation to estimate kidney function. This practice is consistent with the recommendation of the US Food and Drug Administration (FDA) to pharmaceutical industries to use an estimating equation, rather than serum creatinine alone, in pharmacokinetic studies to determine drug dosing in kidney disease. Most pharmacokinetic studies for drug dosing in renal disease were performed using the Cockcroft-Gault equation, since this equation was suggested by the FDA prior to publication of the MDRD study equation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The move toward standardizing all creatinine assays so that they are traceable to reference materials creates a problem with drug dosing according to estimated GFR. The pharmacokinetic studies were performed using serum creatinine values that were highly variable (before standardized reference materials were available), and therefore the results of these pharmacokinetic studies",
"    <strong>",
"     cannot",
"    </strong>",
"    necessarily be reliably translated into current clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/91\">",
"     91",
"    </a>",
"    ]. This could lead to inaccuracies in drug dosing in patients with kidney disease.",
"   </p>",
"   <p>",
"    However, a large simulation study showed that there was a high concordance rate (89 percent) for kidney function estimates obtained by Cockcroft-Gault and by the recalibrated MDRD study equation for the assignment of kidney function categories used for drug dosing adjustment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/92\">",
"     92",
"    </a>",
"    ]. The concordance rate was slightly lower for drugs that had a greater number of kidney function categories. Thus, for most patients, both the MDRD study equation and the Cockcroft-Gault equation can be used to estimate kidney function for drug dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the MDRD estimated GFR is used for drug dosing in very large or small patients, the reported estimated GFR (which is normalized to body surface area) should be multiplied by the estimated body surface area to obtain an estimated GFR in units of",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    (ie, not normalized to body surface area). For patients at the extremes of muscle mass, with unusual diets, or with conditions associated with changes in creatinine secretion, all estimation equations that use the serum creatinine are limited; thus, a measured creatinine clearance or GFR using exogenous filtration markers should be performed especially when prescribing drugs with a narrow therapeutic window. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Measurement of GFR'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H20663240\">",
"     'Creatinine clearance'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     BUN and GFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the blood urea nitrogen (BUN) also varies inversely with the GFR, it is generally less useful than the serum creatinine because the BUN can change independently of the GFR. Two factors contribute to this phenomenon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/12,94\">",
"     12,94",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of urea production is not constant, increasing with a high protein diet and with enhanced tissue breakdown due to hemorrhage, trauma, or glucocorticoid therapy. By comparison, a low protein diet or liver disease can lower the BUN without change in GFR. Thus, liver disease may be associated with near normal values for both the BUN (due to decreased urea production) and the serum creatinine (due to muscle wasting) despite a relatively large reduction in GFR [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/95,96\">",
"       95,96",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The presence of kidney disease in this setting can be documented by a reduction in creatinine clearance, but significant overestimation of GFR can still occur [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/33,50,96,97\">",
"       33,50,96,97",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H20663247\">",
"       'Limitations of using creatinine clearance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 40 to 50 percent of the filtered urea is passively reabsorbed, mostly in the proximal tubule. Thus, when volume depletion is associated with enhanced proximal sodium and water reabsorption, there is a parallel increase in urea reabsorption. As a result, the BUN will rise out of proportion to any change in GFR, and therefore to any change in the serum creatinine (SCr). This elevation in the BUN-to-SCr ratio is one of the suggestive clinical signs of decreased renal perfusion (prerenal disease) as the cause for renal failure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/54/12138?source=see_link\">",
"       \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The measurement of the clearance of urea is useful in one setting. Among patients with severe kidney disease (eg, a serum creatinine greater than 2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [220",
"    <span class=\"nowrap\">",
"     micromol/L]),",
"    </span>",
"    the urea clearance significantly underestimates the GFR. Since the creatinine clearance significantly overestimates this function, one method to estimate the GFR in patients with advanced renal disease is to average both the creatinine and urea clearances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/98\">",
"     98",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; CCr &nbsp;+ &nbsp;CUrea",
"    <br/>",
"    &nbsp; &nbsp; Estimated &nbsp;GFR &nbsp; &nbsp;= &nbsp; &nbsp;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 2",
"   </p>",
"   <p>",
"    The 2005 European Best Practices Guidelines suggest that this calculation is preferred for estimating GFR in advanced kidney failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/99\">",
"     99",
"    </a>",
"    ]. As previously mentioned, the MDRD study equation can also be used in those with significantly decreased GFR. (See",
"    <a class=\"local\" href=\"#H20659769\">",
"     'Estimation equations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Serum cystatin C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the problems with changes in creatinine production and secretion, other endogenous compounds have been evaluated in an effort to provide a more accurate estimation of GFR including symmetric dimethylarginine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/100\">",
"     100",
"    </a>",
"    ] and cystatin C.",
"   </p>",
"   <p>",
"    The best studied is cystatin C, a low molecular weight protein that is a member of the cystatin superfamily of cysteine protease inhibitors. Cystatin C is filtered at the glomerulus and not reabsorbed. However, it is metabolized in the tubules, which prevents use of cystatin C to directly measure clearance. Cystatin C is believed to be produced by all nucleated cells. Its rate of production has been thought to be relatively constant, and not affected by changes in diet, although this is not proven.",
"   </p>",
"   <p>",
"    Although cystatin C has been purported to be unaffected by gender, age or muscle mass, higher cystatin C levels have now been associated with male gender, greater height and weight, and higher lean body mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/97,101,102\">",
"     97,101,102",
"    </a>",
"    ]. Cystatin C levels increase sharply with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/97\">",
"     97",
"    </a>",
"    ]. Analysis of a subsample of 7596 participants drawn from NHANES III revealed that more than 50 percent of individuals over age 80 have an elevated cystatin C level, and non-Hispanic whites and males have higher levels of cystatin C (",
"    <a class=\"graphic graphic_figure graphicRef57111 \" href=\"mobipreview.htm?43/9/44191\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/103\">",
"     103",
"    </a>",
"    ]. Since these data were not adjusted for GFR, it is unclear whether they are related to different levels of kidney function among the populations or differences in the non-GFR determinants of cystatin C. In addition, cystatin is affected by hyper- and hypothyroidism, and has been correlated with markers of inflammation (C-reactive protein), body size (in particular fat mass), and diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/97,104,105\">",
"     97,104,105",
"    </a>",
"    ]. Together, these data suggest that levels of cystatin C are affected by many factors other than GFR.",
"   </p>",
"   <p>",
"    As with creatinine, substantial variation in the cystatin C assay has been observed, even when using the same instrument and the same reagent type by the same laboratory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/106\">",
"     106",
"    </a>",
"    ]. In addition, substantial declines in cystatin C levels over time have been observed with a popular reagent and method. To correct these problems, certified reference materials for cystatin C assays have been generated by the International Federation for Clinical Chemists Working Group for the Standardization of serum cystatin C and the Institute for Reference Materials and Measurements (IRMM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/107,108\">",
"     107,108",
"    </a>",
"    ]. This material,",
"    <span class=\"nowrap\">",
"     ERM-DA471/IFCC,",
"    </span>",
"    was made available to laboratories in 2010. Use of this material by manufacturers and laboratories will enable consistent cystatin C values across laboratories.",
"   </p>",
"   <p>",
"    The serum cystatin C concentration may correlate more closely with the GFR than the serum creatinine concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/109-117\">",
"     109-117",
"    </a>",
"    ]. In multiple studies, serum cystatin C was more sensitive in identifying mild reductions in kidney function than serum creatinine alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/110,114,115\">",
"     110,114,115",
"    </a>",
"    ]. Estimation equations based on serum cystatin C have also been formulated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/117-121\">",
"     117-121",
"    </a>",
"    ]. When comparing cystatin C based GFR estimates to creatinine based GFR estimates, there was no difference in the bias between the equations and precision may be worse with cystatin C based estimates. In one study of over 3000 patients with known CKD, an equation for the estimated GFR based upon cystatin C was nearly but not as accurate as GFR estimated from the serum creatinine adjusted for age, sex, and race when compared to GFR measured by iothalamate clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been proposed that cystatin C-based equations would be more accurate in populations with lower creatinine production, such as the elderly, children, renal transplant recipients, or patients with cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/17,122,123\">",
"     17,122,123",
"    </a>",
"    ]. However, the results from studies comparing creatinine and cystatin C based estimates in these populations have shown variable results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/124\">",
"     124",
"    </a>",
"    ]. As an example, whether cystatin C correlates better with GFR than serum creatinine in patients with diabetic nephropathy is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/125,126\">",
"     125,126",
"    </a>",
"    ]. In addition, steroid use may affect cystatin C levels, therefore limiting its use in transplant recipients. As an example, for the same level of cystatin C, measured GFR was 19 percent higher in transplant recipients than in patients with native kidney disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/17\">",
"     17",
"    </a>",
"    ]. Although cystatin C appears to be more accurate for the assessment of GFR than serum creatinine in certain populations, whether measurement of cystatin C levels will improve patient care is at present unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The addition of age, sex, and race to cystatin C reduced bias in some subgroups defined by these variables. However, a cystatin C based GFR estimation equation that was developed in a diverse population of 5352 individuals did not include race, suggesting that there may be less dependence upon race for cystatin C than for creatinine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H443541\">",
"    <span class=\"h3\">",
"     Creatinine and cystatin C in combination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combining both the serum creatinine and cystatin C into a single equation may better estimate GFR than equations that use either creatinine or cystatin C alone. A combined creatinine-cystatin C equation was initially developed among 5352 individuals who had both measured GFR and serum concentrations of creatinine and cystatin C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/45/36570/abstract/121\">",
"     121",
"    </a>",
"    ]. This combined equation was then compared with the CKD-EPI creatinine and cystatin C-based equations in a separate population of 1119 individuals. The combined creatinine-cystatin C equation produced an estimated GFR that was within 20 percent of the measured GFR in a significantly higher proportion of individuals (77 as compared with 67 percent using equations based upon either creatinine or cystatin C alone). In addition to improved accuracy, the combined equation was more precise and no more biased than the equations using either creatinine or cystatin C alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The normal value for glomerular filtration rate (GFR) depends on age, sex, and body size, and is approximately 130 and 120",
"      <span class=\"nowrap\">",
"       mL/min/1.73",
"      </span>",
"      m",
"      <sup>",
"       2",
"      </sup>",
"      for men and women, respectively, with considerable variation even among normal individuals. GFR frequently decreases with age. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Normal GFR'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20658511\">",
"       'Change in GFR with aging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with kidney disease, a reduction in GFR implies either progression of the underlying disease or the development of a superimposed and often reversible problem. In addition, the level of GFR has prognostic implications in patients with chronic kidney disease, and such patients are staged, in part, according to GFR. However, there is",
"      <strong>",
"       not",
"      </strong>",
"      an exact correlation between the loss of kidney mass (ie, nephron loss) and the loss of GFR. The kidney adapts to the loss of some nephrons by compensatory hyperfiltration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increasing solute and water reabsorption in the remaining, normal nephrons. (See",
"      <a class=\"local\" href=\"#H20658680\">",
"       'Significance of a declining GFR'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/29/5594?source=see_link\">",
"       \"Definition and staging of chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Measurement of GFR is complex, time consuming, and cumbersome to do in clinical practice. In addition, exact knowledge of the GFR is not required for most clinical settings. As such, GFR is usually estimated from serum markers. However, it is occasionally important to have more precise knowledge of the GFR (eg, prior to kidney donation). (See",
"      <a class=\"local\" href=\"#H20658260\">",
"       'How to evaluate GFR: Measurement versus estimation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GFR is measured by determining the urinary clearance of an ideal filtration marker. Inulin is the gold standard filtration marker, but iothalamate and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/14/30949?source=see_link\">",
"       iohexol",
"      </a>",
"      are less cumbersome. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Measurement of GFR'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common methods utilized to estimate the GFR are: measurement of the creatinine clearance; and estimation equations based upon serum creatinine such as the Cockcroft-Gault equation, the Modification of Diet in Renal Disease (MDRD) Study equations, and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Estimation of GFR'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      GFR estimating equations used in practice rely upon creatinine as a marker of kidney function. Serum creatinine can only be used to estimate GFR in individuals with stable kidney function. In addition, creatinine based estimations of the GFR are limited by variations in creatinine production, variations in creatinine secretion, extrarenal creatinine excretion, and issues associated with creatinine measurement.",
"      <a class=\"local\" href=\"#H20664189\">",
"       'Using creatinine to estimate GFR'",
"      </a>",
"      above",
"     </li>",
"     <li>",
"      Measurement of the creatinine clearance can be used to confirm estimated GFR from serum creatinine when there are variations in creatinine production. Measured creatinine clearance is limited by errors in urine collection, as well as creatinine secretion, extrarenal creatinine excretion, and issues associated with creatinine measurement.",
"      <a class=\"local\" href=\"#H20664189\">",
"       'Using creatinine to estimate GFR'",
"      </a>",
"      above",
"     </li>",
"     <li>",
"      Creatinine is freely filtered across the glomerulus and is neither reabsorbed nor metabolized by the kidney. However, approximately 10 to 40 percent of urinary creatinine is derived from tubular secretion by the organic cation secretory pathways in the proximal tubule. If the effect of secretion is ignored, then the creatinine clearance (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?16/8/16513?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) will be equal to the GFR. However, the creatinine clearance and tends to exceed the true GFR by approximately 10 to 20 percent or more since this is the fraction of urinary creatinine that is derived from tubular secretion. In addition, using the creatinine clearance to estimate GFR is limited by errors in urine collection and variation in the degree of creatinine secretion, which increases as GFR decreases. (See",
"      <a class=\"local\" href=\"#H20663240\">",
"       'Creatinine clearance'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20663247\">",
"       'Limitations of using creatinine clearance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common equations used in the United States are the Cockcroft-Gault and the Modification of Diet in Renal Disease (MDRD) Study equations. The CKD-EPI equation is more accurate than the MDRD study equation. The MDRD and CKD-EPI equations are normalized to body surface area. (See",
"      <a class=\"local\" href=\"#H20659769\">",
"       'Estimation equations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The Cockcroft-Gault equation (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?29/57/30609?source=see_link\">",
"       calculator 3",
"      </a>",
"      ) was developed prior to the use of standardized creatinine assays, and has",
"      <strong>",
"       not",
"      </strong>",
"      been revised for use with creatinine values traceable to standardized reference materials. Thus, using the Cockcroft-Gault equation with creatinine values measured by most laboratories in the United States today will result in a 10 to 40 percent",
"      <strong>",
"       overestimate",
"      </strong>",
"      of creatinine clearance. (See",
"      <a class=\"local\" href=\"#H20659776\">",
"       'Cockcroft-Gault equation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The MDRD study equation (",
"      <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/61/10194?source=see_link\">",
"       calculator 4",
"      </a>",
"      ) is the most commonly used estimation equation, and has been re-expressed for use with creatinine values that are standardized to creatinine reference materials measured using gold standard techniques (",
"      <a class=\"external\" href=\"file://www.cap.org/apps/cap.portal?_nfpb=true&amp;cntvwrPtlt_actionOverride=/portlets/contentViewer/show&amp;_windowLabel=cntvwrPtlt&amp;cntvwrPtlt{actionForm.contentReference}=committees/chemistry/chemistry_resources.html&amp;_state=maximized&amp;_pageLabel=cntvwr\">",
"       Gold standard MDRD study equation",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20659783\">",
"       'MDRD study equations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The",
"      <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/gfr_calculator.cfm\">",
"       CKD-EPI equation",
"      </a>",
"      was developed to provide a more accurate estimate of GFR among individuals with normal or only mildly reduced GFR (ie, above 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      ). Among patients with GFRs greater than 60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      , the CKD-EPI equation was associated with less bias, improved precision, and greater accuracy. The CKD-EPI equation results in a lower prevalence estimate of CKD and more accurate risk prediction for adverse outcomes compared with the MDRD study equation. (See",
"      <a class=\"local\" href=\"#H20659797\">",
"       'CKD-EPI equation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Given the data on the improved performance, especially at higher levels of GFR, we suggest using the CKD-EPI equation for the general population. (See",
"      <a class=\"local\" href=\"#H20659818\">",
"       'Choice of equation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to the problems associated with reliance upon serum creatinine, the commonly utilized estimation equations are less accurate in certain populations. These include individuals with normal GFR, children, elderly patients, specific ethnic groups (eg, Asians in the United States), pregnant women, and those with unusual muscle mass, body habitus, and weight (eg, morbid obesity, amputees). (See",
"      <a class=\"local\" href=\"#H20659825\">",
"       'Limitations of estimation equations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the MDRD (or CKD-EPI) estimated GFR is used for drug dosing in very large or small patients, the reported estimated GFR (which is normalized to body surface area) should be multiplied by the estimated body surface area to obtain an estimated GFR in units of",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      (ie, not normalized to body surface area). For patients at the extremes of muscle mass, with unusual diets, or with conditions associated with changes in creatinine secretion, all estimation equations that use the serum creatinine are limited; thus a measured creatinine clearance or GFR using exogenous filtration markers should be performed especially when prescribing drugs with a narrow therapeutic window. (See",
"      <a class=\"local\" href=\"#H20659832\">",
"       'Drug dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The measurement of the clearance of urea is useful in one setting. Among patients with severe kidney disease (eg, a serum creatinine greater than 2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [220",
"      <span class=\"nowrap\">",
"       micromol/L]),",
"      </span>",
"      the urea clearance significantly underestimates the GFR. Since the creatinine clearance significantly overestimates this function, one method to estimate the GFR in patients with advanced renal disease is to average both the creatinine and urea clearances. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'BUN and GFR'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although cystatin C in combination with creatinine appears to be more accurate for the assessment of GFR than serum creatinine in certain populations, whether measurement of cystatin C levels will improve patient care is unknown. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Serum cystatin C'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/1\">",
"      Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med 2006; 354:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/2\">",
"      Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/3\">",
"      Rodr&iacute;guez-Puyol D. The aging kidney. Kidney Int 1998; 54:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/4\">",
"      Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age. Kidney Int 1984; 26:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/5\">",
"      Iseki K, Kinjo K, Iseki C, Takishita S. Relationship between predicted creatinine clearance and proteinuria and the risk of developing ESRD in Okinawa, Japan. Am J Kidney Dis 2004; 44:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/6\">",
"      van Acker BA, Koomen GC, Koopman MG, et al. Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate. Lancet 1992; 340:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/7\">",
"      Petri M, Bockenstedt L, Colman J, et al. Serial assessment of glomerular filtration rate in lupus nephropathy. Kidney Int 1988; 34:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/8\">",
"      Chagnac A, Kiberd BA, Fari&ntilde;as MC, et al. Outcome of the acute glomerular injury in proliferative lupus nephritis. J Clin Invest 1989; 84:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/9\">",
"      Rodrigo E, de Francisco AL, Escallada R, et al. Measurement of renal function in pre-ESRD patients. Kidney Int Suppl 2002; :11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/10\">",
"      Traynor J, Mactier R, Geddes CC, Fox JG. How to measure renal function in clinical practice. BMJ 2006; 333:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/11\">",
"      Rahn KH, Heidenreich S, Br&uuml;ckner D. How to assess glomerular function and damage in humans. J Hypertens 1999; 17:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/12\">",
"      Levey AS. Measurement of renal function in chronic renal disease. Kidney Int 1990; 38:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/13\">",
"      Br&auml;ndstr&ouml;m E, Grzegorczyk A, Jacobsson L, et al. GFR measurement with iohexol and 51Cr-EDTA. A comparison of the two favoured GFR markers in Europe. Nephrol Dial Transplant 1998; 13:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/14\">",
"      Stevens LA, Levey AS. Measured GFR as a confirmatory test for estimated GFR. J Am Soc Nephrol 2009; 20:2305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/15\">",
"      Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985; 28:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/16\">",
"      Jones CA, McQuillan GM, Kusek JW, et al. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998; 32:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/17\">",
"      Rule AD, Bergstralh EJ, Slezak JM, et al. Glomerular filtration rate estimated by cystatin C among different clinical presentations. Kidney Int 2006; 69:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/18\">",
"      Grossman RA, Hamilton RW, Morse BM, et al. Nontraumatic rhabdomyolysis and acute renal failure. N Engl J Med 1974; 291:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/19\">",
"      Oh MS. Does serum creatinine rise faster in rhabdomyolysis? Nephron 1993; 63:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/20\">",
"      DOOLAN PD, ALPEN EL, THEIL GB. A clinical appraisal of the plasma concentration and endogenous clearance of creatinine. Am J Med 1962; 32:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/21\">",
"      Kim KE, Onesti G, Ramirez O, et al. Creatinine clearance in renal disease. A reappraisal. Br Med J 1969; 4:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/22\">",
"      Perrone RD, Steinman TI, Beck GJ, et al. Utility of radioisotopic filtration markers in chronic renal insufficiency: simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99mTc-DTPA, and inulin. The Modification of Diet in Renal Disease Study. Am J Kidney Dis 1990; 16:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/23\">",
"      Bostom AG, Kronenberg F, Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 2002; 13:2140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/24\">",
"      Branten AJ, Vervoort G, Wetzels JF. Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrol Dial Transplant 2005; 20:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/25\">",
"      Myers BD, Chagnac A, Golbetz H, et al. Extent of glomerular injury in active and resolving lupus nephritis: a theoretical analysis. Am J Physiol 1991; 260:F717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/26\">",
"      Dunn SR, Gabuzda GM, Superdock KR, et al. Induction of creatininase activity in chronic renal failure: timing of creatinine degradation and effect of antibiotics. Am J Kidney Dis 1997; 29:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/27\">",
"      Soldin SJ, Henderson L, Hill JG. The effect of bilirubin and ketones on reaction rate methods for the measurement of creatinine. Clin Biochem 1978; 11:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/28\">",
"      Miller WG, Myers GL, Ashwood ER, et al. Creatinine measurement: state of the art in accuracy and interlaboratory harmonization. Arch Pathol Lab Med 2005; 129:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/29\">",
"      Molitch ME, Rodman E, Hirsch CA, Dubinsky E. Spurious serum creatinine elevations in ketoacidosis. Ann Intern Med 1980; 93:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/30\">",
"      Coresh J, Astor BC, McQuillan G, et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 2002; 39:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/31\">",
"      Walser M. Creatinine excretion as a measure of protein nutrition in adults of varying age. JPEN J Parenter Enteral Nutr 1987; 11:73S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/32\">",
"      Ix JH, Wassel CL, Stevens LA, et al. Equations to estimate creatinine excretion rate: the CKD epidemiology collaboration. Clin J Am Soc Nephrol 2011; 6:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/33\">",
"      Proulx NL, Akbari A, Garg AX, et al. Measured creatinine clearance from timed urine collections substantially overestimates glomerular filtration rate in patients with liver cirrhosis: a systematic review and individual patient meta-analysis. Nephrol Dial Transplant 2005; 20:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/34\">",
"      Wang X, Lewis J, Appel L, et al. Validation of creatinine-based estimates of GFR when evaluating risk factors in longitudinal studies of kidney disease. J Am Soc Nephrol 2006; 17:2900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/35\">",
"      Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/36\">",
"      Shoker A, Hossain MA, Koru-Sengul T, et al. Performance of creatinine clearance equations on the original Cockcroft-Gault population. Clin Nephrol 2006; 66:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/37\">",
"      Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/38\">",
"      Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/39\">",
"      Poggio ED, Wang X, Greene T, et al. Performance of the modification of diet in renal disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 2005; 16:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/40\">",
"      Lewis J, Agodoa L, Cheek D, et al. Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. Am J Kidney Dis 2001; 38:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/41\">",
"      Rule AD, Larson TS, Bergstralh EJ, et al. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 2004; 141:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/42\">",
"      Gonwa TA, Jennings L, Mai ML, et al. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl 2004; 10:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/43\">",
"      Froissart M, Rossert J, Jacquot C, et al. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 2005; 16:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/44\">",
"      Hallan S, Asberg A, Lindberg M, Johnsen H. Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis 2004; 44:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/45\">",
"      Lin J, Knight EL, Hogan ML, Singh AK. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol 2003; 14:2573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/46\">",
"      Zuo L, Ma YC, Zhou YH, et al. Application of GFR-estimating equations in Chinese patients with chronic kidney disease. Am J Kidney Dis 2005; 45:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/47\">",
"      Gaspari F, Ferrari S, Stucchi N, et al. Performance of different prediction equations for estimating renal function in kidney transplantation. Am J Transplant 2004; 4:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/48\">",
"      Lamb EJ, Webb MC, Simpson DE, et al. Estimation of glomerular filtration rate in older patients with chronic renal insufficiency: is the modification of diet in renal disease formula an improvement? J Am Geriatr Soc 2003; 51:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/49\">",
"      Vervoort G, Willems HL, Wetzels JF. Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. Nephrol Dial Transplant 2002; 17:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/50\">",
"      Skluzacek PA, Szewc RG, Nolan CR 3rd, et al. Prediction of GFR in liver transplant candidates. Am J Kidney Dis 2003; 42:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/51\">",
"      Ibrahim H, Mondress M, Tello A, et al. An alternative formula to the Cockcroft-Gault and the modification of diet in renal diseases formulas in predicting GFR in individuals with type 1 diabetes. J Am Soc Nephrol 2005; 16:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/52\">",
"      Rigalleau V, Lasseur C, Perlemoine C, et al. Estimation of glomerular filtration rate in diabetic subjects: Cockcroft formula or modification of Diet in Renal Disease study equation? Diabetes Care 2005; 28:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/53\">",
"      P&ouml;ge U, Gerhardt T, Palmedo H, et al. MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant 2005; 5:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/54\">",
"      Fehrman-Ekholm I, Skeppholm L. Renal function in the elderly (&gt;70 years old) measured by means of iohexol clearance, serum creatinine, serum urea and estimated clearance. Scand J Urol Nephrol 2004; 38:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/55\">",
"      Poggio ED, Nef PC, Wang X, et al. Performance of the Cockcroft-Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients. Am J Kidney Dis 2005; 46:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/56\">",
"      Verhave JC, Fesler P, Ribstein J, et al. Estimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass index. Am J Kidney Dis 2005; 46:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/57\">",
"      Coresh J, Stevens LA. Kidney function estimating equations: where do we stand? Curr Opin Nephrol Hypertens 2006; 15:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/58\">",
"      Gera M, Slezak JM, Rule AD, et al. Assessment of changes in kidney allograft function using creatinine-based estimates of glomerular filtration rate. Am J Transplant 2007; 7:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/59\">",
"      Botev R, Malli&eacute; JP, Couchoud C, et al. Estimating glomerular filtration rate: Cockcroft-Gault and Modification of Diet in Renal Disease formulas compared to renal inulin clearance. Clin J Am Soc Nephrol 2009; 4:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/60\">",
"      Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/61\">",
"      Cirillo M, Anastasio P, De Santo NG. Relationship of gender, age, and body mass index to errors in predicted kidney function. Nephrol Dial Transplant 2005; 20:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/62\">",
"      Stevens LA, Coresh J, Feldman HI, et al. Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol 2007; 18:2749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/63\">",
"      Mariat C, Alamartine E, Barthelemy JC, et al. Assessing renal graft function in clinical trials: can tests predicting glomerular filtration rate substitute for a reference method? Kidney Int 2004; 65:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/64\">",
"      Stoves J, Lindley EJ, Barnfield MC, et al. MDRD equation estimates of glomerular filtration rate in potential living kidney donors and renal transplant recipients with impaired graft function. Nephrol Dial Transplant 2002; 17:2036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/65\">",
"      Bosma RJ, Doorenbos CR, Stegeman CA, et al. Predictive performance of renal function equations in renal transplant recipients: an analysis of patient factors in bias. Am J Transplant 2005; 5:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/66\">",
"      Mariat C, Alamartine E, Afiani A, et al. Predicting glomerular filtration rate in kidney transplantation: are the K/DOQI guidelines applicable? Am J Transplant 2005; 5:2698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/67\">",
"      Poggio ED, Wang X, Weinstein DM, et al. Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am J Transplant 2006; 6:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/68\">",
"      Mahajan S, Mukhiya GK, Singh R, et al. Assessing glomerular filtration rate in healthy Indian adults: a comparison of various prediction equations. J Nephrol 2005; 18:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/69\">",
"      Jafar TH, Schmid CH, Levey AS. Serum creatinine as marker of kidney function in South Asians: a study of reduced GFR in adults in Pakistan. J Am Soc Nephrol 2005; 16:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/70\">",
"      Aizawa M, Hayashi K, Shimaoka T, et al. [Comparison of prediction equations of glomerular filtration rate in Japanese adults]. Nihon Jinzo Gakkai Shi 2006; 48:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/71\">",
"      Sasaki S. Nephrologists Sans Fronti&egrave;res: chronic kidney disease in Japan. Kidney Int 2006; 69:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/72\">",
"      Agarwal R. Estimating GFR from serum creatinine concentration: pitfalls of GFR-estimating equations. Am J Kidney Dis 2005; 45:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/73\">",
"      Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006; 17:2937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/74\">",
"      Horio M, Imai E, Yasuda Y, et al. Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis 2010; 56:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/75\">",
"      Yeo Y, Han DJ, Moon DH, et al. Suitability of the IDMS-traceable MDRD equation method to estimate GFR in early postoperative renal transplant recipients. Nephron Clin Pract 2010; 114:c108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/76\">",
"      Imai E, Horio M, Nitta K, et al. Modification of the Modification of Diet in Renal Disease (MDRD) Study equation for Japan. Am J Kidney Dis 2007; 50:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/77\">",
"      Gill J, Malyuk R, Djurdjev O, Levin A. Use of GFR equations to adjust drug doses in an elderly multi-ethnic group--a cautionary tale. Nephrol Dial Transplant 2007; 22:2894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/78\">",
"      Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/79\">",
"      Earley A, Miskulin D, Lamb EJ, et al. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med 2012; 156:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/80\">",
"      Stevens LA, Schmid CH, Greene T, et al. Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis 2010; 56:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/81\">",
"      Kilbride HS, Stevens PE, Eaglestone G, et al. Accuracy of the MDRD (Modification of Diet in Renal Disease) study and CKD-EPI (CKD Epidemiology Collaboration) equations for estimation of GFR in the elderly. Am J Kidney Dis 2013; 61:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/82\">",
"      Matsushita K, Mahmoodi BK, Woodward M, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 2012; 307:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/83\">",
"      Matsushita K, Selvin E, Bash LD, et al. Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2010; 55:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/84\">",
"      White SL, Polkinghorne KR, Atkins RC, Chadban SJ. Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study. Am J Kidney Dis 2010; 55:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/85\">",
"      Skali H, Uno H, Levey AS, et al. Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation. Am Heart J 2011; 162:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/86\">",
"      Stevens LA, Li S, Kurella Tamura M, et al. Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2011; 57:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/87\">",
"      Matsushita K, Tonelli M, Lloyd A, et al. Clinical risk implications of the CKD Epidemiology Collaboration (CKD-EPI) equation compared with the Modification of Diet in Renal Disease (MDRD) Study equation for estimated GFR. Am J Kidney Dis 2012; 60:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/88\">",
"      Choi JS, Kim CS, Bae EH, et al. Predicting outcomes after myocardial infarction by using the Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease study equation: results from the Korea Acute Myocardial Infarction Registry. Nephrol Dial Transplant 2012; 27:3868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/89\">",
"      Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis 2010; 55:622.",
"     </a>",
"    </li>",
"    <li>",
"     Food and Drug Administration: Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function-Study Design, Data Analysis, and the Impact on Dosing. Rockville, MD, US Department of Health and Human Services, May 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/91\">",
"      Stevens LA, Levey AS. Use of the MDRD study equation to estimate kidney function for drug dosing. Clin Pharmacol Ther 2009; 86:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/92\">",
"      Stevens LA, Nolin TD, Richardson MM, et al. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis 2009; 54:33.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nkdep.nih.fgov/professionals/drug-dosing-information.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/94\">",
"      Dossetor JB. Creatininemia versus uremia. The relative significance of blood urea nitrogen and serum creatinine concentrations in azotemia. Ann Intern Med 1966; 65:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/95\">",
"      Papadakis MA, Arieff AI. Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study. Am J Med 1987; 82:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/96\">",
"      Sherman DS, Fish DN, Teitelbaum I. Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis 2003; 41:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/97\">",
"      Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/98\">",
"      Lubowitz H, Slatopolsky E, Shankel S, et al. Glomerular filtration rate. Determination in patients with chronic renal disease. JAMA 1967; 199:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/99\">",
"      European Best Practice Guidelines for peritoneal dialysis. Nephrol Dial Transplant 2005; 20(Suppl 9):3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/100\">",
"      Kielstein JT, Salpeter SR, Bode-Boeger SM, et al. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis. Nephrol Dial Transplant 2006; 21:2446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/101\">",
"      Groesbeck D, K&ouml;ttgen A, Parekh R, et al. Age, gender, and race effects on cystatin C levels in US adolescents. Clin J Am Soc Nephrol 2008; 3:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/102\">",
"      Macdonald J, Marcora S, Jibani M, et al. GFR estimation using cystatin C is not independent of body composition. Am J Kidney Dis 2006; 48:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/103\">",
"      K&ouml;ttgen A, Selvin E, Stevens LA, et al. Serum cystatin C in the United States: the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2008; 51:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/104\">",
"      Manetti L, Pardini E, Genovesi M, et al. Thyroid function differently affects serum cystatin C and creatinine concentrations. J Endocrinol Invest 2005; 28:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/105\">",
"      Stevens LA, Schmid CH, Greene T, et al. Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int 2009; 75:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/106\">",
"      Inker LA, Eckfeldt J, Levey AS, et al. Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) cystatin C equations for estimating GFR with standardized serum cystatin C values. Am J Kidney Dis 2011; 58:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/107\">",
"      Grubb A, Blirup-Jensen S, Lindstr&ouml;m V, et al. First certified reference material for cystatin C in human serum ERM-DA471/IFCC. Clin Chem Lab Med 2010; 48:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/108\">",
"      Blirup-Jensen S, Grubb A, Lindstrom V, et al. Standardization of Cystatin C: development of primary and secondary reference preparations. Scand J Clin Lab Invest Suppl 2008; 241:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/109\">",
"      Newman DJ, Thakkar H, Edwards RG, et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995; 47:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/110\">",
"      Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000; 36:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/111\">",
"      Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 2001; 37:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/112\">",
"      Mussap M, Dalla Vestra M, Fioretto P, et al. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int 2002; 61:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/113\">",
"      Ahlstr&ouml;m A, Tallgren M, Peltonen S, Pettil&auml; V. Evolution and predictive power of serum cystatin C in acute renal failure. Clin Nephrol 2004; 62:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/114\">",
"      Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 2003; 18:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/115\">",
"      Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/116\">",
"      P&ouml;ge U, Gerhardt T, Stoffel-Wagner B, et al. Cystatin C-based calculation of glomerular filtration rate in kidney transplant recipients. Kidney Int 2006; 70:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/117\">",
"      Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008; 51:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/118\">",
"      Grubb A, Nyman U, Bj&ouml;rk J, et al. Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children. Clin Chem 2005; 51:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/119\">",
"      Sj&ouml;str&ouml;m P, Tidman M, Jones I. Determination of the production rate and non-renal clearance of cystatin C and estimation of the glomerular filtration rate from the serum concentration of cystatin C in humans. Scand J Clin Lab Invest 2005; 65:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/120\">",
"      Grubb A, Bj&ouml;rk J, Lindstr&ouml;m V, et al. A cystatin C-based formula without anthropometric variables estimates glomerular filtration rate better than creatinine clearance using the Cockcroft-Gault formula. Scand J Clin Lab Invest 2005; 65:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/121\">",
"      Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/122\">",
"      White C, Akbari A, Hussain N, et al. Estimating glomerular filtration rate in kidney transplantation: a comparison between serum creatinine and cystatin C-based methods. J Am Soc Nephrol 2005; 16:3763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/123\">",
"      P&ouml;ge U, Gerhardt T, Stoffel-Wagner B, et al. Calculation of glomerular filtration rate based on cystatin C in cirrhotic patients. Nephrol Dial Transplant 2006; 21:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/124\">",
"      Stevens LA, Padala S, Levey AS. Advances in glomerular filtration rate-estimating equations. Curr Opin Nephrol Hypertens 2010; 19:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/125\">",
"      Oddoze C, Morange S, Portugal H, et al. Cystatin C is not more sensitive than creatinine for detecting early renal impairment in patients with diabetes. Am J Kidney Dis 2001; 38:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/126\">",
"      Perkins BA, Nelson RG, Ostrander BE, et al. Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 2005; 16:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/45/36570/abstract/127\">",
"      Deinum J, Derkx FH. Cystatin for estimation of glomerular filtration rate? Lancet 2000; 356:1624.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2359 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-83C710A96E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_45_36570=[""].join("\n");
var outline_f35_45_36570=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF KIDNEY FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GLOMERULAR FILTRATION RATE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Normal GFR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20658511\">",
"      - Change in GFR with aging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20658680\">",
"      Significance of a declining GFR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20658806\">",
"      ASSESSMENT OF GFR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20658260\">",
"      How to evaluate GFR: Measurement versus estimation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Measurement of GFR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Estimation of GFR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20664189\">",
"      - Using creatinine to estimate GFR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1505493\">",
"      Normal values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1505542\">",
"      Requirement for stable kidney function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20665137\">",
"      Limitations of using creatinine",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H1505177\">",
"      - Variation in creatinine production",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H1505184\">",
"      - Variations in creatinine secretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H1505415\">",
"      - Extrarenal creatinine excretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H1505422\">",
"      - Measurement issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20663240\">",
"      - Creatinine clearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20663247\">",
"      Limitations of using creatinine clearance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20659769\">",
"      - Estimation equations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20659776\">",
"      Cockcroft-Gault equation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20659783\">",
"      MDRD study equations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20659790\">",
"      Evaluation of the MDRD and Cockcroft-Gault equations in specific populations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20659797\">",
"      CKD-EPI equation",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H20659804\">",
"      - CKD-EPI is superior when GFR is normal or mildly reduced",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H20659811\">",
"      - CKD-EPI results in lower prevalence of CKD and better risk prediction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20659818\">",
"      Choice of equation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20659825\">",
"      Limitations of estimation equations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20659832\">",
"      Drug dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - BUN and GFR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Serum cystatin C",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H443541\">",
"      - Creatinine and cystatin C in combination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2359\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2359|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/1/19\" title=\"figure 1\">",
"      Serum creatinine and GFR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/15/8446\" title=\"figure 2\">",
"      Distribution of serum creatinine among US males and females",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/13/42199\" title=\"figure 3\">",
"      CKD-EPI and MDRD Study equations in estimating measured GFR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/9/44191\" title=\"figure 4\">",
"      Differences in cystatin C according to demographic factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?16/8/16513?source=related_link\" title=\"calculator 1\">",
"      Calculator: Creatinine clearance (measured)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?4/27/4529?source=related_link\" title=\"calculator 2\">",
"      Calculator: Body Surface Area (Mosteller, square root method)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?29/57/30609?source=related_link\" title=\"calculator 3\">",
"      Calculator: Creatinine clearance estimate by Cockcroft-Gault equation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?9/61/10194?source=related_link\" title=\"calculator 4\">",
"      Calculator: Glomerular filtration rate estimate by abbreviated MDRD study equation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35190?source=related_link\">",
"      Calculation of the creatinine clearance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38198?source=related_link\">",
"      Chapter 1A: Introduction to renal function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/29/5594?source=related_link\">",
"      Definition and staging of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/60/35785?source=related_link\">",
"      Diagnostic approach to the patient with acute kidney injury (acute renal failure) or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41875?source=related_link\">",
"      Drugs that elevate the serum creatinine concentration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21690?source=related_link\">",
"      Indications for and complications of renal biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/41/21151?source=related_link\">",
"      Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39509?source=related_link\">",
"      Radiologic assessment of renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/0/41988?source=related_link\">",
"      Reciprocal serum creatinine concentration and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_45_36571="Gyn menstrual history";
var content_f35_45_36571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Menstrual history",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        All women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age of menarche (onset of first period)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prior history of menstrual irregularity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prior history of heavy or intermenstrual bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prior history of dysmenorrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Women of reproductive age and in the menopausal transition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Date of last menstrual period (lmp) (first day of bleeding or spotting)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Date of previous menstrual period",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Current cycle length (interval between lmp and previous menstrual period) and regularity (cycle pattern over past year)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number of days of bleeding in an average menses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Current or recent heavy or intermenstrual bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Current or recent postcoital bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Current or recent dysmenorrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presence of moliminal or premenstrual symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Postmenopausal women",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age at last menses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of hormone therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of postmenopausal bleeding",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_45_36571=[""].join("\n");
var outline_f35_45_36571=null;
var title_f35_45_36572="Length time bias b";
var content_f35_45_36572=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F81258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F81258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Length-time bias",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 319px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cases that progress rapidly from onset (O) to symptoms and diagnosis (Dx) are less likely to be detected during a screening examination.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fletcher RH, Fletcher SW. Prevention. In: Clinical Epidemiology - The Essentials, 4th ed. Lippincott Williams &amp; Wilkins, Baltimore 2005. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_45_36572=[""].join("\n");
var outline_f35_45_36572=null;
var title_f35_45_36573="Secondary causes osteoporosis";
var content_f35_45_36573=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F54926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F54926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Secondary causes of osteoporosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Drugs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Glucocorticoids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Immunosuppressants (cyclosporine)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Antiseizure medications (particularly phenobarbital and phenytoin)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            GnRH agonists and antagonists",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Heparin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cancer chemotherapy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Endocrine disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acromegaly",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Adrenal atrophy in Addison's disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cushing's syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Eating disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Endometriosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hyperparathyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hyperprolactinemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hyperthyroidism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypogonadism (primary or secondary)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diabetes mellitus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Gastrointestinal disease/nutritional disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Alcohol-related liver disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Celiac disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chronic active hepatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chronic cholestatic disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastrectomy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inflammatory bowel disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Jejunoileal bypass",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Malabsorption syndromes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreatic insufficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Parenteral nutrition",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Primary biliary cirrhosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Severe liver disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vitamin D and/or calcium deficiency",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Marrow-related disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amyloidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hemochromatosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hemophilia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Leukemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lymphoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mastocytosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Multiple myeloma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pernicious anemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sickle cell anemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thalassemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Organ transplantation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bone marrow",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Heart",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Kidney",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Liver",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lung",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Miscellaneous causes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ankylosing spondylitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chronic obstructive pulmonary disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Congenital porphyria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Epidermolysis bullosa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hemophilia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Idiopathic hypercalciuria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Idiopathic scoliosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Multiple sclerosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rheumatoid arthritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Genetic disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypophosphatasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Osteogenesis imperfecta",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Homocystinuria due to cystathionine deficiency",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc 2002; 77:454. Copyright &copy; 2002 Mayo Foundation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_45_36573=[""].join("\n");
var outline_f35_45_36573=null;
var title_f35_45_36574="Contents: Tuberculosis";
var content_f35_45_36574=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?8/24/8590\">",
"       Pulmonary, Critical Care, and Sleep Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Tuberculosis",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Tuberculosis",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Diagnosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/10/20648\">",
"           Diagnosis of latent tuberculosis infection in HIV-negative adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/56/9098\">",
"           Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/52/32586\">",
"           Diagnosis, treatment, and prevention of drug-resistant tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/10/1194\">",
"           Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/18/37160\">",
"           Interferon-gamma release assays for diagnosis of latent tuberculosis infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/35/12856\">",
"           Tuberculous pleural effusions in HIV-negative patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Drug resistant disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/53/5978\">",
"           Clinical manifestations, diagnosis, and treatment of extensively drug-resistant tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/52/32586\">",
"           Diagnosis, treatment, and prevention of drug-resistant tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/20/7497\">",
"           Epidemiology and molecular mechanisms of drug-resistant tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/59/34743\">",
"           Epidemiology of extensively drug-resistant tuberculosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Extrapulmonary disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/2/28713\">",
"           Central nervous system tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/21/20826\">",
"           Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/22/34150\">",
"           Epidemiology and pathology of extrapulmonary and miliary tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/49/37656\">",
"           Skeletal tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/40/5767\">",
"           Tuberculosis and the eye",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/7/27768\">",
"           Tuberculous lymphadenitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/36/2633\">",
"           Tuberculous pericarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/48/36614\">",
"           Tuberculous peritonitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/35/12856\">",
"           Tuberculous pleural effusions in HIV-negative patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         HIV infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/43/20154\">",
"           Approach to the HIV-infected patient with pulmonary symptoms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/46/12009\">",
"           Diagnosis of latent tuberculosis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/10/1194\">",
"           Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/55/17272\">",
"           Monitoring the HIV-infected patient on antituberculous medications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/12/4298\">",
"           Treatment of latent tuberculosis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/35/19002\">",
"           Treatment of pulmonary tuberculosis in the HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/47/22261\">",
"           Tuberculous pleural effusions in HIV-infected patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/13/18649\">",
"           Epidemiology of tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/17/43289\">",
"           Immunology of tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/53/13143\">",
"           Latent tuberculosis infection in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/54/22378\">",
"           Microbiology and pathogenesis of tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/14/16614\">",
"           Mycobacterium bovis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/43/14005\">",
"           Renal disease in tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/4/23625\">",
"           Tuberculosis disease in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/26/29096\">",
"           Tuberculosis in pregnancy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Prevention",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/12/40136\">",
"           BCG vaccination",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/46/12009\">",
"           Diagnosis of latent tuberculosis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/12/4298\">",
"           Treatment of latent tuberculosis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/13/9432\">",
"           Treatment of latent tuberculosis infection in HIV-negative adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/52/20294\">",
"           Tuberculosis transmission and control",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pulmonary disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/47/39673\">",
"           Clinical manifestations and evaluation of pulmonary tuberculosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/6/10341\">",
"           Adherence to tuberculosis treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/52/32586\">",
"           Diagnosis, treatment, and prevention of drug-resistant tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/2/30757\">",
"           Ethambutol: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/61/41943\">",
"           Isoniazid hepatotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/44/19142\">",
"           Isoniazid: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/62/34788\">",
"           Pyrazinamide: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/26/24998\">",
"           Rifampin and other rifamycins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/60/18375\">",
"           Second-line antituberculous therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/21/19802\">",
"           Treatment of pulmonary tuberculosis in HIV-negative patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/35/19002\">",
"           Treatment of pulmonary tuberculosis in the HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/26/29096\">",
"           Tuberculosis in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/35/12856\">",
"           Tuberculous pleural effusions in HIV-negative patients",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-2C999D6035-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f35_45_36574=[""].join("\n");
var outline_f35_45_36574=null;
var title_f35_45_36575="Eosinophilic esophagitis Endosc";
var content_f35_45_36575=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eosinophilic esophagitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper endoscopy in a 36-year-old man with dysphagia. Multiple rings are present in the proximal to mid esophagus giving it the appearance of a trachea. Small whitish papules are also visible representing eosinophilic abscesses on histology. The patient's symptoms responded to oral fluticasone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric D Libby, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_45_36575=[""].join("\n");
var outline_f35_45_36575=null;
